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Abstract
A variety of phosphonamidate-containing peptides were synthesised as 
potential inhibitors of the HIV-1 protease. These transition state analogues were 
designed using known sequences from HIV-1 protease substrates and 
incorporated a unique Phe-Pro scissile bond mimic in an attempt to achieve 
selectivity over the mammalian aspartic proteases. Such compounds were found to 
be moderate inhibitors of the HiV-1 protease possessing iCgo values in the 1-100
pM range, both in in vitro and in vivo assays. However, the phosphonamidate 
methyl ester analogues showed a marked ability to enter ceils and this feature was 
highlighted in the 1:1 ratio of in vivo/ in vitro iCso values (generally for peptidic 
inhibitors, this ratio is 10-10000 fold higher, indicating poor cell uptake properties). 
Optimisation of the methyl ester analogues was attempted by alteration of the 
binding residues flanking either side of the phosphonamidate moiety. However, 
such alterations had only a small effect on inhibitor potency and the trends 
observed for the more potent hydroxyl-containing inhibitors were not seen with our 
compounds. These results suggest hydrogen-bond donating capacity as a key 
requirement for potent inhibition of the HiV-1 protease, a feature which the methyl 
ester analogues lack!
Due to the associated problems with peptidic inhibitors, the development 
towards two novel non-peptidic inhibitors of the HiV-1 protease was undertaken. 
Both cyclic inhibitors were designed to optimise the key interactions at the core of 
the active site of the enzyme in an attempt for selective, highly potent, low 
molecular weight inhibitors. Such inhibitors were designed to replace a structural 
water molecule in the flap region of the enzyme, whilst maintaining the key 
interactions with the catalytic aspartates. For this purpose cyclic compounds 
possessing both alcohol functionality and ring heteroatoms were synthesised. The
first suifur-containing analogue produced a moderate inhibitor (pM) of the HiV-1 
protease and provided a lead compound for further development. The second 
seven membered ring analogue was designed on the basis of a recent literature 
compound and the synthesis incorporated a novel b/s-ketone, derived from diethyl 
L-tartrate. This synthesis has yet to be completed and is currently under 
investigation in our group by Neii Piggot.
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CHAPTER ONE
:
INTRODUCTION TO HIV-1
...
1.0 Introduction.
1.1 Générai introduction.
The search for a cure for the acquired immune deficiency syndrome (AIDS), 
continues to be one of the highest research priorities worid wide. If current 
estimates of the dimension of the disease are accurate, millions of individuals 
wiii be in the terminai stages of the disease during the next decade. The 
immediate discovery of an effective therapy is therefore crucial.
AIDS is a disease that cripples the human immune system and the general 
consensus of opinion at present is that it is caused by the human 
immunodeficiency virus (HiV). Infection by the virus, which targets the CD4 
receptor protein of human helper T-cells, eventually produces profound defects 
in cell-mediated immunity.^ Over time, infection leads to a severe depletion of 
T-cells resulting in opportunistic infections and ultimately death.
The only two treatments for HIV infection so far approved are directed 
against the viral enzyme, reverse transcriptase (RT).2 These are Zidovudine, 
(3’-azido-3’-deoxythymidine (AZT)), a ‘suicide’ precursor substrate and 2’, 3 - 
dideoxyinosine (ddl), a chain termination inhibitor. Both of these therapies 
suffer from two major drawbacks; they are highly toxic^ and resistant mutants 
have already appeared against AZT. The speed at which these mutants have 
appeared does not bode well for ddl. Additionally, some patients cannot 
I I  tolerate AZT therapy at ail.
I#
a
I
I
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1.2 The immune system.
The body is protected by a diverse army of ceils and molecules that work in 
concert. Their ultimate target is an antigen, which is usually a foreign molecule 
from a bacterium or other invader. Specialised antigen-presenting ceils, such 
as macrophages, roam the body, ingesting and fragmenting the antigens they 
find into antigenic peptides. Pieces of these peptides are joined to major 
histocompatibility complex (MHC) molecules and are displayed on the surface 
of the cell. Other white blood cells, called T-lymphocytes (T-cells), have receptor 
molecules that enable each of them to recognise a different peptide-MHO 
com bination. T-celis activated by that recognition divide and secrete
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iymphokines, or other chemical signals, that mobilise other components of the 
immune system. One set of ceils that respond to these signals are the B- 
lymphocytes (B-celis), which can identify antigens free in solution. When 
activated, the B-ceiis divide and differentiate into plasma ceils that secrete 
antibody proteins, which are soluble forms of their receptors. By binding to 
antigens that they find, the antibodies can neutralise them or precipitate their 
destruction by complementary enzymes or by scavenging cells. Some T- and B- 
ceils become memory cells that persist in the circulation and boost the immune 
system’s readiness to eliminate the same antigen if it presents itself in the 
future. Reduction in the number of T-ceiis can lead to a decline in immune 
function which can ultimately allow invasion by foreign molecules.
1.3 The human immunodeficiency virus.
The first viral species to be associated with AIDS was found both in the 
Western worid and Central Africa and has now come to be known as the human 
immunodeficiency virus-1 (HIV-1 ).4 Soon after the discovery of HiV-1, another 
major and distinct species of virus, called the HlV-2 was identified in West 
Africa.^ HIV, a lentivirus, is a member of the family of retroviruses, Retroviridae.^ 
The genomes of HIV-1 and HIV-2 are about 40% identical, but that of HIV-2 is 
about 80% identical to the genome of simian immunodeficiency virus (SiV). 
Although two related and pathogenic strains of HiV have been found, HIV-1 is 
the pathogen of greater consequence and therefore the following discussion 
will concentrate on this subtype.
The spherical HIV-1 (diameter approx. 1100 Â) comprises two portions, an 
envelope and a core.
One part of the envelope is a lipid biiayer that is similar to the plasma 
membrane of human ceils. Embedded in this layer are three proteins that 
complete the envelope; the transmembrane protein (gp41), surface protein 
(gp120) and matrix protein (MA pi 7). The abbreviation for the protein (p) or 
glycoprotein (gp) is followed by a number that gives the approximate molecular 
size of the protein in kilodaltons as determined by electrophoresis.
A structural representation of HIV-1 is shown below (Figure 1.1).
w
OP120
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Figure 1.1. Schematic representation of Infectious HIV.
(reproduced with the kind permission of Scientific American).
The core portion is roughly bullet-shaped, with an outer capsid protein (CA, 
p24). inside, there are two molecules of RNA and four viral enzymes, the 
protease (Pr), reverse transcriptase (RT), ribonuclease H (RN) and integrase 
(IN).
1.3.1 The viral life cycle of HiV.
The primary cell type in which HiV-1 repiicates is the human T4-
iymphocyteJ However, many other cell types have been shown to be infected 
by the virus, including ceiis in the brain,® gastrointestinal tract,® kidney,^® liver,^^ 
lung,i^ skin fibroblasts^® and the nervous systemJ^ Some of these targets do 
not display the receptor protein CD4, which suggests that CD4 is not the soie
vehicie for virai entry into cells. There must also exist a second receptor which
helps to expedite this process.
The replication cycle of HIV and other retroviruses within infected ceils can 
be divided into two phases; the pre-integration and post-integration phases. 
The pre-integration phase is carried out almost exclusively by enzymes and 
proteins encoded within the infecting virion, while a number of steps in the post- 
integration phase, in which viral genes are expressed and new virions are 
assembled, are performed by cellular enzymes. The events of the life cycle can 
be summarised as follows (see overleaf. Figure 1.2):
I) The external glycoprotein portion of the viral envelope protein, gp120, 
recognises and binds with affinity to the extracellular component of the receptor 
protein CD4.
ii) The membrane portion of the viral envelope fuses to the lymphocyte 
membrane, followed by injection of the virion into the cell. This process is 
mediated by gp41.
iii) The virion is uncoated by a proteolytic event in which the HiV-1 protease 
may play a major role.i® The viral RNA genome, the nucleocapsid proteins and 
the viral enzymes, reverse transcriptase (RT), integrase (IN) and protease (Pr) 
are released into the cytoplasm.
iv) The viral RNA is transcribed into DNA by reverse transcriptase.
v) The viral DNA then translocates to the cell nucleus where it is irreversibly 
integrated into the chromosomal DNA by the integrase enzyme. This forms the 
provirus which is now a permanent feature of the lymphocyte. These events
complete the pre-integration stage of the cycle.
CD4 molecule
uncoating
unintegrated 
circular DNAcellular DNA
genomic RNA
reverse transcriptase 
unintegrated RNase H linear DNAintegrated proviral DNA
messenger RNA
•  synthesisgenomic RNA
glycosylation
assembly and 
budding
HIV
mature HIV virions
Figure 1.2. The life cycle of HIV-1 within a human T4-Iymphocyte.
In the post-integration phase, the transcription and translation of the HIV 
provirus is subject to compiex regulation by both c/s-acting eiements within the 
DNA genome and by several frans-acting viral proteins, such as tat and rev, 
which are unique to HiVJ®'^^
vi) A primary RNA transcript is made by the host RNA polymerase II. This 
transcript provides both the messenger RNA (mRNA) for the synthesis of the 
virai polyproteins and the viral RNA which will be incorporated into the new 
virions.
vii) The host ceiiuiar ribosomes translate the provirai mRNA into virai 
polyproteins.
v iii) Cellu lar enzymes carry out post-translational modification of the 
polyproteins such as glycosylation of the envelope proteins and myristoyiation 
of the N-termini of the viral poiyproteins. This latter modification appears to be 
essential for attachment of these proteins to the ceil membrane and thus aid 
alignment of adjacent molecules.
ix) The glycoprotein envelope now displayed on the surface of the infected ceil 
probably drives assembly and sequestration of the poiyproteins and genomic 
RNA in an area of the host cell that is highly concentrated in viral eiements. 
Non-infectious, ‘immature’ particles then leave the cell in a process often 
referred to as ‘budding’.
x) Maturation of the fuiiy-formed ‘immature’ virion particles which have budded 
from the cell is effected by the HlV-1 protease. The protease catalyses its own 
release and then specifically cleaves the viral poiyproteins to yield the 
functional enzymes and structural proteins of the virion core. This processing 
completes the replication cycle of HlV-1. The resulting mature virion particles 
(see Figure 1.1.) are now able to promote a new infection in an adjacent T4- 
lymphocyte.
A number of steps in the life cycle of HIV-1 are potential targets for antiviral 
therapy. These include the cellular CD4 receptor, the enzymes reverse
transcriptase, ribonuciease H, integrase, protease, regulatory proteins needed 
for viral transcription, processing of viral mRNA, processing of viral proteins (e.g. 
glycosylation, myristoyiation), assembly at the plasma membrane and budding 
of virus particles. Of these, the reverse transcriptase and protease enzymes 
have received the greater attention. The HiV-1 protease is of particular interest 
to our work and several excellent reviews discussing the HIV-1 protease as a 
possible therapeutic target for AIDS have been published."'®’ 19. 20,21
The HIV-1 protease has an important role at the pre-integration stage of the 
cycle, such as destabilisation of the virion core and so inhibition of the protease 
may prevent proviral integration. The post-integration role of the protease 
involves the production of the mature infectious virion from the ‘immature’ virion 
and so inhibition of the protease may stop the spread of the virus from infected 
to non infected cells. The early and late role of the protease offers an immediate 
advantage over reverse transcriptase inhibitors, which act solely at a pre­
integration stage. Inhibition of the protease should be effective at both pre- and 
post-integration stages. This theory has been supported by the fact that 
protease inhibitors have been found to block maturation of virions shed from 
chronically-infected T4-lymphocytes, as well as to attenuate acute infection of 
uninfected T4-lymphocytes, suggesting that the protease does indeed have an 
early and late role in the viral cycle.
However, inhibitors of reverse transcriptase have recently been shown to be 
more effective against an acute infection than in reducing the population of 
active virus in chronicaiiy-infected T4-iymphocytes.®® This supports the pre­
integration role and therefore drugs based on reverse transcriptase inhibitors 
should be more effective for patients who are at the earlier stages of the 
disease.
1.3.2 The HIV genome.
HIV-1 exhibits the same 5’-LTR-gag-po/-env-LTR-3’ genomic organisation as 
ail retroviruses and further encodes several proteins with regulatory or unknown 
function. The genomic organisation of HiV-1 is shown overleaf (Figure 1.3).
gag
LTR pol
vpr□ [r ^
vif
2 3  4
p17 p24 P7 p6
MA CA NC NC
FRAME SHIFT
10 11
gpi20 Î gp4i
PR RT RN IN
5 6 
Pr1 e09^d-poi
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env
Figure 1.3. The HIV-1 genome; containing (i) LTR - long terminal 
repeat, (ii) vpr - activator of v iral proteins, (iii) rev  and tat - 
regulatory genes, (iv) v if - promotes viral In fectiv ity , (v) vpu - 
p rom otes  v ira l budding , (v ii)  nef - unknown fu n c tio n , (v iii)  
components of the Pr^B0 9 9^ p^ol will be defined in section 1,4.4.
The gag and pol regions are initiaiiy translated by the host ribosomes into 
large poiyprotein precursors that are later processed to yield the mature 
structural and catalytic proteins found in the virion. Translation of the HIV-1 gag  
open reading frame results in a 55kD precursor which contains the
viral structural proteins. The HiV-1 pol open reading frame is translated as a 
gag-pol fusion polyprotein, Pri as a result of a ribosomal frameshift
from the gag to the pol frames at a specific site positioned before the gag  
termination codon. Pri contains the protease, reverse transcriptase,
ribonuciease H and integrase. The proteolytic maturation of and
Pr^609^9'P^l is absolutely essential for the successful completion of the viral life 
cycle and the production of infectious virions (see section 1.3.1).
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1.4 The HIV-1 protease.
1.4.1 Classification.
From the genomic sequence of the virus, Ratner and co-workers postulated 
that the second open reading frame {pol) of HiV-1 encoded a protease 
analogous to those of other retroviruses.® More significantly, Toh et al. 
recognised that the highly conserved triad Asp-Thr-Gly (DIG), found in other 
retroviral sequences was homologous to the catalytic site of proteases 
belonging to the aspartic acid family and proposed that the viral enzymes were 
of this class.®®
The aspartic proteases, so named because of the highly conserved pair of 
aspartic acid residues in their active site have long been recognised as 
enzymes from vertebrates, plants and fungi. Non-viral aspartic proteases, such 
as pepsin, renin, cathepsin D and chymosin have been extensively studied over 
the years and consequently much is known about their mechanism, amino acid 
sequence and structure. This has obvious benefits to the study of HiV-1 
protease.
Further evidence confirmed the classification of the HIV-1 protease. First, the 
enzyme was susceptible to inhibition by the classical aspartic acid inhibitor, 
Pepstatin A (see Figure 1.4).®^  Second, the enzyme was irreversibly inactivated
= H 1! â
Figure 1.4. Pepstatin A.
by 1, 2-epoxy-3-(4-nitrophenoxy)propane (EPNP)®® (see overleaf, Figure 1.5) 
which was previously shown to inhibit pepsin by estérification of one or both of 
its active site aspartate residues.®® Third, site-directed mutagenesis of the 
active site Asp-25 to Asn-25 by Kohl et al. completely abolished enzyme 
activity.®^
OoN
Figure 1.5. EPNP.
Ultimately, elucidation of the crystal structure of both native HiV-1 protease®®’ ®®* 
®® and HiV-1 protease complexed with inhibitors (see section 1.4.8) confirmed 
the classification of this enzyme.
1.4.2 Structural properties.
Despite the notable DTG sequence conservation, the retroviral proteases 
were found to have significant structural differences to their mammalian and 
fungal counterparts. For instance, HIV-1 protease contains only 99 amino acid 
residues, compared to over 200 residues for the non-viral proteases. The non- 
viral proteases are monomeric and contain the DTG sequence twice in their 
sequence. These bi-lobai proteins contribute one aspartate residue per lobe to 
the active site. However, the DTG sequence only appears once in the HIV-1 
protease case. These observations led Pearl and Taylor ®1 to suggest that the 
catalytically active form of HIV-1 protease was in fact a homodimer, with each 
monomer contributing one of the two conserved aspartates to the active site. 
This prediction has since been borne out by crystaiiographic studies (see 
Figure 1.15, section 1.4.8). The solution of the three-dimensional structure of 
HiV-1 protease shows that the enzyme possesses a strict C-2 axis of symmetry, 
whereas the non-viral proteases have an approximate two fold axis. HiV-1 
protease contains two identical 'flap’ regions, analogous to the single flap found 
in the non-viral proteases, which form in part the substrate/ inhibitor binding 
sites. Another structural feature, which distinguishes the HIV-1 protease from 
the non-viral proteases, is that in ail structures of HIV-1 protease-inhibitor 
complexes solved to date, within the 'flaps’ is a water molecule which is 
hydrogen-bonded in a tetrahedral fashion to the amide hydrogens of ile-50 and 
lle-50’ residues in the flaps. This water molecule appears to play an important 
role in binding to both the flaps and inhibitor. The 0-2 nature of the enzyme and
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the flap water molecule have prompted investigation into selective inhibitor 
design for the HIV-1 protease and will be discussed fully in sections 1.4.6
(viii) and 2.6.2.
1.4.3 Preparation and purification.
An understanding of the protein chemistry and enzymoiogy of the HiV-1 
protease is an obvious prerequisite for inhibitor development and thus 
adequate amounts of HIV-1 protease are required. Although the natural source 
of HIV-1 protease is the virus itself, most researchers avoided this method of 
isolation. However, Liilehoj et a/, purified minute quantities of protease directly 
from the virus and lived to tell the tale.®® More popular methods of preparation 
include total synthesis and recombinant techniques. Schneider and Kent®® 
synthesised an enzymatically active 99-residue protease based on the 
sequence of HiV-1. Nutt et al.^^ also prepared HiV-1 protease by total synthesis 
using solid-phase peptide methodology and demonstrated that refolding of the 
poiyprotein yielded active enzyme that behaved as the expected dimer. Gel 
filtration chromatography confirmed the size of the protein by calibration against 
standard proteins. Many laboratories have cloned and expressed the HIV-1 
protease in bacteria®^» ®® and yeast.®® Expression in Escherichia coll of 
recombinant constructs containing the coding region of HiV-1 protease 
demonstrated that the enzyme is able to catalyse its own release from larger 
precursors. This may provide clues to the release of protease from the 
poiyprotein in the maturation step of the viral life cycle (see section 1.3.1 ).
A number of purification procedures have been reported, including affinity 
chromatography®^ and HPLC.®®
1.4.4 Substrate specificity.
The HiV-1 protease when processing the viral poiyproteins, and
Pri 60^^5 -^po/ is required to make highly specific cleavages. The cleavage sites 
of the HIV-1 protease within the gag and pol region are shown overleaf.
11
gag pol env
23 10 11
pi 7 p24 P7 p6
MA OA NC NC gpi20 gp41
PR RT RN IN
78
Pr^e0939-Pol
where MA = matrix protein 
CA = capsid protein 
p7 NC = nucieocapsid protein 
p6 NC = nucieocapsid protein
Pr = protease 
RT = reverse transcriptase 
IN = integrase 
RN = ribonuclease
The cleavage sites (*) of the HIV-1 protease within the Pr1605'a^-po/are as 
follows:
(P4)-(Pi)
1. Ser-Gln-Asn-Tyr
2 . Ala-Arg-Val-Leu
3. Ala-Thr-lle-Met
4. Pro-Gly-Asn-Phe
5. Ser-Phe-Asn-Phe
6 . Thr-Leu-Asn-Phe
7. Leu-Glu-Lys-Glu
8 . Ala-Glu-Thr-Phe
9. Arg-Lys-lle-Leu
(Pr)-(P4-)
Pro-ile-Val-Gln-
Ala-Giu-Aia-Met-
Met-Gln-Arg-Gly-
Leu-Gln-Ser-Arg-
Pro-Gln-lle-Thr-
Pro-lIe-Ser-Pro-
Pro-lle-Val-Gly-
Tyr-Val-Asp-Gly-
Phe-Leu-Asp-Gly-
The complete proteolytic processing of the PrSSS^^fl'and Pr^609^9-pol 
requires only eight discrete cleavages. However, the enzyme seems to tolerate 
a variety of amino acid residues in the P rP ^  cleavage sites (the Pp, P .^ 
terminology of Schechter and Berger^Q has been adopted and prescribes that
amino acid residues are numbered P^  P2  from the scissiie bond to the amino
terminus and P^ « Pg' from the scissiie bond towards the carboxy terminus).
Three of the cleavage sites (1, 5 and 6), consist of aromatic amino acid-proline 
residues and th is  type of cleavage site is indeed unique to
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r e t r o v i r u s e s / 0  Therefore inhibitors which incorporate these P rP r  residues 
may deemed to be specific for the retrovirus. The other cleavage sites show a 
general pattern for hydrophobic residues in the P -^P^* positions. Analysis of the 
proteolytic processing of HIV-1 protease led to the proposal that residues 
flanking the cleavage site could be assigned to one of three classes:
Class 1 contains Phe-Pro or Tyr-Pro at P^-Py.
Class 2 contains Arg at Pjand Phe-Leu at P^-Py.
Class 3 contains Gin or Glu at Pg-.
In an effort to further characterise the enzyme and to provide information 
required for 'first generation' inhibitor design, the substrate specificity of HIV-1 
protease was examined. Oligopeptides which incorporate the P^-Pr cleavage 
site were synthesised and an examination of the preferred residues spanning 
P4 -P 3 . were tested as substrates. Darke etaL showed that the HIV-1 protease 
was able to specifically cleave oligopeptides corresponding to all of the eight 
cleavage sites. Seven residues spanning P4-P3, were required for efficient 
cleavage at the P^-P^-amide bond. These findings are in agreement with 
crystallographic structures of HIV-1 protease-inhibitor complexes, where the 
enzyme may accommodate the equivalent of a heptapeptide, spanning the P4- 
P3. residues. The relative rates of cleavage for polypeptides containing the 
natural cleavage sites may reflect a regulatory role.^^ Systematic replacement 
of the residues in Ser-Gln-Asn-Tyr*Pro-lle-Val and Lys-Ala-Arg-Val-Leu*Ala- 
Glu-Ala heptapeptide substrates gave the following trends; (+) indicates a 
suitable residue and {-) indicates an unsuitable residue.
P3 Gin, Cys, Tyr, Arg, Val, Asn, Asp and Glu all (+); Pro {-).
Pg Val, lie, Leu, Phe, Ala, Asp and Asn all (+); Gly and Pro {-).
Pi Tyr, Phe, Met, Leu and norleucine all (+); Glu, Arg, lie and Val (-).
Pg. lie, Ala and Leu all {+); Trp, Phe and Gly (-).
These data are useful for medicinal chemists engaged in inhibitor design. 
Inhibitors could be derived from the known HiV-1 substrates, by incorporation of 
the preferred residues into the P4 -P3 , positions of the inhibitor. Replacement of 
the scissiie amide bond at P-i-Pf with non-hydrolysable isosteres which mimic
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the transition state or reaction intermediate of peptide cleavage can lead to tight 
binding inhibitors (see section 1.4.6 for a more detailed discussion).
The specificity of HIV-1 protease has also been studied in recombinant 
p r o te in s .43 Random mutagenesis of the Pi-P^« positions at the three gag-pol 
cleavage sites produced proteins which showed variable susceptibility to 
c ie a v a g e .4 4  Few or no changes were tolerated at the Pr-RT junction (site 6) and 
RT-iN (site 8 ); however the p6-Pr (site 5) accepted a variety of changes. 
Replacement of the natural Phe-Pro cleavage site with residues as diverse as 
Gly-His and Ala-lle resulted in processing equivalent to that of the natural 
substrate. Therefore the HIV-1 protease is not restricted to the eight substrate 
cleavage sites and so inhibitor design has greater flexibiiity in the choice of 
residues for the P^-Pf positions. For instance, it may be possibie to produce 
potent inhibitors that do not contain natural P^-Py residues. Other regions that 
proved sensitive to change included residues in the active site area (Aia22- 
Leu33) and flap region (Iie47-Gly52). From crystal structures of protease- 
inhibitor complexes it can be seen that residues in these regions form an 
extensive network of hydrogen-bonds with bound inhibitors. Presumably, the 
same type of hydrogen-bonding occurs in the case of substrates and so 
disruption of this bonding network would cause a loss in binding potential. A 
third region included residues Thr74-Arg87. Seiective modification of Arg-87 
and Asn-88 destabiiised the dimeric form of the protease and ied to enzyme
inactivation. 45
1.4.5 Catalytic mechanism.
The nature of aspartic protease catalysis has been widely studied over the 
years. The large amount of sequence homology amongst the mammalian 
aspartic proteases and the sensitivity to the same inhibitors, indicates that they 
operate via the same mechanism. Initially, it was proposed that the aspartic 
proteases operated via a covalent mechanism, in which one of the active site 
aspartates reacted with the substrate to form an enzyme bound covalent 
intermediate. Two variations of the covalent mechanism were proposed; the 
amino-enzyme m e c h a n is m 4 6  and the acyl-enzyme m e c h a n is m .4 7  These are 
outlined overleaf ( Figures 1.6 and 1.7).
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Figure 1.6. The amino mechanism where E represents enzyme.
NH-Y X NH-Y X
O - + HaN-YQ -  O- H I Ï  1 1
o^ E ' ^ O  o^ e ^ o
Figure 1.7. The acyl enzyme mechanism.
However, kinetic studies and examination of protease-inhibitor complexes 
has led to the proposal that the aspartic proteases operate via a general acid- 
general base mechanism, which involves both of the aspartates and a 
nucleophilic water molecule (Figure 1.8 ). The first key experiments to dispute 
the covalent mechanisms came from labelling studies. Antonovas carried out 
labelling experiments using Hg^^O as solvent and found that ^^0 -iabel was 
incorporated into uncleaved substrate. This could only be explained by a 
nucleophilic water mechanism.
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L==0
Asp 25
Asp 25'
Asp 25
Asp 25'
O
Asp 25 Asp 25’
Figure 1.8. The general acid-general base mechanism.
In this mechanism, the reaction intermediate is a gem diol, which collapses 
to form products as shown. However, the gem diol intermediate could collapse 
to reform the substrate. The ''^O-label would be incorporated into the gem diol 
from the solvent H2^^0 and on breakdown, the gem diol could produce ^^O- 
label incorporation into the carboxyl of the product or into the amide carbonyl of 
reformed substrate. Labelled substrate cannot be explained via a covalent 
mechanism, as hydrolysis of any enzyme bound covalent intermediate with 
H2‘’®0 , would result in ‘’^O-label incorporation into the active site carboxyls; this 
is not observed. The analysis of protease-inhibitor complexes Is consistent with
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a general acid-general base mechanism. Inhibitors which mimic the gem diol 
intermediate, bind to both catalytic aspartates, one of which is protonated and 
one is not.
By virtue of the fact that the HIV-1 protease belongs to the aspartic acid 
family, one would expect that this enzyme operates by the same mechanism, as 
outlined in Figure 1.8 . The key features of this mechanism are as follows; a 
water molecule is hydrogen-bonded to the Asp-25 and Asp-25’ residues, of 
which, one is protonated. Binding of the substrate facilitates general acid 
protonation of the scissiie amide carbonyl from Asp-25 and general base 
deprotonation of the lytic water molecule by Asp-25' to form the aforementioned 
gem diol tetrahedral intermediate. Synchronous deprotonation of one of the 
gem diol hydroxyls by Asp-25 and proto nation of the departing prolyl nitrogen 
by Asp-25’, renders the free carboxyl and amino fragments and restores the 
aspartyl residues to their initial protonation states.
Results from pH dependence studies of the kinetic constant K|  ^ for 
several oligopeptide substrates show a ‘bell-shaped’ curve over the pH range 
3.4-6.5 and indicate that an un protonated group of pKa 3.3 and a protonated 
group of pKa 5.5-6.1 are required for catalysis.^^ This is in agreement with the 
general acid-general base mechanism. However, the mechanism shown in 
Figure 1.8 , show only the main features. The position of the water molecule in 
the active site and the nature of the residues involved in catalysis have been the 
subject of debate. Several derivations of the general acid-general base 
mechanism have been proposed which share some central common features, 
such as the involvement of the aspartate diad and a nucleophilic water 
molecule. However, they differ in the following way:
i) the proposed protonation state of the tetrahedral intermediate,
ii) the timing of proton switches in the breakdown of this intermediate,
iii) the direction of binding of the scissiie carbonyl with respect to the aspartate 
diad and
iv) the nature of the Bronsted/ Lewis acid component.
For a more detailed account, refer to the mechanisms of James,^® Polgar,^^ 
P e a rl,® 2  Blundell®^ and Davies^. All of these mechanisms propose a gem diol/ 
gem diolate intermediate and so the use of transition state mimicry is valid for all
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cases. The nature of the gem diol could be investigated using both neutral and 
negatively charged transition state mimics. For instance, if the mechanism 
proceeds via a gem-diolate intermediate, negatively charged inhibitors would 
be closer mimics and so should bind more tightly. On the other hand, if the 
mechanism proceeds via a neutral gem diol intermediate, negatively charged 
inhibitors would be poorer mimics and so may bind less tightly.
1.4.6 Inhibition of the HIV-1 protease.
Due to its critical role in the processing of mature virus, the HIV-1 protease 
has become a popular therapeutic target for AIDS. Early efforts in inhibitor 
design were based on transition state m im ic ry .^ s  This involves replacement of 
the scissiie amide bond at P-|-P .^ with non-hydrolysable functional groups which 
mimic the gem diol tetrahedral intermediate for the enzymic reaction. By binding 
the transition state of a reaction tightly, enzymes can lower the activation energy 
of a reaction and thus, mimicking the transition state with non-hydrolysable 
isosteres should lead to tight binding inhibitors. This strategy has proven 
successful for inhibitors for the aspartic protease, renin, an important enzyme 
involved in blood pressure regulation.Exam ples of transition state analogues 
include reduced amides, statines, hydroxyethylenes, dihydroxyethylenes, 
hydroxyethylamines, difluoroketones and phosphinic acids, all of which are 
shown overleaf in Figure 1.9.
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Reduced amide
OH
HN
HN
Hydroxyethylene
OH
R O
Norstatine
HN
Hydrated difiuoroketone 
OH
Hydroxyethylamlne 
OH 
' ,H OH
Dihydroxyethylene
HN,
OH
"CHa
,CH
Staline
OH Hg
Phosphlnate
Hydroxyethylurea
Figure 1.9. Transition state mimics for the HiV- 1  protease.
Armed with the results from the study of renin inhibition and the fact that 
substrates of HIV-1 protease were known, rapid progress has been made in 
designing inhibitors for the HIV-1 protease. Incorporation of transition state 
mimics into substrates of HIV-1 protease has been successful in producing a 
variety of inhibitors. More significantly, the effectiveness of each transition state 
analogue has been compared. Dreyer e ta lF  incorporated each isostere into a 
Ser-Ala-Ala-Phe*Pro(Gly)-Val-Val-OMe substrate and found a wide range of 
inhibition (Kj= 62-19000 nM). These inhibitors can be ranked by potency in the 
order: reduced amide ((1) least potent) < phosphinic acid (2) < statine (3) < 
difiuoroketone (4) < hydroxyethylene ((5) most potent) (shown overleaf in 
Figure 1.10). These trends have been reported by other groups in which 
peptide analogues of different substrate sequences have been studied.^^» s8,59,
19
Sor-Ala-Ais*
H
(1)
N K| =  19000 nM.
Val-Val-OMe
SorAla-Ala
O
: ' 7 C T 'V al-V ai-O M eO OH 
(2 )
Val-V al-O M e
OH
(3)
V a l-V a l-O M eBoc-Ser-Ala-Ala
(4)
Ki =  4500  nM.
K  = 8 1 0 n M .
K) =  160 nM.
OH
(5)
Ki = 62 nM.
Figure 1.10. Comparison of dIpeptide isosteres within a single
peptide template.
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A closer examination of these transition state mimics may shed some light 
on the observed trends. Each class of transition state isostere will be 
considered individually.
(i) Reduced amides.
The reduced amide concept was used by Szelke et 61 to create potent 
inhibitors of renin. It was thought that the potency stemmed from an ionic 
interaction between the protonated secondary amine and the unionised 
aspartate in the active site. However, if true, this type of interaction cannot be 
considered to be one of transition state mimicry. It Is not clear why the reduced 
amides are less potent towards HIV-1 protease, although a recent study by 
Hyland et al. has shown that the pH dependence of a close analogue to (1 ) is 
consistent with binding of this cationic inhibitor to the protease only when both  
of the catalytic aspartates are unprotonated. However, at the pH optimum for the 
protease (pH 4.5-6.0), one of the aspartates is protonated. Considering the 
reduced amide isostere purely as a transition state mimic, may explain Its lack 
of potency. Although tetrahedral in nature, this mimic does not possess either 
oxygen (or equivalent heteroatom) of the gem diol intermediate and so 
interactions with the catalytic aspartates should be poor. Another reduced 
amide inhibitor based on the Phe-Pro cleavage site was synthesised by
Cushman etal.^^ A heptapeptide analogue, Thr-Leu-Asn-Phe-y-ICHgNJ-Pro-lle-
Ser was found to possess an IC50 of 1.4 |iM (IC50 -the concentration of inhibitor 
required to reduce enzyme activity by 50%). More significantly, it was found that 
the enzyme only bound the (2S)-phenyla!anine epimer, indicating the enzyme’s 
preference for the natural amino acid form. The (2R)-phenylalanine epimer was 
found to be inactive. A more potent reduced amide inhibitor is compound (6 ) 
which was derived from a substrate sequence which incorporates the p1-p7
cleavage site within the region. Replacement of Met at P^-Py with
norleucine led to a substrate whose K|  ^value is among one of the most 
efficiently processed substrates of the HIV-1 protease.^i Correspondingly, 
incorporation of this P-|-Pv site into compound (6 ) led to increased potency (Kj = 
780 nM).63
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Ac-Thr-lle
H
O
GIn-Arg-NHg
(6 ); Norleucine based Inhibitor (Kj = 780 nM).
Optimisation of the residues in the Pi-P^ sites can have a considerable 
influence on inhibitor potency. Urban and c o w o rk e rs ® ^  investigated the nature 
of the residues in the P^-Pg. regions and optimised their reduced amide
inhibitors. Their lead compound (7), Boc-Phe-xy-ICHgNHj-Phe-lle-Phe-OMe 
possessed a Kj value of 23 nM, considerably more potent than any other 
reported inhibitor from this class. However, changing the Phe at P^ to a Gly 
residue causes an approximate 70 fold decrease in potency, with Boc-Phe-\|/- 
[CH2NH]-Gly-lle-Phe-0 Me having a Kj value of 1650 nM. This result highlights 
the importance of the Py residue and may explain the lower potency of 
compound (1 ) In the study of Dreyer et a/.®^  In most cases, Phe-Phe at P^-Py 
produces more potent inhibitors than those based on Phe-Pro at PrP-i- This is 
unfortunate, considering that inhibitors based on Phe-Pro were hoped to show 
selectivity towards the HIV-1 protease.
OMe
(7); A potent reduced amide inhibitor (K; = 23 nM),
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Further optimisation of compound (7) at the P2- site produced Boc-Phe-\}/- 
[CH2NH]-Phe-Glu-Phe-OMe which gave a Kj value of 0.2 nM, the most potent of 
all the reduced amide inhibitors.
Although Dreyer’s initial study on the comparison of transition state 
analogues within a single peptide template provided a useful guide to potency, 
perhaps a study based on optimised inhibitors would provide a stronger basis 
for direct comparison. The study of Urban clearly shows the sort of effect that 
optimisation in the P1-P3- region can have. When comparing transition state 
analogues within unoptimised inhibitors, especially in the P^-P^, region, it is 
difficult to tell whether the observed lack of potency is due to the transition state 
analogue or the lack of optimisation. By studying optimised inhibitors there can 
be no doubt.
(ii) Phosphinic acids.
Bartlett and Kezer®® designed phosphinic acids as inhibitors of the aspartic 
protease, pepsin. These inhibitors are amongst the most potent compounds 
reported for pepsin. The phosphorus atom provides the correct tetrahedral 
geometry and two oxygen atoms and so would be expected to be a good mimic 
of the gem diol intermediate. However, incorporation of the phosphinic acid 
moiety into an HIV-1 protease substrate gave compound (2) (see Figure 1.10),
a moderate inhibitor (Kj = 4.5 pM). However, it must be noted that compound (2) 
is unoptimised in the Py region. The poor inhibition of these compounds may be 
due to their anionic nature at the assay pH (6.0). The pKa of phosphinic acids®® 
generally fall in the range 3.0-3.5 and so at the assay pH would be negatively 
charged. Literature precedent®^ indicates that a negatively charged species 
should be repelled by the negatively charged aspartate in the active site. The 
fact that phosphinic acids are potent inhibitors of pepsin may be due to the fact 
that pepsin exhibits maximum enzymic activity at a lower pH (< 4.0), at which a 
larger proportion of the inhibitor would exist in the neutral form. pH Dependence 
studies of a variety of phosphinic acids show the enzyme's preference for the 
unionised form. The optimisation of these compounds was undertaken by 
Grobelny et a/,®® who demonstrated that tetrahedral phosphinates incorporated 
into peptides spanning P2-P3’ function effectively as highly potent inhibitors of 
HIV-1 protease. As in the reduced amide case, affinity for the enzyme was
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sensitive to substitution at the P-j and P^’ sites with the Phe-Phe isostere 
providing superior binding to its Phe-Pro counterpart (see compounds (8) and 
(9) below). Phe-Pro isosteres were poor inhibitors, confirming earlier reports.®^ 
The binding affinity of phosphlnate inhibitors was also sensitive to pH; a 500- 
fold increase in affinity was observed for some compounds as the pH was 
lowered from 6.5 to 4.5, thereby neutralising the charged phosphlnate.
Ph
pH
.Val-Val-NHBz
Ph
(8 ); Possessing a Kj value of 0.6 nM at pH 4.5.
^al-Val-NHg
(9); Possessing a Kj value of 450 nM at pH 4.5.
However, this type of pH dependence is not definite. Recent results from 
Abdel-Meguid etal.^^ have shown potent inhibition with symmetrical phosphinic 
acids at pH 6.0, where the ionised form would exist. This suggests that either 
the intrinsic Kj is very small (picomolar) or that the ionised form is indeed a 
potent inhib itor. Their analysis of the pH dependence of Kj fa iled to 
unambiguously answer these questions, due to the similarity in pKa values of 
their inhibitor (pKa 3.1) and the active site aspartate residue (pKa 3.1-3.3) that 
must be protonated for an inhibitor to bind to HIV-1 protease. However, their 
crystallographic results suggest a protonated phosphlnate in the enzyme 
complex.®®
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(iii) Statines and norstatines.
The natura l product pepstatin (see Figure 1.4) conta in ing  the 
hydroxymethylene isostere (statine), helped to classify the HIV-1 protease as an 
aspartic protease. Pepstatin is a highly potent inhibitor of the mammalian 
aspartic proteases, often giving Kj values in the low nanomolar range. Pepstatin 
led the way in the search for aspartic protease inhibitors. The tetrahedral 
hydroxyl bearing carbon is the potent part of the inhibitor and is believed to 
have a dual role. First, the hydroxyl mimics to some extent the gem diol 
intermediate and second, it has been proposed^® that the statine group may act 
as a ‘bisubstrate’, in which the binding sites of both the substrate and the 
nucleophilic water molecule are occupied. Structural analyses of aspartic 
protease-inhibitor complexes support these th e o r ie s .^ h  72 Pepstatin A, is only a 
moderate inhibitor of HIV-1 protease (Kj -  IjiM ). Incorporation of the statine 
moiety into an HIV-1 protease substrate gave compound (3) which possesses a 
Kj value of 0.81 pM. This is a surprising result considering that the residues in 
pepstatin are not optimised for the HIV-1 protease and yet pepstatin is 
approximately equipotent to the substrate analogue. Richards et al7^ reported 
that acetyl pepstatin, (see below compound (1 0 )) is significantly more potent 
towards the HIV-1 protease (Kj = 20 nM). A seventy fold increase in potency for 
a simple modification to the P4 residue is incredible, considering that the acetyl 
group is far removed from the active site.
" Î  Y  H 2“ f  H OH O
(10); Acetyl pepstatin (Kj = 20 nM).
The norstatine based inhibitors incorporate the (hydroxymethyl)carbonyl 
isostere (see Figure 1.9). Mimoto etal7^ reported potent inhibitors based on the 
Phe-Pro cleavage site. Their lead compound incorporated the unnatural amino
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acid, phenylnorstatine ((2R,3S)-3-amino-2-hydroxy-4-phenylbutyric acid). 
However, the (2S,3S)-epimer was found to be 20 times more potent, showing a 
preference for (S)-stereochemistry at the hydroxyl bearing carbon. This 
allophenylnorstatine derivative (compound (11)) gave a Kj value of 5 nM.
Ser-Phe-Asn — N Pro-lle-Val-NHa
OH
(1 1 ); Allophenylnorstatine based inhibitor (K; = 5 nM).
Krantz etalJ^  optimised their norstatine based inhibitors and produced their 
most potent inhibitor, compound (12), which gave a Kj value of 0.58 nM. The 
most active epimer also possesses the (S)-configuration at the hydroxyl bearing 
carbon.
o*^ \ nh -^ Bu
(12); Highly potent norstatine based inhibitor (Kj = 0.58 nM).
Optimisation of the Pg residue was achieved using a (naphthyloxy)acetyl 
protecting group on the N-terminus. This type of unnatural amino acid analogue 
has become increasingly popular in inhibitor design. Often an increase in 
potency over the natural amino acids can be achieved. Second, these 
unnatural amino acid residues are often proteolytically stable and are therefore 
less susceptible to metabolic degradation. In some cases these residues 
improve solubility as well. Both of these factors are important in drug delivery.
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(iv) a-a-Dlfluoroketones.
a-a-Difluoroketones are potent inhibitors of several classes of enzymes by 
virtue of their propensity to form hydrates (see Figure 1.9), which converts the 
sp2 hybridisation of the carbonyl to sp^. In principle, these hydrates should be 
excellent mimics of the enzyme-generated tetrahedral intermediate. This is 
borne out by the finding that these compounds are very potent inhibitors of 
pepsin and renin.^®- ^7 was found that incorporation of the difiuoroketone 
moiety into an HIV heptapeptide substrate gave compound (4) possessing a Kj 
value of 160 nM. Sham et al7^ optimised the P .^ position with a phenylethyl 
substituent. Compound (13), although smaller than compound (4), gave an IC50 
value of 1.0 nM.
Obz-Gly-Vcil —  N
(13); Possessing an ICgq value of 1.0 nM.
An extremely potent difiuoroketone inhibitor was synthesised by Sham e t 
al7^ Compound (14) below gave a Kj value of 0.1 nM. An interesting feature of 
this compound is that it is almost symmetrical.
Ph
N—Val-Cbz
Cbz-Val— N
Ph
(14); Symmetry-based difiuoroketone (K; = 0.1 nM).
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These type of C- 2  symmetric inhibitors complement the C- 2  homodimeric 
nature of the HIV-1 protease and represent an important advance in the 
development of inhibitors for this enzyme. For instance, their selectivity for HIV-1 
protease over the momomeric aspartic proteases should be greatly enhanced. 
(For a fuller discussion of the C-2 symmetric inhibitors see section 1.4.6 (viil)).
(v) Hydroxyethylamines.
The hydroxyethylamine moiety has produced some of the most potent HIV-1 
protease inhibitors to date. Unlike most of the previously mentioned transition 
state analogues (with the exception of the reduced am ides), the 
hydroxyethylamlne group accommodates the incorporation of proline or its 
analogues into the inhibitor, thus allowing the scissiie Phe-Pro bond to be 
replaced more exactly. However, the mimicry is not exact, as an additional 
methylene group is required for stability. Roberts and co-workers®® (Roche, UK) 
reported the following compound (15) (Ro 31-8959) as an extremely potent 
inhibitor of HIV-1 protease with a Kj value of 0.12 nM. The preferred absolute 
configuration at the hydroxyl bearing carbon is (R). The norstatine based 
inhibitors (see compound (1 2 )) show an identical preference for the relative 
stereochemistry of their hydroxyls, although, due to priority differences, their 
hydroxyls are assigned the (S)-configuration. The decahydroisoquinoline 
moiety contributes considerably to the potency of this compound, the 
corresponding derivative containing a prolyl group in this position is more than 
50-fold less potent. This trend is reversed in the case of the norstatines^® and so 
the conformation of the prolyl residue may be an important recognition element 
for the enzyme. The extra CH2 in the hydroxyethylamine inhibitors will obviously 
alter the conformation of the prolyl residue, whereas the amide prolyl in the 
norstatine inhibitors is closer in representation to the prolyl residue in a Phe-Pro 
substrate.
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H
N
OHO
CONH
(15); Ro 31-8959, a highly potent inhibitor (K j=  0.12 nM).
Roche were the first to incorporate unnatural amino acid residues into their 
design for HIV-1 protease inhibitors. Ro 31-8959 incorporates a quinoline 2- 
carbonyl protecting group as a P3 substituent and the aforementioned 
decahydroisoquinoline moiety. Both of these residues contribute to the potency 
of this inhibitor, which is still amongst the most potent inhibitors of viral infectivity 
and is currently being evaluated in a clinical setting. Many of the recent 
inhibitors have been derived from this leading compound.
In contrast to the preference for the (R)-configuration for the hydroxyl bearing 
carbon in compound (15), Rich etal.^^ found a preference for the (S)-epimer In 
a series of hydroxyethylamine inhibitors. In compound (16), the (S)-epimer (Kj = 
0.24 nM) was found to be 80-fold more potent than the (R)-epimer. However, it 
was found that when inhibitors lacked the Pg» substituent the (R)-epimer was 
more active than the (S)-epimer:
p,. Pg,
Cbz-Asn-Phe-\j/ICH(OH)CH2N]-Pro-0  tBu. 
Cbz-Asn-Phe-Y[CH(OH)CH2N]-Pro-0 %u.
IC50 = 450 nM (S)-hydroxyl
ICso= 51 nM (R)-hydroxyl
These results show that the substituents in the P4-P3’ positions have a major 
influence on the binding of hydroxyethylamine inhibitors. There is a shift in 
preference from the (R)-epimer in smaller inhibitors to the (S)-epimer in longer 
inhibitors.
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OH
Ac-Ser-Leu-Asn—N
lle-Val-OMe
(16); (S)-Epimer (K, = 0.24 nM).
Merck (USA) have made an outstanding contribution to the development of 
HIV-1 protease inh ib ito rs. Tucker et reported an optim ised 
hydroxyethylamine inhibitor based on the Phe-Phe cleavage site. Compound 
(17) (Kj value of 5 nM) incorporates the quinoline 2-carbonyl Pg substituent and 
a chiral aminohydroxyindanol moiety as a Pg- substituent in an effort to increase 
potency.
CONHo
(17); Phe-Phe based hydoxyethylamine inhibitor (Kj = 5 nM).
In an effort to develop the HIV-1 protease inhibitors as potential drugs, 
researchers have begun the search for lower molecular weight, non-peptidic 
inhibitors (see section 1 .4 .7  for a discussion on the problems associated with 
peptide-based drugs). With this goal in mind, medicinal chemists have begun 
the search for ligands that show comparable potencies to their peptide-based 
counterparts. Two recent reports highlight the progress already being made in 
this area. Ghosh at a/.^s have replaced the Pg and Pg residues in the Ro 31- 
8959 inhibitor by a single cyclic sulfolane residue. The conformationally
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restricted c/s-2 -isopropylsulfolane ligand in compound (18) succeeds in 
producing a highly potent inhibitor (Kj value of 3 nM).
OHH
N
(18); Possessing a sulfolane ligand (K; = 3 nM).
One explanation for the observed potency is that the sulfolane oxygens are 
making specific interactions in the Sg binding domain, in a similar fashion to the 
hydrogen-bonding normally observed between the primary amide oxygen of the 
asparagine side chain and the NH residues of Asp-29 and Asp-30 in the S2 
subsite. Thompson et a l.^  (Merck, USA) replaced the P2 Asn residue in Ro 31- 
8959 with a chiral tetrahydrofuranylglycine (Thfg) ligand. An IC50 value of 0.054 
nM was achieved for compound (19), the inhibitor derived from the (2S,3’R) 
ligand, showing four times the potency of Ro 31-8959.
OH
(19); incorporating the (3’R)-Thfg iigand (iCgo = 0.054 nM).
In contrast, the inhibitor incorporating the (28,3’S) Thfg ligand was 100-fold 
less potent than compound (19). This strong stereochemical preference 
supports the aforementioned hydrogen-bonding phenomenon as an important
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factor for ligand binding in the Sg subsite. A recent structure activity study of 
inhibitors incorporating these novel Pg ligands as well as a novel pyramizine 
amide Pg ligand has produced a number of subnanomolar inhibitors.®^
(Vi) Hydroxyethylenes.
To date, the hydroxyethylene isostere has been the most extensively utilised 
moiety in the design of HIV-1 protease inhibitors. Incorporation of the 
hydroxyethylene isostere into a heptapeptide analogue by D reyer,produced 
compound (5), the most potent inhibitor in the series (Kj value of 62 nM). Unlike 
statine based analogues, compound (5) and the hydroxyethylene series in 
general, preserve the atomic spacing of the dipeptide backbone. Compound (5) 
is an isosteric replacement for the dipeptide Phe-Gly. The stereochemical 
configuration of the 4-hydroxyl group is crucial for potent inhibition with the 
(4S)-epimer of compound (5) being 80 times more potent than the (4R)-epimer. 
Removal of the N-terminal in compound (5), led to an increase in affinity with
Ala-Ala-Phe-\|/[CH(OH)GHg]-Gly-Val-Val-OMe possessing a Kj value of 18 nM. 
Considering that Phe-Gly is not a characteristic cleavage site for the HIV-1 
protease, these compounds provide promising leads. One drawback for this 
series is that exact mimics of the Phe-Pro cleavage sites cannot be achieved. 
Incorporation of a proline residue at P^ would produce an amino-hemiacetal 
which would probably decompose in solution to produce an enamine (see 
below, Figures 1.11 and 1.12.).
Figure 1.11. Amlno-hemlacetai.
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OH
Amino-hemiacetal
OHc
Enamine
Figure 1.12. Probable fate of an amino-hemiacetal in solution.
However, Dreyer et a lP  used a frans-cyclopentyl ring as a proline mimic in 
the Py position. Compound (20) was found to be a moderate inhibitor of HIV-1 
protease (Kj = 500 nM).
Val-Val-OMeOH
O
(20); Phe-Pro mimic (K; = 500 nM).
The synthesis of two similar analogues based on Leu-Pro (Rich et and 
Tyr-Pro (Thompson et a/.)^^ have also been reported with the latter analogue, 
possessing an IC50 value of 110 nM. No biological data was given for the Leu-
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Pro analogue.
McQuade et a lP  (Upjohn, USA) reported the pentapeptlde inhibitor, 
compound (21) (Kj value of 70 nM), which incorporated the cyclohexylalanine- 
Val isostere. Cyclohexylalanine (Cha) residues are good replacements of Phe 
at Pi and our own inhibitors have successfully incorporated the Cha residue in 
this position.
(21); Cha-Val hydroxyethylene inhibitor (K; = 70 nM).
Aminomethylpyridine is a popular residue in the Pg. position, providing a 
proteolytically stable C-terminus. Other optimised inhibitors include those based 
on the Phe-Phe cleavage site. Lyle et a fP  (Merck, USA) developed the 1- 
amino-2 -hydroxyindan (previously shown in compound (17)) ligand as an 
effective surrogate for the residue and produced subnanomolar inhibitors 
that span only the P2-P2’ subsites. The hydroxyl group in the indan appears to 
replace the Pg- oxygen carbonyl in a critical hydrogen-bond to the enzyme. 
Compound (22) possesses an IC50 value of 0.3 nM.
H OH
(22); Highly potent pentapeptlde inhibitor (ICgg = 0.3 nM).
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Vacca et a/.^° (Merck, USA) produced compound (23) which Incorporates a 
styrene residue at P-j* and an aminobenzimidazole moiety at P2'. This 
compound is one of the most potent inhibitors of HIV-1 protease to date, giving 
an IC50 value of 0.03 nM.
Ph
OH
Boo—NH
Ph"
(23); The most potent inhibitor of HlV-1 protease to date.
These latter examples demonstrate that small, but potent, HIV-1 protease 
inhibitors of minimal peptide character are achievable. A significant amount of 
structure activity relationship data has now been compiled and many optimised 
hydroxyethylene inhibitors now exist. 92,93,94,
(vii) Modified hydroxyethylenes.
There have been several reports of inhibitors containing modified 
hydroxyethylene isosteres. Thaisrivongs and Ashorn efa/.^s, 96, (Upjohn, USA) 
have incorporated the dihydroxyethylene isostere (see Figure 1.9) into a series 
of inhibitors, of which compound (24), a Cha-Val analogue was the most potent 
in the series (Kj value < 1 nM). Compound (24)  also c p jta in s  the 
naphthoxyacetyl (Noa) protecting group, which contributes to the potency of this 
inhibitor. More recently, an extensive structure activity study has been reported 
by the same researchers.^^
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OH O
N o a -H is -N
OH O
(24); Dihydroxyethylene Inhibitor (Kj value < 1  nM).
Getman et al.^^ (Monsanto, USA) incorporated a hydroxyethylurea isostere 
into a series of compounds (see Figure 1.9). Compound (25) was found to be 
the most potent inhibitor in the series, possessing an IC50 value of 3 nM. This 
inhibitor has similar features to Ro 31-8959 and shows the same preference for 
the (R)-configuration at the hydroxyl bearing carbon.
H
N
N
H
OH
CONH
H
(25); Hydroxyethylurea inhibitor (IC5 0  = 3 nM).
Sham eta!.^^ (Abbott, USA) have incorporated novel substituted hydrazines 
into a series of compounds and the Phe-Phe mimic, compound (26) produced 
an IC50 value of 5 nM.
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N
H
O H
(26); Incorporating a substituted hydrazine (IC5 0  = 5 nM).
Finally, Ghosh et (Merck, USA) reported the stereoselective synthesis 
of a novel dipeptide mimic and its conversion into a potent HIV-1 protease 
inhibitor. Compound (27) possesses an IG50 value of 3 nM and shows a 
preference for the (S)-configuration at the hydroxyl bearing carbon.
O H
NH
N —  C bzNH
0  =
(27); Possessing a novel dipeptide Isostere (iCgg = 3 nM).
These last three examples show the very subtle changes being made by 
medicinal chemists in order to transform such molecules into prospective 
therapeutic agents.
(viii) 0-2 Symmetric inhibitors.
The high degree of symmetry of the HIV-1 protease prompted Kempf and co- 
workers^oT 102 (Abbott, USA) in the design of 0-2 symmetric inhibitors. They 
postulated that inhibitors based on symmetry might provide improvements over
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traditional substrate-based inhibitors in terms of potency, specificity and 
reduced peptide character. For instance, symmetrical inhibitors should show 
selectivity for retroviral proteases as the active site of the mammalian aspartic 
proteases are less symmetric. The design of these inhibitors was achieved via  
an examination of the tetrahedral intermediate of peptide cleavage (see below).
(i) Placement of a C-2 axis of symmetry through the tetrahedral gem diol carbon 
led to the core structure (A).
(ii) Dissection of the scissile amide bond with a C-2 axis provided the diol (B).
(iii) A two fold rotation of the remaining N-terminus provides core structures (A) 
and (B) respectively (see below, Figure 1.13).
H HQ .OH
Pb
C2Pi P
OH
H NH
Ph‘ Ph
(A)
, N ^
Ph
Pi
o h v  y HO OH 
H2N . ^ ^ J  L  ,NH.
P h ' Ph(B)
Figure 1.13. Design of 0-2 symmetric Inhibitors.
Extension of these core structures with suitable peptide residues resulted in 
nanomolar or subnanomolar inhibition. Compound (28) was derived from the
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core structure (A) and possesses an IC5 0  value of 3 nM.
OH
Cbz— N N— Cbz
(28); C-2 Symmetric inhibitor (iCgg = 3 nM).
An identical Cbz-Val extension of core structure (B) produced a compound 
possessing an IC50 value of 0.22 nM. Interestingly, this diol was not highly 
sensitive to the stereochemistry of the hydroxyls with the (3R,4R)- and (3R,4S)- 
e pi mers being equipotent. Recently, both classes of inhibitor have been the 
subject of an extensive structure activity study and the same researchers have 
produced a large number of subnanomolar inhibitors."*^^ Compound (29) 
(A-77003) provided the best balance of activity and so lubility  and is 
subsequently under clinical development (IC50 < 1 nM).
PhOH
N-ValCHg
OH
Ph'
(29); (A-77003) C- 2  Symmetric diol (IC5 0  < 1 nM),
The work of Kempf and colleagues has prompted the synthesis of C-2 
symmetric inhibitors of a variety of other transition state analogues. These 
include phosphinic a c i d s , d i f l u o r o k e t o n e s , ^ ^  sulfides, sulfoxides and 
sulfones and dihydroxyethylenes. Several elegant syntheses of symmetrical 
dihydroxyethylenes have been reported starting from D -m a n n ito l .^ ° G ,  107 
However, no inhibition data has been reported for this symmetrical class of
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inhibitor so far.
(ix) Non-peptide based Inhibitors.
To date, very few non-peptide inhibitors of HIV-1 protease have been 
reported. The antifungal antibiotic cerulenin, compound (30) was found to be a 
weak inhibitor of HIV-1 protease (IC50 = 2.5 mM). ‘'o®
(30); Antibiotic cerulenin (iCgq = 2.5 mM).
The chemical mechanism of inactivation of HIV-1 protease by cerulenin has 
not yet been elucidated, although a mechanism involving estérification of one of 
the catalytic aspartates by reaction with the epoxide is a possibility. Desjarlais 
ef have used a structure based, molecular modelling approach to discover 
novel inhibitors of HIV-1 protease. Compounds are docked into the active site of 
the enzyme and their steric complementarity with the three-dimensional 
structure of the active site is assessed. This method identified haloperidol,
compound (31) as a weak inhibitor of the enzyme (K; value of 100 jiM). This 
technique should prove very useful in uncovering novel 3D pharmacophores 
from which inhibitors can be designed and synthesised.
Cl
HO
(31); Haloperidol identified from a crystailographic data base
(Kj = 100 pM).
A penicillin derived symmetrical dimer has been reported recently by
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Humber and c o - w o r k e r s A s  an alternative to peptide-based inhibitors they 
embarked on a screening program in order to identify novel inhibitors for the 
HIV-1 protease. A crude sample of a penicillin dimer was shown to be active. 
However, when the sample was purified, the main component was inactive. The 
active component was shown to be a diester which was derived from the
opening of the p-lactam ring of the peniciliin dimer. By reacting the dimer with 
appropriate amines a series of active compounds were produced of which 
compound (32) was the most active (IC50 value of 0.9 nM).
NH
Ph
HN
CONHCH.
(32); A penicillin derived symmetrical dimer (IC5 0  = 0.9 nM).
Various other non-peptide inhibitors of the HIV-1 protease have been reported 
including carboxylates,^^^ didemnaketals,^^^ flavones,^^^ poronated porphyrins 
ii4&nd most recently even fullerene derivatives!^
1.4.7 Effects of inhibitors against HIV-1 infected cell culture.
The Kj and IC50 values of all of the inhibitors mentioned so far are 
indicative of their effect against the HIV-1 protease in an in vitro assay. 
Therefore factors such as celi uptake and metabolic degradation do not need to 
be considered and these values provide an indication of affinity for the enzyme. 
These initial assays can identify potential problems such as aqueous 
insolubility. A more realistic guide to an inhibitor's potential as a therapeutic 
agent is provided in an in vivo or viral assay. In the case of the HIV-1 protease, 
the inhibitor is tested in two differing ways. First, the direct observation of 
inhibition of HIV-1 protease in chronically-infected T-lymphocytes is realised by 
treatment of the infected cell culture with inhibitors for a 24-48 hour period prior
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to examination of the extent of processing of the viral polyproteins. The viral 
polyproteins are isolated by immunoprécipitation and the extent of polyprotein 
processing is determined by gel electrophoresis. The second type of study 
involves acute infection of virus-naive T-lymphocytes. Inhibitors and infected 
virus are added simultaneously and after several days, the extent of viral 
inf activity is determined by the quantification of three parameters: p24 gag  
antigen and reverse transcriptase activity released into the medium and the 
population of syncytia, the multi nuclear giant T-lymphocytes that form during the 
infection period.
Both the chronic and acute infection assays were conducted on the 
hydroxyethyiene inhibitors. Compound (5) and similar hexa and heptapeptide 
analogues were found to block Pr553^d and Pr160^^5^"P°/ processing in 
chronically-infected T-lymphocyte cultures and prevented the spread of HIV 
infection in lymphoid cell lines at 25-100 jiM.''"'® It should be noted that these 
values are representative of a particular strain of virus and the same inhibitors 
may have differing activities against other strains and so direct comparison of 
antiviral data is difficult. However, these antiviral results show significantly 
higher iCgo values than the in vitro results and indicate poor celi uptake, poor 
solubility or metabolic degradation of the inhibitors. As mentioned earlier, these 
problems are of particular concern for peptidic inhibitors. In fact, peptidic 
inhibitors longer than hexapeptides are generally inactive when tested against 
infected cells. For instance, compound (16), an octapeptide analogue (K; = 0.24 
nM) was found to be inactive at concentrations >10 |iM i.e 40,000 times the Kj 
value.
Physical evidence for the effect of inhibitors comes in the form of electron 
microscopy. This technique has revealed that the virion particles produced by 
the inhib itor-treated lymphocytes contained apparently defective core 
structures; virions possessing “crescent-shaped” cores were preponderant 
while virions containing mature (see Figure 1.1), bullet-shaped cores 
represented smaller p o p u l a t i o n s . ^ 7^, 118
Inhibitors with decreasing peptide character have shown increasing antiviral 
activity. Compound (21 ) (Kj -  70 nM) was found to have an ICyg value of 1 |xM in 
an antiviral assay.®® The dihydroxyethylene inhibitor, compound (24) (Ki < 1 
nM) gave an IC-ioo of 1 |iM in a similar assay and showed an equivalent potency
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to AZT.95 Compound (23) (Kj = 0.03 nM) and compound (22) (Kj = 3 nM) gave 
IC-ioo values of 12 nM®° and 200 nM®® respectively, highlighting increasing 
antiviral activity for smaller, less peptidic inhibitors. The C-2 symmetric 
inhibitors, compounds (27) and the equivalent diol analogue produced ICgo 
values of 400 nM’'®^  and 20 nM^®2 respectively. The hydroxyethylamine 
inhibitor, compound (15) Ro 31-8959, is one of the most potent inhibitors of 
antiviral infectivity to date (IC50 = 2 nM) and is currently being evaluated in a 
clinical setting. The remaining task is to convert potent antiviral inhibitors into 
safe, effective drugs for human administration.
1.4.8 Structural aspects of HIV-1 protease and its enzyme-inhibitor 
complexes.
Determination of the crystal structure of native HIV-1 protease confirmed the 
homodimeric architecture of the enzyme, with each monomer related to each
other by a 2-fold rotation. The protein contains a p-sheet structure, similar to that 
found in mammalian and fungal proteases.^^® The active site triad Asp-25-Thr- 
26-Gly-27 occurs within a loop that forms a number of hydrogen-bonds with the 
corresponding loop of the other monomer in a fashion often described as the 
"fireman's grip".^^® The "fireman's grip" is a characteristic of the aspartic 
proteases and its effect within pepsin is shown below (Figure 1.14). The HIV-1 
protease also contains two identical “flap" regions (see overleaf. Figure 1.15) 
which move as much as 7 A upon binding of an inhibitor.®®
Asp-215
CHq Thr-216
%  CH2CO2H I
CHgCOgH
Asp-32
y*— 9 ^  nThr-33 H3C'
Figure 1.14. The “fireman’s grip” in pepsin.
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Figure 1.15. Overall fold of llganded HIV-1 protease.
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The crystal structures of enzyme-inhibitor complexes have provided vital 
information to medicinal chemists involved in inhibitor design. Structures of the 
HIV-1 protease complexed with four inhibitors that differ in terms of structure 
and potency have been reported. These include acyl pepstatin (1 0 ), 2^1 the 
reduced amide (6),®  ^ the hydroxyethylamine (16)^22 and the C-2 symmetric 
inhibitor (28).'*02 These inhibitor structures share several common attributes. 
Compounds (10), (16) and (28) all possess a secondary alcohol group and in 
all structures this hydroxyl group is positioned equally among the four oxygen 
atoms of the catalytic aspartates. This suggests that other substituents of these 
inhibitors may be of secondary importance and may explain the lower potency 
observed for classes of inhibitor which do not contain such a hydroxyl or 
hydrogen-bond donating species. One striking feature of all four inhibitor 
complexes is a tightly bound water molecule that bridges the two enzyme flaps 
to the inhibitor through hydrogen-bonds formed by the lle-50/ lle-50’ amide 
hydrogens and the Pg and Py carbonyl oxygens of the inhibitor. Other crucial 
hydrogen-bonds include the P2 / P-i and P y / P2' amide hydrogens of the 
inhibitors to the carbonyl groups of Gly-27 and Gly-27’. All of these important 
hydrogen-bonding interactions are shown schematically in Figure 1,16.
The presence of the flap water molecule and the symmetrical nature of the 
enzyme provide features which can be exploited in selective inhibitor design. 
Swain et a/.^23 suggested that it should be possible to develop such inhibitors 
which incorporate these structural details. For instance, compounds which 
interact with or dislodge the water molecule should provide highly potent, 
specific inhibitors for the enzyme. With this objective in mind, we are currently 
investigating two types of novel non-peptidic inhibitors, which will be discussed 
in section 2.6.2.
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Asp 29' G ly27
Asp 25’ Asp 25 N
9 y ^ ? ° ~ ^  T  HI Cl • /  r\ Q !
Gly 48' Gly 48
e 50
-N
lie 50’ \
Figure 1.16. Key hydrogen-bonding interactions between the HiV- 1  
protease and a hydroxyethyiene inhibitor.
1.4.9 Summary.
The development of inhibitors for the HIV-1 protease has escalated over the 
last few years. Armed with the known substrate sequences of the HIV-1 
protease and the results from renin inhibition, medicinal chemists rapidly 
synthesised a range of classical transition state analogues, exemplified by 
compounds (1 -11). These compounds provided the hydroxyethyiene, 
hydroxyethylamine and the dihydroxyethylene isosteres as potent inhibitors for 
the enzyme. However, as the lesson of renin inhibition had shown, the use of 
peptidic analogues as drugs was p r o b l e m a t i c . ^23,124 First, these compounds 
are generally too large and are therefore prone to rapid elimination from the 
body by hepato-biliary extraction. Due to their abundance of peptide bonds, 
these inhibitors are prone to metabolic degradation by a host of the body’s own 
proteolytic enzymes and so have a short duration of action. These compounds 
show poor aqueous solubility which contributes to their low oral bioavailability. 
Therefore, medicinal chemists are faced with the challenge of transforming 
these compounds into therapeutically useful agents. Researchers have already 
begun the task of replacing the peptide residues with low molecular weight 
ligands of equal or greater potency. Fortunately, the HIV-1 protease is
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accommodating to a wide variety of residues and so this provides more 
flexibility in ligand design. Molecular modelling and the study of enzyme- 
inhibitor complexes has enabled the discovery of a number of novel ligands, 
some of which have been extremely successful in producing highly potent, 
small, minimal-peptide inhibitors. Compounds 17 ,18 ,19 ,2 2  & 23 are perfect 
examples. Compounds 25-27  highlight the subtle changes being made in 
order to improve the pharmacokinetics of these inhibitors. It remains to be seen 
if these changes are successful.
The work of Kempf and colleagues has provided an alternative direction in 
the design of novel inhibitors for the HIV-1 protease. These inhibitors, designed 
from the unique architecture of the enzyme offer selectivity over the mammalian 
aspartic proteases. Optimisation of these compounds has produced inhibitors 
with increasing activity towards viral infectivity.
From searches of crystailographic data banks, several non-peptidic 
inhibitors of the HIV-1 protease have been discovered. At present, this 
technique has only unmasked weak inhibitors for the enzyme, although the 
discovery of more potent leads is imminent. An alternative to random searching 
is one of computer aided design. With the key features for inhibitor potency 
being a preference for a hydroxyl bearing carbon to interact with the catalytic 
aspartates and a liking for Phe mimics at both and P .^, novel non-peptide 
structures can be studied which incorporate these functionalities. Used in 
conjunction with the X-ray data from enzyme-inhibitor complexes, the important 
hydrogen-bonding interactions can be maintained and optimised.
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CHAPTER TWO
RESULTS AND DISCUSSION
2.0 Results and discussion.
2.1 Design of HiV-1 protease inhibitors.
In a continuing search for therapies for AIDS the HIV-1 protease, a member 
of the aspartic protease family, has been identified as a promising target. 
Protease activity is vital for maturation of the virus and several approaches have 
been used to produce inhibitors, based upon substitution of the scissile amide 
bond of HIV-1 protease substrates with non-cleavable analogues.^^
We chose to employ the phosphonamidate moiety as a transition state mimic 
due to its very close electronic and geometric resemblance to the tetrahedral 
transition state/ high energy stable intermediate for peptide bond cleavage, see 
below (Figure 2.1).
PH
Tetrahedral intermediate Phosphonamidate
Figure 2.1.
The phosphonam idate moiety fu lfils  many of the trans ition  state 
requirements. For instance, this moiety provides the correct tetrahedral 
geometry, whilst providing both oxygen atoms of the gem diol tetrahedral 
intermediate. Phosphorus-oxygen single and double bonds are approximately 
10-15% longer than the corresponding carbon-oxygen bonds.^^s This allows 
the P=0 double bond in the phosphonamidate to mimic the lengthening of the 
carbonyl bond as it is attacked by the lytic water molecule. In contrast to many 
other transition state mimics, the phosphonamidate moiety also possesses a 
nitrogen atom at Py in the correct position. Potentially this could be important in
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maintaining the hydrogen-bonding interactions in the enzyme's active site. In 
addition to potential as inhibitors, phosphonamidate analogues are suitable for 
probing the mechanism of the protease. For instance, phosphorus containing 
transition state mimics allow the use of NMR spectroscopy to study inhibitor- 
enzyme interactions in detail. However, in the short term we have only 
investigated these compounds as HIV-1 protease inhibitors.
As the pKa value for the phosphonamidate is approximately 3 .0 , at the pH 
optimum for the HIV-1 protease (pH 5.5) it will exist predominantly as the anion. 
Thus, the phosphonamidate would not be a good mimic for a neutral gem-diol 
te trahedral intermediate. However, as the exact nature of the stable 
intermediate in amide hydrolysis by the aspartic proteases is unknown, we 
decided to investigate the neutral phosphonamidate methyl ester as well. In this 
way we could provide two possible mimics for the stable intermediate and thus 
compare their interactions, see below (Figure 2.2).
V '^ NR*2
H "A 
Substrate
HI HO. .OH N.
H- \  
Gem-diol
NR’o
H ,0-
/  \
X  ^NR\
H" %
Phosphonamidate methyl ester
R NR',
H" %
Gem-diolate Phosphonamidate
Figure 2.2. Comparison of the possible stable Intermediates and
phosphonamidate analogues.
The phosphonamidate methyl esters are the synthetic precursors to the 
phosphonamidates and so are readily available. The methyl esters have been 
found to be acid stable and so also offer an immediate advantage over the 
phosphonamidates. The phosphorous-nitrogen bond in phosphonamidates is 
acid labile and these compounds are known to have short half-lives in
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solution.127
Despite iaoking a hydrogen-bond donor, the phosphonamidate methyl ester 
has been shown to be a good mimic of the gem-diol intermediate in terms of 
charge density distribution. The charge congruency of the phosphonamidate 
methyl ester and the gem-diol tetrahedral intermediate has been proved by 
semi-empirical quantum mechanical calculations.128 The results are given 
below in (Figure 2.3), with the partial charges residing on each atom shown.
- 0.628 - 0.463
0.243
0.186.O—CH
N CH;
- 0.5591.093
- 0.108
- 0.393 - 0.422
- 0.147
N- CH;
- 0,6130.471
0.454
Figure 2.3. Charge density comparison of a model 
phosphonamidate methyl ester and a model amide hydrate.
The crucial points of similarity are the oxygens and the nitrogen of the 
hydrate and of the phosphonamidate methyi ester. The partial charges on the 
oxygens can be seen to be similar, showing again the close analogy between 
the two moieties. An ab in itio  caicuiation was recently carried out on 
phosphonamidates and similar results to those above were obtained.129 in the 
same study it was found that the stable intermediate for acid-catalysed peptide 
bond hydrolysis is likely to be the neutral amide hydrate. Phosphonamidates 
were not good models for this stable intermediate but phosphonamidate methyl 
esters were found to be better. Although useful, these studies do not highlight 
the important hydrogen-bonding interactions between the enzyme and bound 
inhibitors. The fact that analogues containing hydroxyl groups tend to be the 
most potent inhibitors towards the HiV-1 protease suggests that both a 
hydrogen-bond acceptor and donor are required for optimisation of the 
interactions with the catalytic aspartates. The phosphonamidate methyl esters
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possess hydrogen-bond acceptors but lack hydrogen-bond donating capacity.
Our initial targets (see below, Figure 2.4) were derived from the sequence of 
the protease-reverse transcriptase junction in the gag^pol poiyprotein (Leu-Asn- 
P h e - P r o - l i e - S e r - ) . i 3 o  This sequence has been used in the design of several 
successful inhibitors.®*^
CONH2
°  OR
Where R = CH3 Compound (44)
R = Li Compound (48)
(B oc-(2S)-A sn-Phe-Y[P(O R )0-N ]-(2S)-Pro-(2S)-lle-N H -iB u.)
Figure 2.4.
Incorporation of the unique Phe-Pro scissile bond mimic into the design was 
expected to confer selectivity for the inhibition of the HIV-1 protease over the 
mammalian aspartic p r o t e a s e s . F o r  synthetic ease, the inhibitor also 
incorporates the Val surrogate, isobutyl amine, in the P3. position and the 
tertiarybutoxy carbonyl (Boo) protecting group as a P3 substitute. Initially, the 
carbobenzyloxy (Cbz) protecting group was used in this position, but it was 
found that this group was unstable to the conditions required for the 
deprotection of the phosphonamidate methyl ester (see section 2 . 2  (iii)).
2.2 Synthesis of phosphonamidate-containlng peptide inhibitors.
The phosphonamidate analogues were synthesised by coupling activated 
aminophosphonic acid haif esters (35) to various peptides, as outlined overleaf 
in Scheme 2.1. The half esters were activated by conversion to the appropriate
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acid ch lo ride , using th ionyl ch loride. Treatm ent of the resu lting  
chlorophosphonate derivative (36) with a range of peptides gave the 
phosphonamidate methyl ester analogues in moderate to good yield (40-80%).
Ph /
NH
OMe
Ph
XCompound 33
X = OH Compound 3 5 
X = Cl Compound 3 6
OGH;NH
O
Compound 42
Scheme 2.1. The synthesis of compound 44.
(i) 2.2 eq. NaOMe, MeOH, r.t.; (ii) 2.5 eq. NaOH, MeOH, r.t.; (iii) SOCIg, CHgClg, 
r.t. then; (iv) HN-Pro-lle-NH-iBu.HCI (40), NEtg, CHgClg, r.t.; (v) Pd/C, Hg, MeOH, 
r.t.; (V i )  Boc-Asn, iBuOCOCI, NMM, THF, -15°C.
The phosphonamidate (48) was produced from the methyl ester (compound 
(44)) by treatment with 4 eq. lithium hydroxide in dioxan. The stereochemistry of 
the 4 diastereomers of compound (44), was assigned using a combination of X- 
ray crystallography on the synthetic intermediate (42), chemical degradation, 
^H, 13c and 3ip NMR spectroscopy, as discussed in section 2.3.
(i) Synthesis of peptide fragments.
The peptide fragments were synthesised using mixed anhydride coupling 
reactions. This method of peptide coupling was chosen because of its
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advantages in speed, yield and ease of purification. Also, the enzyme has a 
binding preference for amino acid residues possessing the (S)-configuration 
and so racémisation of these stereogenic centres must be kept to a minimum 
during inh ib ito r synthesis. The mixed anhydride method uses a lkyl 
chloroformâtes as peptide forming reagents. A suitably protected amino acid 
reacts with the alkyl chloroformate in the presence of a base, to form an 
anhydride. A second amino acid is then added, which reacts with the anhydride 
to form the peptide linkage (see below. Scheme 2.2).
O
01*^0
NMM
Scheme 2.2. The mixed anhydride peptide coupling reaction.
The first step of the reaction is believed to be the attack of the tertiary base 
on the alkyl chloroformate to form a quaternary compound which in turn reacts 
with the carboxylic acid. The steric bulk of the base is important if racémisation 
is to be minimised and It has been found that methylamine reacts fastest, but 
causes maximum racémisation. 132 Base, solvent, temperature and alkyl 
chloroformate variations were examined and It was found that the best results 
were obtained using a com bination of N -m ethylm orpholine (NMM), 
isobutylchloroformate and tetrahydrofuran (THF). Consequently, this same 
combination was used in the course of this work.
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The Pro-lle-NH-iBu (40) tripeptide fragment was synthesised using Boc 
amino protection. The first step consisted of a coupling reaction between Boc- 
Isoleucine and isobutyiamine (as exemplified in Scheme 2 .2) to give the amino- 
protected dipeptide analogue, Boc-lle-NH-iBu (37) in 85% yield. Subsequent 
deprotection using hydrogen chloride gas in ethyl acetate yielded lle-NH-iBu 
hydrochloride (38) in 90%. This method of deprotection was chosen in 
preference to trifluoroacetic acid as the latter method led to problems during 
crystallisation. The second step involved condensing Boc-Pro with the dipeptide 
lle-NH-iBu to afford the tripeptide analogue Boc-Pro-lle-NH-iBu (39) in 91% 
yield. Subsequent deprotection in a similar manner gave the desired peptide 
fragment, Pro-lle-NH-iBu (40) as the hydrochloride salt in 81% yield.
The tripeptide fragment provides the P.;, to P3. residues of the inhibitor (see 
Figure 2.4). Variation of these residues is straight forward and during the course 
of this work, peptides incorporating (2S)-phenylalanine, (2R)-phenylalanine and 
glycine at P-|. were also synthesised. 2-(Aminomethyl)-pyridine (AMP) and 2- 
(aminomethyl)-benzlmidazole (AMB), popular residues in a host of HIV-1 
protease inhibitors, were used to replace isobutyiamine at the P3. position.
(ii) Synthesis of the aminophosphonic acid derivatives.
The methyl phosphonic acid derivatives (35) used in the chlorophosphonate 
coupling reactions were prepared by Paul Hawkins, using the method of 
Oleksyszyn and c o w o r k e r s , to yield the diphenyl phosphonate analogue
(3 3 ) as shown in Scheme 2 .1 . This method invo lves condensing 
phenylacetaldehyde, benzyl carbamate and triphenyl phosphite in the presence 
of glacial acetic acid. The diphenylphosphonate analogue (33) was obtained in 
31% yield. Transestérification of the diphenyl phosphonate using sodium 
methoxide provided the corresponding dimethyl phosphonate (34) in 72% 
yield. Subsequent saponification to the methyl phosphonic acid derivative (35), 
was achieved in 63% yield.
Although the three component reaction is inefficient, the reaction has been 
reproduced several times on a larger scale (30 g) and provides the analogue 
complete with suitable Cbz nitrogen protection. The Cbz group is easily 
removed by hydrogenolysis and allows extension in the P2 and P3 positions, as 
shown in Scheme 2 .1.
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Variation of the aldehyde In the three component coupling reaction allows a 
variety of residues to be examined. Hawkins^^^ prepared analogues which 
incorporated phenylalanine, cyclohexylalanine, norleucine, leucine and valine 
respectively. Of these, the phenylalanine and cyclohexylalanine derivatives 
have been incorporated into a variety of phosphonamidate containing inhibitors. 
Incorporation of the other residues is presently being addressed in the 
laboratory by David Perrey.
A stereoselective route to optically active a-aminophosphonic acids would 
be useful and many methods are available (reviewed in^^ej These include 
reso lu tion"'and alkylation, using chiral a u x ilia r ie s .F o r instance, the number 
of diastereomers produced after the chlorophosphonate-peptide coupling step 
would be reduced from four to two (see section 2.3 (iii)). However, as the 
stereochemistry at phosphorus would be difficult to control, a chromatographic 
resolution step would still be required. Also, the inhibitory effect at P^  with 
respect to stereochemical preference, was found to be small in the case of the 
phosphonamidate analogues (see section 2 .5 ) and so stereoselective 
syntheses were not pursued.
(iii) The chlorophosphonate-peptide coupling reaction.
The key step in this synthesis proved to be the coupling of the peptide 
fragment with the chlorophosphonate derivative (36). High yields for this two 
step reaction were required and so an examination of both the acid chloride and 
phosphonamidate formation steps were undertaken. Model coupling reactions 
using readily available isobutyiamine were carried out prior to tripeptide 
couplings. Using a m odification of the method of B a rtle tt,^^9 the 
chlorophosphonate (36) was produced from (35) using 2 equivalents of thionyl 
chloride in anhydrous dichloromethane. Isobutyiamine (2.5 equivalents) was 
added in situ to give Cbz-Phe-\|/[P(0Me)0-NH]-iBu (41) (see overleaf. Figure
2.5). The formation of the acid chloride was verified by ^H NMR and a 
quantitative conversion was achieved within 4 hours as judged by the downfield
shift for both the methyl phosphonate ester and the a CH (CH*) signals. 
Optimisation of the coupling reaction was achieved by repeatedly flushing away 
the gaseous by-products from the chlorination reaction using argon. In this
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manner, the model phosphonamidate analogue (compound (41)) was obtained 
in a yield of 80% after one recrystallisation.
.OCH;
NH
Figure 2.5. (41); Produced in the model coupling reaction.
In an analogous manner, proline methyl ester was condensed with the acid 
chloride (36) in a yield of 50%. The lower yield was attributed to the increased 
steric bulk of the secondary amino group. Rather than extending in a linear 
fashion from the pro line methyl ester of this phosphonamidate analogue, it was 
decided to use a convergent synthesis. Thus, the tripeptide fragment, Pro-lle- 
NH-iBu (40) was coupled to the acid chloride (36) in an optimised yield of 65%, 
to give the four expected diastereomers of compound (42);
i) Cbz-(R)-Phe-y[(R)-P(OMe)0-N]-(2S)-Pro-(2S)-lle-NH-iBu.
ii) Cbz-(R)-Phe-y[ (S)-P(OMe)0-N]-(2S)-Pro-(2S)-lle-NH-iBu.
iii) Cbz-(S)-Phe-y[ (R)-P(OMe)0-N]-(2S)-Pro-(2S)-lle-NH-iBu.
iv) Cbz-(S)-Phe-v[ (S)-P(OMe)0-N]-(2S)-Pro-(2S)-lle-NH-iBu.
Four well resolved ^^P coupled doublets were observed in the NMR at Ô 
3.60, 3.66, 3.69 & 3.74 respectively, due to the methyl phosphonate ester group 
and are indicative of the number and amount of each diastereomer (see Figure
2.6). Interestingly, the diastereomers were produced in unequal amounts, with
two diastereomers (Ô 3.74 & 3.66) comprising 31% & 34% respectively and the 
other two (Ô 3.69 & 3.60) comprising 19% & 16% respectively. The 
aforementioned NMR study of the acid chloride formation also showed no
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stereochemical preference, as judged by equal NMR peak heights for the 
methyl phosphonate ester group. Thus, the diastereoselectivity must have 
arisen from the chlorophosphonate-peptide coupling reaction and may have 
been the result of a preferential attack at phosphorus.
1
Figure 2.6. 600 MHz ^H NMR showing 4 diastereomers of
compound (42).
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For instance, attack at phosphorus would be expected to go with inversion 
and so the preferred diastereomers may result from the attack of the incoming 
amino fragment from the opposite side of the benzyl chain (i.e. the least 
hindered side), thus producing a phosphonamidate analogue where the prolyl- 
peptide is trans with respect to the benzyl chain (see below. Figure 2,7). Using 
the same argument, the unfavoured diastereomers would result from an attack 
on the same side as the benzyl chain (i.e. the most hindered side), resulting in 
the prolyl-peptide being cis with respect to the benzyl chain.
^  II^ OCHa
V P
Favoured (R, S)
OCH
Unfavoured (8, 8) Favoured (8, R)
- f V
0CH3
Unfavoured (R, R)
Figure 2.7. Theoretical explanation for observed 
diastereoselectivity.
Although speculative, this theoretical argument has implications with regard 
to the absolute stereochemical assignments and will be discussed in section 
2.3.
Each diastereomer of compound (42) was separated using column 
chromatography (EtOH: CH2CI2 5:95), individually hydrogenolysed and then 
extended with Boc-(2S)-asparagine to yield the individual diastereomers of 
compound (44). Each diastereomer was tested as an inhibitor of the HIV-1
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protease, the results of which will be discussed in section 2.5,
The removal of the phosphonamidate methyl ester protection proved to be 
difficult. Our initial method used a reagent first prepared by B a r t l e t t . T h e  
lithium propane-1-thiolate reagent (45) in HMPA had been used successfully in 
the removal of hindered methyl esters. The thiolate anion effectively cleaves the 
alkyl-oxygen bond through nucleophilic displacement at carbon, to yield the 
lithium salt of the acid. The reagent was prepared initially in HMPA, as It had 
been shown that this solvent supported the greatest rates of cleavage for methyl 
e s t e r s .  141 in our case HMPA caused lots of problems. By TLC, the reaction 
proceeded readily, but the removal of the HMPA proved difficult. Also, due to the 
carcinogenic nature of HMPA, DMF was used as a suitable replacement. A 
model reaction with the isobutyl phosphonamidate methyl ester (compound 
(41)) produced the lithium salt of the phosphonamidate in reasonable yield. The 
result was encouraging and thus the déméthylation to provide the target
molecule (originally, (Cbz-(2S)-Asn-Phe-\|/[P(OMe)0-N]-(2S)-Pro-(2S)-lle-NH- 
iBu.) was attempted. However, the thiolate anion readily attacked the benzyl 
portion of the Cbz group of the terminal asparagine group and competed with 
the removal of the phosphonamidate methyl ester even at 1.1 equivalents of 
reagent (see below. Figure 2.8).
Figure 2.8. Possible decomposition of Cbz group by 
propane-1 -thlolate.
A closer examination of the literature, revealed an alternative method by the 
same author. Bartlett had used lithium hydroxide to remove the methyl ester 
group of his p h o s p h o n a m i d a t e s .  1 ^ 9 ,1 4 2  He had used the th io l reagent 
successfully in the production of phosphinic acid inhibitors.®^ This could imply 
that the phosphonamidates are more stable as the lithium salt. Model reactions
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of lithium hydroxide were successful, with the production of the lithium salt of the 
isobutyl phosphonamidate (compound (46)) in 77% yield. Following the 
success of the model phosphonamidate methyl ester deprotection using lithium 
hydroxide, This method was used in the deprotection of the phosphonamidate 
methyl ester of the target compound (44). However, our initial target, the Cbz- 
(2S)-Asn analogue of compound (44) could not be prepared due to the facile 
débenzylation of the Cbz group. This was surprising considering that the 
terminal Cbz group of the shorter model (compound (41 )) remained untouched 
by both reagents. Therefore the amino terminal protecting group was altered to 
a base stable Boc group to facilitate selective phosphonamidate methyl ester 
deprotection. Hence, the new target became Boc-(2S)-Asn-Phe-\|/[P02 -N]-(2S)- 
(Pro)-(2S)-lle-NH-iBu (Compound (48)). The lithium hydroxide déméthylation 
reaction proceeded very slowly in a variety of solvents (acetone, dioxan and 
acetonitrile), although complete cleavage was achieved using four equivalents 
of lithium hydroxide in dioxan at room temperature for 24 hours (indicated by the 
disappearance of the methyl ester doublets at ~ Ô 3.6 in the iH NMR). This 
déméthylation method for the deprotection of single diastereomers should be 
unsuitable, as the long reaction times and excess amounts of lithium hydroxide 
should facilitate racémisation. For this reason several other methods were 
investigated. The use of tertiarybutylamine, a very selective reagent used in the 
cleavage of phosphate and phosphonate esters^^s proved to be totally 
ineffective in phosphonamidate methyl ester cleavage. Bartlett and co- 
w orkers i44 had successfully used trimethylsilyl bromide (TMSBr) in the 
deprotection of the methyl esters of their phosphonate peptide inhibitors of 
pepsin. McKenna and co-workersi4s had previously used this reagent in the 
facile dealkylation of phosphinic acid esters and so this method of deprotection 
seemed promising. Deprotection of compound (44) was attempted and it was 
found that TMSBr was reactive enough to remove both the phosphonamidate 
methyl ester and the Boc group from the asparagine residue preferentially at 1.1 
eq. This method appeared to be the most efficient way of phosphonamidate 
methyl ester deprotection but was not viable due to the accessibility and relative 
reactivity of the terminal protecting groups. Therefore our synthetic strategy was 
altered as follows (see overleaf. Scheme 2.3).
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UOCH3
h
0 H
o
Compound 42
I, II, III
CONH
.OLi
Compound 48
Scheme 2.3. Alternative phosphonamidate methyl ester
deprotection.
(I) Pd/C, Hg, MeOH, r.t.; (ii) 2.2 eq. TMSBr, CHgClg, r.t.; 
iBuOCOCi, NMM, THF, -15°C, (b) 1 eq. LiOH.
(a) Boc-(2S)-Asn,
The phosphonamidate (48) was prepared by sequential removal of the 
benzyloxycarbonyl and phosphonamidate methyl ester protecting groups 
through catalytic hydrogenolysis followed by treatment of the free amine with 
trimethylsllyl bromide, prior to reaction with Boc-(2S)-asparaglne using the 
mixed anhydride method. The use of TMSBr proved to be a facile method of 
phosphonamidate methyl ester deprotection. However, during the course of the 
TMSBr reaction the newly formed phosphonamidate was prone to cleavage at
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the phosphorus-nitrogen bond. As this bond is known to be acid labile 
isobutylene was used to scavenge the acid produced during the reaction. This 
successfully prevented cleavage and the deprotected compound was extended 
with Boc-(2S)-asparagine in the usual manner (see Scheme 2.3).
The inherent problems associated with the phosphonamidates such as their 
ionised nature at the optimum pH of the HIV-1 protease, their acid instability and 
the difficulty of phosphonamidate methyl ester deprotection caused us to 
abandon them as possible therapeutic agents. Indeed the phosphonamidates 
were found to be moderate inhibitors of the HIV-1 protease (see section 2.5). 
More significantly, the synthetic accessibility, the ease of resolution and the acid 
stability of their methyl ester counterparts made them far more attractive 
compounds and consequently were further developed in the course of this work. 
Similar phosphonamidate methyl ester analogues were prepared in order to 
optimise the inhibitory effect of this class of compounds. For instance,
analogues incorporating Cha-y[P(OMe)0-N]-(2S)-Pro (50), Phe-y[P(0Me)0- 
NH]-(28)-Phe (51), Phe-\|/[P(0Me)0-NH]-(2R)-Phe (64), Cha-i|/[P(OMe)0-NH]- 
(2S)-Phe (52) and Phe-\|/[P(0Me)0-NH]-Gly (65) were synthesised in a similar 
manner and tested for inhibition against the HIV-1 protease (see section 2.5).
2.3 Absolute stereochemical assignment of compound 42.
The d iastereom ers of compound (42 ) were separated by s ilica  
chromatography and designated 1-4 in order of their elution. With these 
individual diastereomers in hand the task of assigning the ir absolute 
stereochemistry at both P^  (CH*) and at phosphorus was undertaken. In this 
way each individual diastereomer could be tested for inhibition against the HIV- 
1 protease and the preferred stereochemistry at both carbon (CH*) and 
phosphorus examined.
After considerable effort, crystals were grown of the individual diastereomers 
of 3 and 4. Although both samples produced thin crystals, the X-ray crystal 
structure of diastereomer of 4 was solved from a very limited data set. The 
stereochemistry at carbon (CH*) was found to be (R) and the stereochemistry at 
phosphorus was also found to be (R) (The structure of diastereomer 4 is shown 
overleaf in Figure 2.9).
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CCD 0(2)
cas>OCDCO)
0(3)C(2Q)NO)co yCC4)
CC2) C(22)
CCS) CC2D
NC2) NC3)CCS) 0(5)CC7) C(28)
N<4)COO)CCS) CC23)
0(6) CC30)CC32) CC24) CC26)
CODCODCUT) CC25)
CC27)C02)CQB)
C03)
Figure 2.9. The crystal structure of
Cbz-(R)-Phe-\j/{(R)-P(OMe)0-NH2S)-Pro-(2SHIe-NH-IBu (42).
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Further Information was gained by studying the 600 MHz NMR spectra of 
each individual diastereomer of compound (42) (see overleaf, Figure 2.10). The
chemical shifts of the a-hydrogen of the (2S)-Pro residue were 5 4.11, 4.10, 
4.26, and 4.32 for diastereomers 1-4 respectively (all relevant chemical shift 
data is given in Table 2.1). After studying these values, it was predicted that D1 
and D2 had the same stereochemistry at phosphorus, as it was assumed that 
the same stereochemistry at phosphorus would cause a similar effect on the
chemical shift of the a-hydrogen of the (2S)-Pro residues. Similarly, it was 
predicted that D3 and D4 had the same stereochemistry at phosphorus 
(a lthough d iffe ren t from D1 and D2). Therefore, using the known 
stereochemistry of D4 (R, (CH*), R, (Phos.)) the stereochemistry at phosphorus 
was assigned as follows:
D1 (X, (OH*), 8 , (Phos)),
D2(x, (OH*), S, (Phos)),
D3 (X, (CH*), R, (Phos)),
D4 (R, (CH*), R. (Phos)).
The stereochemistry at carbon (CH*) was more difficult to predict using 600 
MHz ■'H NMR alone as the chemical shifts of the (CH*) protons were very 
similar. An examination of the chemical shifts of both of the protons of the 
adjacent benzyl group (ArCjH.2CH*) proved inconclusive as well. Therefore, a 
study of the 600 MHz ‘‘ H NMR spectra of the individual diastereomers of 
compound (44) was undertaken. The a-hydrogen chemical shifts of the (2S)- 
Pro residue again indicated a (D1 & D2) and (D3 & D4) partnership with respect 
to the same stereochemistry at phosphorus. By extending compound (42) with 
(2S)-Boc-Âsn a fixed stereogenic centre had been placed adjacent to the (CH*)
and so it was hoped that an inductive effect, (similar to that for the (28)-Pro a- 
hydrogen’s) would be observed. Indeed, the values of the chemical shifts of the 
(CH*) protons for D2 and D3 were higher than those of D1 and D4. The 
chemical shifts of the asparagine CH2 protons also indicated a (D1 & D4) and 
(D2 & D3) partnership with respect to the same stereochemistry at carbon.
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Figure 2.10. 600 MHz NMR of (R,S) diastereomer
of compound (42).
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Table 2.1, 600 MHz ^H NMR data for compounds (42) and (44).
6QQ MHz NMR Data.
Compound, (42) .C.o.mpQüQd..(44)
D 1.) a-H Pro
PO(OCHa)
CH*
ArCüs
4.11 ppm.
3.74
4.46
2.88 & 3.18
D1.) a-H Pro
POCOCids)
CH*
ArCJdg 
a-H Asn 
CH2 Asn
4.15 ppm.
3.75
4.74
2.95 & 3.17
4.32
2.46 & 2.62
D 2.) a-H Pro
POCOCHa)
CH*
ArCHn
4.10 ppm.
3.69
4.49
2.84 & 3.21
D2.) a-H Pro
POCOCJda)
CH*
ArCHg
a-H Asn 
CH2 Asn
4.16 ppm.
3.76
4.81
2.80 & 3.27
4.35
2.18 & 2.46
D3.) a-H Pro
P0(0CM3)
CH*
ArCJd,2
4.27 ppm.
3.66
4.46
2.89 & 3.18
D3.)a-H Pro
PO(OCÜ3)
CH*
ArCÜ2
a-H Asn 
CH2Asn
4.25 ppm.
3.66
4.78
2.86 & 3.16 
4.55
2.07 & 2.21
D4.) a-H Pro 
P0(0CH3) 
CH* 
ArCüg
4.32 ppm.
3.60
4.45
2.80 & 3.28
D4.) a-H Pro
PO(OCHa)
CH*
ArCjd.2
a-H Asn 
CH2Asn
4.38 ppm.
3.62
4.66
2.84 & 3.28
4.36
2.45 & 2.64
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From the X-ray structure and the 600 MHz ^H NMR data, the absolute 
stereochemistry was tentatively assigned as follows:
D1 (R,(CH*),S,(Phos)),
02 (S,(CH*),S,(Phos)),
03 (S,(CH*), R, (Phos)),
04 (R, (CH*), R. (Phos)).
In order to unambiguously assign the stereochemistry at carbon, a series of 
acid hydrolysis experiments on the individual diastereomers of compound (42) 
(see overleaf. Scheme 2.4) was undertaken. Refluxing in a mixture of glacial 
acetic acid and 6 M HCI for two hours degraded compound (42) into a mixture 
of the hydrochloride salts of proline, isoleucine and isobutylamine and a 
phenylalanine phosphonic diacid derivative. Thin layer chromatography of the 
hydrolysis mixture gave spots with Rf values of 0.5, 0.67, 0.9 and 0.2 
respectively. By isolating the phenylalanine derivative, a comparison of the
direction of optical rotation with that of the known [a]o values for the enantiomers 
of (1-amino-2-phenyl)ethyl phosphonic acid (49) could be u n d e rta k e n .in  this 
way, the absolute stereochemistry of the phenylalanine carbon (CH*) in the 
original diastereomer could be deduced.
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" V x KI H0
Compound 42
Reflux 6 M HCI / glacial acetic acid, 2h.
01 H,N
Compound 49
+ HCI salts of Pro, He, & iBu.
Scheme 2.4. Acid hydrolysis experiment.
Initial preparative TLC experiments were carried out on the hydrolysis 
mixture, using an isopropanol, conc. ammonia and water (26:6:5) solvent 
system. The methyl phosphonic acid derivative (35) was hydrolysed in an 
identical manner to compound (42) to give the required phosphonic diacid (49). 
This sample was used together with standard solutions of proline, isoleucine, 
and isobutylamine to identify which band of the TLC plate was required in order 
to isolate the required phenylalanine derivative. Initially, problems were found in 
separating the phenylalanine and proline derivatives, therefore the volume of 
ammonia in our system was doubled. This increased the separation and 
allowed the successful isolation of the phenylalanine derivative. It was found
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that at least 50 mg of compound (42) was required in order to isolate sufficient 
phenylalanine derivative for the optical rotation experiment (100% recovery of 
the phenylalanine derivative would give 16 mg, however a proportion of this is 
lost.). The literature [a]Q values are -49° and +52° respectively (c 1 in 1 M 
NaOH) for the (R) and (S) enantiomers of (49).'*'^® Due to the small amounts of 
phenylalanine derivative recovered, we looked at the sign of optical rotation as 
a guide to the stereochemistry at carbon rather than the amount of rotation. 
Diastereomer 1 was degraded and the phenylalanine derivative isolated, after 
preparative TLC using the modified solvent system (isopropanol, conc. 
ammonia, water, 26:12:5). The optical rotation for D1 in 1 M NaOH was 
negative. This implied that the stereochemistry at carbon was (R). This was in 
agreement with the tentative assignment made on the basis of ^H NMR. The 
sodium salt of the phenylalanine derivative (49) from D1 gave an identical ^H 
NMR to the previously prepared racemic compound. The possibility of 
racémisation at (CH*) under the acidic conditions was of particular concern and 
so to test the validity of this experiment, the hydrolysis of D4 (stereochemistry 
known) was completed. The optical rotation was negative, which implied that 
the stereochemistry at carbon was (R) (in agreement with the X-ray structure). 
For completeness, the same experiments for D2 and D3 were carried out and 
positive optical rotations were observed for both D2 and D3. This implied that 
the stereochemistry at carbon was (S). Hence, the total stereochemical 
assignment had been achieved. Solving the absolute stereochemistry of the 
diastereomers of compound (42) (see below), automatically provided the 
absolute stereochemistry of the corresponding diastereomers of compound 
(44),
D1 (R,(CH*),S,(Phos)),
D2 (S,(CH*),S,(Phos)),
D3 (S.(CH*), R,(Phos)),
D4 (R, (CH*), R, (Phos)).
Interestingly, these stereochemical assignments are in accord with those 
predicted from the thereotical argument based on preferential attack at 
phosphorus (see Figure 2.7).
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2.4 Phosphorus-based protease inhibitors.
Phosphorus-containing peptide analogues have been used extensively in 
the inhibition of the zinc and aspartic protease enzymes (reviewed in® )^. indeed, 
these analogues have produced some of the most potent inhibitors of both 
ciasses. Although the zinc proteases and the aspartic proteases differ in many 
respects, they are related by mechanism; both catalyse the direct addition of 
water to the scissile carbonyl of the amide bond, with formation of a tetrahedrai 
intermediate. Both mechanisms involve basic cataiysis from a carboxylate side 
chain and acidic or Lewis acidic catalysis from another group in the active site. 
Zinc performs this roie in the case of thermoiysin and carboxypeptidase A.
The zinc proteases, thermoiysin and the digestive enzyme carboxypeptidase 
A have received a great deal of attention. Eariy work in this area uncovered the 
naturaiiy occurring phosphoramidon (see below, Figure 2 .11), as a potent 
inhibitor of thermolysin.'^^^ The crystal structure of phosphoramidon bound to 
thermoiysin was subsequentiy soived'*'^® and heiped in the eiucidation of the 
ca ta lytic  mechanism of the zinc proteases. Sim ilar inh ib ito rs fo r the 
mechanisticaiiy related enzyme carboxypeptidase A soon followed.”''^ ®
N
H
HO
HO OH
Figure 2.11. Phosphoramidon, the naturally occurring thermoiysin
Inhibitor.
Bartiett and co-workers have made an outstanding contribution in the area of 
phosphorus-containing analogues. His group synthesised phosphonamidate- 
containing peptides as highly potent inhibitors of both t h e r m o l y s i n ^ ^ z  and 
carboxypeptidase A.^ ®® These inhibitors are ideally suited due to their ionised
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nature at the assay pH. In contrast to the aspartic proteases, the zinc proteases 
proceed via a gem dioiate intermediate which coordinates to the zinc in the 
active site. Thus the ionised phosphonamidate is able to coordinate to the zinc 
in an analogous manner. This theory has been well supported  by 
crystaiiographic studies.’’®®-''®'' Bartlett and Kezer®® synthesised phosphinic acid 
analogues as inhibitors tor the aspartic protease, pepsin. Their most potent 
inhibitor gave a Kj value of < 0.07 nM at pH 3.5. The aspartic proteases operate 
via a neutral gem diol intermediate (see Figure 1.8) and therefore this high 
potency is probably due to the fact that at pH 3.5 the phosphinic acid is 
predominantly protonated and thus binds tightly to the catalytic aspartates. 
These inhibitors are found to be less effective against the aspartic protease, 
peniciilopepsin which operates at a higher pH. In fact, a pH dependence study 
has shown that Kj increases with increasing pH, suggesting that the enzyme 
binds only the neutral (protonated) form of the inhibitor.®^ A lthough 
mechanisticaiiy similar, the subtle differences between the zinc and aspartic 
proteases can have a profound effect on the design of inhibitors. Clearly, 
achieving high potency for one class of enzyme does not guarantee that the 
same level of potency will be achieved with the same inhibitor.
(i) Phosphorus-based inhibitors for the HIV-1 protease.
The use of phosphorus-based inhibitors for the HiV-1 protease has been 
investigated by a number of groups. The observation that phosphinic acids were 
highly potent inhibitors of the aspartic protease, pepsin, provided a good basis 
for HiV-1 protease inhibitors. Grobelny et a/.®® synthesised potent phosphinic 
acid inhibitors and observed a similar pH dependence to that observed by 
Bartlett (see section 1.4.6 (II)). Peyman and co-workers''®^ synthesised the first 
symmetrical phosphinic acid inhibitors for the HiV-1 protease. The compound 
overleaf (see Figure 2 .12) as a mixture of stereoisomers gave an IC50 value of 
36 nM. Whilst optimising symmetry, this compound has the disadvantage of 
positioning the benzyl side chain at P '^ incorrectly (the backbone spacing of the 
peptide substrate is not preserved). More recently, the same compound was 
synthesised by Abdei-M eguid and co-workers.®® They resolved the 
stereoisomers and the most potent isomer (the one which incorporates the 
natural amino acid stereochemistry) gave a Kj value of 3 nM at pH 6 .
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Val-CbzCbz-Val
Ph
Figure 2.12. C-2 symmetric phosphinic acid inhibitor.
Despite its low Kj value this compound was found to be a weak inhibitor 
when tested in an antiviral assay, most probably due to poor cell penetration.69 
The methyl ester derivative of this compound was not an inhibitor of HIV-1 
protease (Ki > ImM), nor was it found to be active in an antiviral assay. This 
latter result is of particular interest to our work on the phosphonamidate methyl 
esters and its relevance will be discussed in section 2.5 (ii).
During the course of this work the first phosphonamidate inhibitors for the 
HIV-1 protease were reported by McLeod and co-workers."' 7^ They showed that 
phosphonamidate methyl esters were as active against the HIV-1 protease, as 
their phosphonamidate counterparts (see below, Figure 2.13).
o
ORCFgCONH
(i)
CFgCONH
Q
W/ORP.
o
(ii)
R = (-) or CH3
Figure 2.13. The phosphonamidate inhibitors of McLeod et aL
The phosphonamidate (R = (-)) of compound (i) gave a K| value of 52 pM 
and the phosphonamidate methyl ester of (i) gave a Kj value of 44 pM, whilst the
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phosphonamidate (R = (-)) of compound (ii) gave a Kj value of 45 pM and the 
phosphonamidate methyl ester of (ii) gave a Kj value of 80 pM. Under the assay 
conditions the phosphonamidates were reasonably stable (t /^2 of (i) and (ii), 5 
h. and 30 h, respectively), with the methyl esters being acid stable (less than 2 
% decomposition over a week at pH 3.5). Whilst these compounds were only 
modest inhibitors of the HIV protease, the fact that they were inhibitors at all was 
encouraging, considering that these compounds were racemic at and were 
only dipeptide mimics. The HIV-1 protease is known to require hexapeptide 
substrates (see section 1.4.4) and the shortest inhibitors so far published are 
tetrapeptide mimics (see section 1.4.6 (v) and (vi)).
2.5 Results of inhibitor testing.
A variety of phosphonamidate methyl ester analogues were prepared and 
tested against the HIV-1 protease, in both in vitro and in vivo assays. The in  
vitro assays were performed at St. Andrews primarily by David Perrey and Paul 
Hawkins. These analogues were also tested in an in vivo assay by Derek 
Kinchington at St. Bartholomew’s Hospital.
The in vitro assays were based on the method of Griffiths et al.^62 The 
substrate used (KARV-Nle-Phe(NO)2-EA-Nle-G-NH2) in our assays produced a 
K|vi value of 33 jalV^s under the assay conditions, which compares well with the 
literature value of 35 The assay relies on monotoring a decrease in
absorbance at 300 nm, due to the cleavage of the Nle-Phe(N0 2 ) bond. By 
measuring the initial rates at various concentrations of inhibitor (typically 0 to
100 pM), a Dixon plot^^s can be produced in which the IC50 value can easily be 
extracted..
Our initial target was tested both as the methyl ester (44) and the 
phosphonamidate (48). The phosphonamidate (48) was tested as a mixture of 
two epimers at the a-carbon (CH*) of the phosphophenylalanine residue and 
produced an IG50 value of 90 pM. At the assay pH (5.6) the phosphonamidate is 
negatively charged and so would repel the negatively charged aspartate 
residue in the active site.67 This rather high value confirmed the expectation that 
the anionic compounds would be poor inhibitors and attention was turned to the
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methyl esters. All four diastereomers of the methyl ester analogue (44) were 
tested individually and the results are shown below in Table 2.2.
Table 2.2 Test results for compound (44).
Compound Configuration iCgg (pM)
at (CH*,P) in vitro in vivo
BoC“N“F“[\|/]"P"l"NH-iBu.
44 i (R, R) 30 45
44 ii (R, S) 80 >100
44 iii (S, S) 100 >100
44 iv (S, R) >100 >100
(Where [\y] = P0 (0 CH3))
These results show that the differences in potencies between the 
phosphonamidate and the methyl esters is very small. This is in agreement with 
results obtained by McLeod et However, the results above show a 
preference for the (R )-configuration at both the a-carbon of the 
phosphophenylalanine residue (CH*) and at phosphorus. The (R)-configuration 
at carbon is expected due to its equivalence to the (S)-configuration in the 
natural substrate. The preferred configuration at phosphorus is difficult to 
Interpret, especially as the methyl group on the phosphonamidate would not be 
expected to interact favourably with the aspartates. The relative potencies of 
each of the diastereomers was disappointing, considering the effort for both 
resolving and determining the absolute stereochemistry of each analogue. For 
instance, the results obtained by Cushman etal.^^ showed a strict preference for 
the (2S)-Phe epimer at P^  (see section 1.4.6 (i)).
As a matter of course, the individual diastereomers of the synthetic 
intermediate (compound (42)) were tested. In this shorter compound, the Pg Boc 
group had been deleted and the Pg asparagine residue replaced by a 
carbobenzyloxy moiety. These compounds were also tested in the in vivo assay 
and the results are shown overleaf in Table 2.3.
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Table 2.3 Test results for compound (42).
Compound Configuration IC 5 0 (^M)
Cbz-F-[\|/]-P“l-NH-iBu.
at (CH*,P) in  v itro in vi\
42 i (R, R) 5 3
42 ii (R,S) 25 25
42 iii (S,S) N.D. 25
42 iv (S, R) N.D. > 1 0 0
The results again highlighted the preference for the (R)-configuration at both 
CH* and at phosphorus. Surprisingly, these smaller inhibitors appeared to be 
more potent than the diastereomers of compound (44), despite lacking a P3 
residue. The in vivo result fo r the (S,S)-diastereomer was surprising, 
considering that this stereoisomer possessed the unnatural amino acid 
configuration at P^  and so would be expected to bind less tightly than the (R,S)- 
diastereomer.
The importance of the P^  residue in compound (42) was investigated by 
replacing Phe with a Cha (cyclohexylalanine) residue. Compound (50) was 
resolved into two pairs of diastereomers. The results for the most potent pair are 
given below in Table 2.4.
Table 2.4 Test results for compounds (50), (51), (52) & (55).
Compound Configuration IC 5 0  (jiM)
at (CH*,P) in  v itro  in  vivo
Cbz-Cha-[\|/]-P-l-NH-iBu.
50 (mix. 2 diast.) 16 8
Cbz-F-[\|/]-(2S)-F-l-NH-iBu.
51 (mix. 4 diast.) 2 2
Cbz-Cha-[xj/]-(2S)-F-l-NH-iBu.
52 (mix. 4 diast.) 2 5
H2N -F # ]-(2S)-F-l-NH-iBu.
55 (mix. 4 diast.) 30 20
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These results show that Cha can be used to replace the natural Phe residue 
in the P^  position without a significant change in potency and compare to that 
predicted for a mixture of the (R,R)- and (R,S)-diastereomers of compound (42).
The literature indicated that a large number of the most potent inhibitors of 
the HIV-1 protease conta ined e ithe r a phenyla lan ine residue or a 
phenylalanine surrogate in the P^ . position (for examples see section 1.4.6). 
Thus, the (2S)-Pro residue at P .^ in compound (42) was replaced with a (2S)- 
Phe residue. Compound (51) proved impossible to resolve using silica 
chromatography and was, therefore, initially tested as a mixture of four 
diastereomers (see Table 2.4). The small effect observed with respect to 
configuration for the resolved diastereomers did not warrant the resolution of 
fu rther compounds prior to testing. Since the mixture contained four 
diastereomers, the most active diastereomer may have possessed an IC50 value 
of at most 500 nM. Even as a mixture, the Phe-Phe based inhibitor was more 
potent than the most active diastereomer of the corresponding Phe-Pro 
analogue (compound (42 i)). Similarly, the Phe residue at P^  in compound (51) 
was replaced with a Cha residue and the result for compound (52) is given in 
Table 2.4. This result was in agreement with compound (50) in which Cha at P^  
was found to be equipotent to the Phe analogue In this position. Removal of the 
Cbz group in compound (51) gave compound (55) and led to a 10 fold 
reduction in potency (see Table 2.4) and showed that the Cbz group was 
compatible with the binding requirements of the S2 pocket.
Table 2.5 Test results for compounds (56), (60) & (61).
Compound Configuration IC 5 Q (pM)
at (CH*,P) in vitro in vivo
Boc-N-F-[\|/]-(2S)-F-l-NH-iBu.
56 (mix. 4 diast.) 100 >100
Qua-N-F-[\fr]-(2S)-F-l-NH-iBu.
60 (mix. 4 diast.) 45 50
Qua-N-Cha-[\j/]-P-l-NH-iBu.
61 (1 diast. unknown) 20 15
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Compound (55) was extended with Boc-(2S)-asparagine, to give compound 
(56) (see Table 2.5), which again showed a reduction in potency, compared to 
the shorter analogue. Having observed this reduction in potency for P3 
containing inhibitors, the Boc group at this position was replaced. Literature 
precedent indicated that a suitable group in the P3 position was the quinoiine-2- 
carbonyl (Qua) moiety (see below, Figure 2.14). This residue was first used 
successfully in the highly potent Ro 31-8959 inhibitor (see section 1.4.6 (v) 
(15)).
Figure 2.14. The quinoline-2-carbonyl (Qua) moiety.
Thus compound (60) (see Table 2.5) was prepared from compound (55) 
and Qua-(2S)-asparagine (59) using mixed anhydride chemistry. Qua-(2S)- 
asparagine (59) was synthesised in a simple one pot reaction from quinaldic 
acid ch lo ride , using asparagine under m odified Schotten-Baum ann
conditions. 164
In accord with the observations reported in the literature, introduction of the 
Qua residue in the P3 position caused an increase in potency compared to 
compound (56). However, compound (60) was 20 fold less potent than 
compound (51), again highlighting the preference for the shorter analogue. 
Clearly, the nature of the optimal P3 residue is different for the phosphonamidate 
methyl ester analogues than for the more potent hydroxyl containing inhibitors. 
In some cases occupation of the S3 pocket of the enzyme can cause 
conformational effects that can improve the key interactions at the core of the 
enzyme’s active site. This may explain why longer hydroxyl containing inhibitors 
are more potent than those lacking such a P3 residue, since their hydroxyl 
groups may be pushed closer to the active site aspartates, therefore, optimising 
the hydrogen-bonding in teractions. Pushing the methyl group of the 
phosphonamidates closer to the catalytic aspartates would cause an adverse 
interaction, since the methyl esters lack a hydrogen-bond donor.
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In a similar manner the Cbz group from compound (50) was removed and 
and the N -term ina l extended with Q ua-(2 S)-asparag ine (5 9 ). After 
chromatographic resolution a pair of diastereomers were obtained, with the 
most potent diastereomer possessing an ICgo value of 20 jiM (compound (61), 
see Table 2.5). This result, in agreement with the finding for compound (60), 
showed that Qua improved inhibitor potency compared to the Boc group in the 
Pg position, although the shorter compound (50) still maintained the greater 
potency.
At this point, it seemed that optimisation of the phosphonamidate methyl 
esters would be very difficult, as implemented alterations seemed to produce 
very small changes in potency. However, due to the close correlation of in vivo 
to in vitro IG50 values (the implications of which, will be discussed in section 2.5
(ii)), the importance of the Py position was investigated in more depth. Two 
approaches were pursued; first the (2S)-Phe residue in compound (51) was 
replaced with the unnatural (2R)-Phe residue (compound (64)) and second the 
benzyl side chain was removed by replacing the (2S)-Phe residue with a Gly 
residue (compound (65)).
Table 2.6 Test results for compounds (64), (65), (6 8 ) & (69).
Compound Configuration IC 5 0  (}xM)
at (CH*,P) in vitro in vivo
Cbz-F-M-(2R)-F-l-NH-iBu.
64 (mix. 4 diast.) 1 N.D.
Cbz-F-[\|f]-G-l-NH-iBu.
65 (mix. 4 diast.) >30 N.D.
Cbz-F-M-(2S)-F-NH-iBu.
68 (mix. 4 diast.) 40 N.D.
Cbz-F-M-(2S)-F-(0Me).
69 (mix, 4 diast.) 100 100
It was expected that a drop in potency would be observed when replacing 
the natural Phe residue with its unnatural counterpart (64). Surprisingly, this 
analogue was equally potent to compound (51). However, the literature
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seemed to indicate that the Sy pocket of the enzyme, was accommodating to a 
variety of different residues of differing size. For instance, the highly potent 
hydroxyethylene inhibitor (compound (23)) discussed in section 1.4.6 (vi) 
contained a styrene residue in this position. This particular residue is 2 carbon 
units longer than the benzyl side chain of the Phe residue and shows that the 
By  subsite is large enough to bind groups that are bigger than the natural 
residue. In fact, the high potency of compound (23) probably arises from the 
increased hydrophobic interactions of the aromatic ring with those residues in 
the Sv subsite of the enzyme.
The removal of the benzyl side chain caused at least a 30 fold reduction in 
potency. An accurate IC50 value for compound (65) could not be obtained due
to insolublity of the inhibitor at concentrations above 40 pM. This decrease in 
potency highlights the importance of the P ,^ residue and is in agreement with 
other findings (see section 1.4.6 for several examples). Finally, the effect of 
sequentially removing the P3. and Pg- residues was examined. First, lle-NH-iBu 
at Pg' and P3. was replaced by isobutylamine, to give (6 8 ). This modification 
caused a 20 fold reduction In potency (see Table 2.6) compared to compound 
(51). Second, (2S)-Phe-lle-NH-iBu was replaced by (2S)-Phe-(OMe) (69) and 
a 50 fold reduction in potency was observed (see Table 2.6) compared to 
compound (51). These results highlight the importance of the P3. and Pg- 
residues for binding.
(i) Comparison of in vitro and in vivo assay results.
The most striking feature from the inhibitor assay results is the close 1:1 
correlation of in vivo to in vitro IC50 values (see overleaf. Table 2.7). Generally, 
peptidic inhibitors lose potency in an in vivo assay due, primarily, to their 
inability to enter cells. The ratio of in vivo to in vitro IC50 values can be as great 
as 10,000:1 (see section 1.4.7 for a fuller discussion). The phosphonamidate 
methyl ester analogues show a marked ability to enter cells and this 
compensates for their moderate potency (jiM) in the in vitro assay. Interestingly, 
the uptake properties appear to be totally independent of inhibitor size and 
composition. For instance, larger peptide inhibitors appear to be less effective 
than smaller peptide inhibitors in the in vitro assay (compare compounds (44) 
and (42)) and yet the 1:1 ratio is still observed for the larger analogues. For
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other classes of inhibitor, the ratio of in vivo to in vitro IC50 values is much 
greater for larger peptide inhibitors than for smaller analogues (compare 
compounds (16) and (22) section 1.4.7).
The only feature of our compounds that is different to the other more potent 
inhibitors is the transition state Isostere. The residues chosen in the Pg-Pg. 
positions are in common with many other inhibitors and so it appears that the 
phosphonamidate methyl ester group may be responsible for the uptake 
properties. This may explain why the 1:1 ratio is independent of size, as all of 
the analogues possess this functionality. Of greater relevance is the low anti 
viral activity of the aforementioned phosphinic acid and phosphinic acid ester 
inhibitors (see section 2.4 (i)). These analogues are closest in terms of the 
transition state isostere to our compounds and yet do not exhibit our cell uptake 
properties. A study of the metabolism and mechanism of cell uptake would be 
needed in order to clarify this observation. For instance, metabolites could be 
isolated from cell lysates and characterised in order to check if the inhibitory 
effect was due to the inhibitor or a common metabolite. If the phosphonamidate 
methyl ester functionality was the key to efficient uptake, it would be worthwhile 
incorporating this group into the more potent hydroxyethylene inhibitors. In this 
way, improved uptake could be achieved whilst retaining the potency of the 
hydroxyethylene functionality.
Table 2.7. Summary of in  v itro  and in  vivo inh ib ition  data.
C om pound C on figu ra tion  IC50 (nM)
at (CH*,P) in  v itro  in vivo
Boc-N-F-[\j/]-P-l-NH“iBu.
44 i (R,R) 30 45
44 ii (R, 8 ) 80 >100
44 iii (8 , 8 ) 100 >100
44 iv (8 , R) >100 >100
Cbz-F-M-P-l-NH-iBu.
42 i (R,R) 5 3
42 ii (R ,8 ) 25 25
42 ii (8 , 8 ) N.D. 25
42 iv (8 , R) N.D. >100
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Cbz-Cha-[\y]-P-l“NH-iBu.
50 (mix. 2 diast.) 16 8
Cbz-F-[\|/]-(2S)-F-!-NH-iBu.
51 (mix. 4 diast.) 2 2
Cbz-Cha“[\|/]-(2S)-F-l-NH-iBu.
52 (mix. 4 diast.) 2 5
H2N-F-M-(2S)-F-l-NH-iBu.
55 (mix. 4 diast.) 30 20
B0C“N-F”[\|f]-(2S)“F-l-NH-iBu.
56 (mix. 4 diast.) 100 >100
Qua-N-F-[y]-(2S)-F-l-NH-iBu.
60 (mix. 4 diast.) 45 50
Qua-N-Cha-[\j/]-P-l-NH-iBu.
61 (1 diast. unknown) 20 15
Cbz-F-M-(2R)-F-l-NH-iBu.
64 (mix. 4 diast.) 1 N.D.
CbZ”F"[\jr]-G“l-NH-iBu.
65 (mix. 4 diast.) >30 N.D.
Cbz-F-M-(2S)-F-NH-iBu.
68 (mix. 4 diast.) 40 N.D.
Cbz-F-[\|/]-(2S)-F-(OMe).
69 (mix. 4 diast.) 100 100
(ii) Summary.
Although, phosphonamidate-containing peptide analogues have proved to 
be highly potent inhibitors of the zinc proteases, the same level of potency is not 
observed for the HIV-1 protease. This is probably due to their ionised nature at 
the assay pH (5.6), which causes a repulsive interaction between the negatively 
charged inh ib itor and the negatively charged active site carboxylate. 
Phosphonamidates in general have an acid labile phosphorus-nitrogen bond 
and for this reason phosphonamidates offer no potential as therapeutic agents, 
due to their instability in the gut. Their ionised nature at physiological pH (7.4)
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would prevent them from crossing cell membranes, as the lipid bilayers are 
highly impermeable to ionised molecules.
The problem of ionisation is not inherent in the phosphonamidate methyl 
ester analogues and consequently these neutral compounds have been shown
to be moderate inhibitors (pM) of the HIV-1 protease. Due to their increased acid 
stability and unique cell uptake properties, these analogues were studied as 
potential anti-AIDS drugs. However, optimisation of the methyl ester analogues 
proved difficult, as the alteration of the side chain binding residues caused only 
small effects on the inhibitor potency. The stark trends observed for the more 
potent hydroxyethylene and hydroxyethylamine inhibitors were not followed by 
the phosphonamidate methyl esters. Optimisation of the hydroxyl-containing 
inhibitors Is more easily achieved as these analogues possess the key features 
for inhibitor potency; hydrogen-bond donating and accepting ability. The 
phosphonamidate methyl ester analogues lack hydrogen-bond donating 
capacity and so optimisation towards the same level of potency as the hydroxyl- 
containing inhibitors, cannot be realised. However, these analogues may unveil 
a unique cell uptake mechanism which can be exploited in the development of 
future therapeutic agents and for this reason alone, warrant further 
investigation.
2.6 Non-peptidic inhibitors.
2.6.1 Introduction.
As an alternative to peptide-based inhibitors, the syntheses towards two 
novel non-peptidic HIV-1 protease inhibitors was undertaken. Selective, non- 
peptidic inhibitors of the HIV-1 protease offer clear advantages over peptide- 
based inhibitors (the problems associated with peptide-based inhibitors have 
been discussed in section 1.4 .7 ). By removal of the peptide bonds and 
reduction of the molecular weight of inhibitors, it was hoped that problems with 
short duration of action, rapid clearance and solubility could be eliminated. This 
task is far from easy considering that the actual peptide bonds, play a key role in 
the hydrogen-bonding between inhibitor and enzyme. However, it appears that 
the key interactions occur within the and Py region and therefore, residues in 
the ?2 , Pg, Pg' and Pg. seem to play only a secondary role in inhibitor binding.
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2.6.2 Design of non-peptidic inhibitors.
X-ray crystaiiographic data have provided useful information with regard to 
the key hydrogen-bonding interactions within the active site of the HIV-1 
protease (see Figure 1.16, section 1.4.8). Studies of peptide-based inhibitors 
have identified the hydroxyethylene and hydroxyethylamine analogues as 
highly potent inhibitors of the HIV-1 protease. These inhibitors contain 
secondary hydroxyl groups which replace the nucleophilic water molecule (see 
Figure 1.8, section 1.4.5) associated with the aspartic acid residues at the 
active site of the enzyme. These hydrogen-bonding interactions appear critical 
for inhibitor potency, as similar inhibitors that lack this hydroxyl tend to be poorer 
inhibitors of the HIV-1 protease. A second feature in the design of HIV-1 
protease inhibitors first alluded to by Swain et involves the flap water 
molecule. This flap water molecule has a major role in hydrogen-bonding both 
to the substrate/ inhibitor and the enzyme flaps (see Figure 1.16, section 1.4.8). 
Rationally replacing this flap-binding water molecule in the HIV-1 protease 
offers the opportunity to design selective inhibitors without relying on residues 
far removed from the central catalytic region of the active site.
In simple terms a compound which incorporated a hydroxyl group, residues 
to interact at the S-j and By sites and a heteroatom to replace the flap water 
molecule was required. It became immediately apparent that a cyclic structure, 
which incorporated all of these features was necessary. This type of inhibitor 
should bind in the active site whilst maintaining interactions with the aspartates, 
in the and Si - sites and the flap region (see overleaf, Figure 2.15).
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Figure 2.15. Proposed hydrogen-bonding interactions of the cyclic
inhibitors.
From a literature study and results from our own work on the phosphorus- 
based inhibitors, benzyl and cyclohexylalanine were identified as desirable 
residues in the and Py positions. Additionally, the C-2 symmetry of the 
inhibitor was maintained as a requirement for selectivity (see section 1.4 .6  
(viil)).
Incorporation of the heteroatom within the ring fixes the lone pair geometry 
of this atom and so enables the correct orientation for hydrogen-bonding to the 
flap amide hydrogens of lle-50 and lle-50’ (as shown in Figure 2.15). The 
distance between the catalytic aspartates and the flap water molecule is 
approximately 5.5 Â and so places a constraint on inhibitor design, although 
some flexibility will be tolerated as the flap region is known to move as much as 
7 Â upon binding of an inhibitor (see section 1.4.8).
An obvious starting point would be to synthesise a tetrahydropyranol (X=0) 
analogue. However, modelling studies by Gani revealed that the methylene
groups a to the oxygen atom would probably interact adversely (i.e. bang 
against) the flap residues. Replacing the oxygen atom with a sulphur atom 
seemed to overcome this problem, as the carbon-sulfur bonds (1.80 Â) were 
longer than the corresponding carbon-oxygen bonds (1.40 Â). Additionally, the 
the lone pairs on the sulfur atom are larger and so should be more accessible
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for hydrogen-bonding to the flap amide hydrogens of lle-50 and lle-50'. 
However, molecular modelling can over estimate steric repulsion and so 
analogues in which X = carbon, oxygen and sulfur were synthesised.
Using simple base catalysed aldol chemistry (reviewed in'*®®) adapted from 
an undergraduate procedure, analogues were prepared that contained Phe 
mimics at P^  and Py. Reaction of tetrahydrothiopyran-4-one, tetrahydropyran-4- 
one and cyclohexanone with benzaldehyde under basic conditions yielded the 
the cyclic sulfur (70), oxygen (71 ) and carbon (72) ketone analogues in 62, 65 
and 77% respectively (see below, Figure 2.16).
Where X = S, O and CH2.
Figure 2.16. Cyclic ketone precursors (70)-(72).
The oxygen and sulfur ketone analogues were first prepared by Leonard et 
a/. 166 and have subsequently been used in the synthesis of potential anti­
inflammatory agents.167 Our base catalysed method provides a milder 
alternative to the literature where these ketones have been synthesised using 
the same reagents under acidic conditions. Except in the case of the sulfur 
analogue our yields are better as well.
These ketones were selectively reduced with sodium borohydride to yield 
the respective alcohols (73) and (74) in good yield (> 90%) (see overleaf. 
Scheme 2,5).
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Scheme 2.5. Synthesis of the cyclic alcohol analogues (73) & (74).
(i) 2 eq. Benzaldehyde, NaOH, EtOH, r.t.; (ii) NaBH^, EtOH, r.t.then H2O.
Although these cyclic alcohols did not possess the desired sp^ geometry at 
Pi and P^ . (see Figure 2.15) they provided useful leads. Reduction of the double 
bonds was attempted using hydrogen gas over a palladium/ carbon catalyst but 
produced a variety of Isomers which proved impossible to separate in the short 
term. However, the sulfur analogue (73) (shown in Scheme 2.5) was found to
be a moderate inhibitor of the HIV-1 protease (IC50 40 pM). An accurate IC50
value of (7 3 ) could not be achieved due to inh ib ito r in so lub ility  at 
concentrations > 30 pM. A similar solubility problem was observed with the 
oxygen analogue (74) and so as of yet, no other IC50 values have been 
produced. However, these analogues are currently being fully investigated in 
the laboratory by Donald McNab. Future work includes oxidation of the sulfur, to 
provide sulfoxide and sulfone analogues. These analogues will be used to 
probe the flap interactions, as the additional distance provided by the oxygen 
atoms may improve hydrogen-bonding interactions with the flap. These 
analogues are likely to have improved aqueous solubility over the cyclic sulfide 
as well. Incorporation of sp^ character, with the correct stereochemistry at P^  
and Py will be attempted. Introduction of side chains a to the sulfur should 
improve inhibitor potency by binding in the Sg and S2' subsites. Introduction of a 
hydrogen-bond donor on the aromatic ring (e.g OH or NHg) of the P^  and P^ . 
residues may improve potency by hydrogen-bonding to the carbonyls of Gly-27 
and Gly-27’ (see Figure 2.15). Modelling studies are currently in progress to 
determine whether this type of interaction can be achieved and to predict at 
which position on the aromatic ring the hydrogen-bond donor needs to be 
located.
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Towards the end of this work our attention was drawn to the following 
compounds''^® (see below, Figure 2.17). The core cyclic urea analogue (Hi) was 
identified using crystallographic structural information from several HIV-1 
protease-inhibitor complexes and 3D data base searching.
HN" ^NH
HO OH HO OH
(in) (iv)
Figure 2.17. Non-peptidic, cyclic urea HIV-1 protease Inhibitors.
The core structure (III) (Kj= 3 |iM) was then optimised to yield a variety of 
highly potent inhibitors. The cyclic urea analogue (iv) (Kj = 3 nM) possessing 
cyclopropylmethyl side chains was found to be 100% orally bioavailable in rats 
and provides an extremely selective non-peptidic inhibitor of the HIV-1 
protease. X-ray crystallographic studies revealed that these novel, cyclic 
inhibitors linked the aspartates to the flexible flaps via a hydrogen-bond network 
that did not include an intervening water molecule. Thus, these inhibitors had 
indeed displaced the flap water molecule and the X-ray study confirmed that 
these analogues were functioning in a manner, predicted in the design of our 
cyclic sulfur analogues.
Having examined these cyclic urea analogues, it appeared that these 
compounds needed to rotate by 90° in order to optimise the lone pair geometry 
of the urea carbonyl with respect to the flap amide hydrogens. Thus, the side 
chains appeared to be important factors in this process. On the basis of the 
cyclic urea analogues, the following inhibitor was designed (see overleaf. 
Figure 2.18). Introduction of sp^ character within the ring served two purposes; 
First, the Pi and Py residues need to rotate in order to bind in the and By 
subsites, thus optimising the orientation of the lone pair geometry of the ketone 
carbonyl. Second, the double bonds within the ring should provide a
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conformation in which both the ketone carbonyl and the hydroxyls lie 
approximately in the same plane. This is a requirement as a line through the 
nucleophilic water molecule and the flap-binding water molecule in the active 
site of the enzyme forms an axis of nearly C-2 symmetry.
o
HO OH
Figure 2.18. Novel, C-2 symmetrical non-peptidic inhibitor.
From retrosynthetic analyses of this inhibitor, several synthetic routes were 
identified. Of these, the shortest route containing arguably the most interesting 
chemistry was employed (see below. Scheme 2.6).
f  1
E t O " ^  f ^ O E t
HO OH
I, II "SCO's,,XX^__XX„/OCH3 N 1 i N
I J  %  ICHg 5  "o CHa
Compound (76)
HO OH
Iv, V
Compound (77)
Scheme 2.6. Proposed synthetic route to cyclic inhibitor.
(i) Acetone, conc. HgSO^; (ii) NH(0Me)CH3. HOI, NaOMe, MeOH; (ill) 
cyclohexylmethyl MgBr, ether, 0 °C; (iv) RCH2COCH2R, base, then diketone 
(77); (v) aqueous acid.
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Due to the C-2 nature of the molecule, b/s-chemistry could be used in order 
to minimise the number of reactions required. Diethyl L-tartrate already 
possesses the required (R,R)-absolute stereochemistry for the hydroxyls and so 
was identified as an ideal precursor. The ketal (75) was formed in 60% yield 
using acetone and a catalytic amount of conc. H2SO4 by the method of 
Ikemoto.’'®® However, this extremely simple preparation was abandoned as 
optical rotation experiments revealed épimérisation. Similar methods of ketal 
protection had also produced é p i m é r i s a t i o n . However, ketal protected 
dimethyl L-tartrate was available from Aldrich and so was subsequently used in 
the preparation of the diketone (77). The ketal protected b/s-N-methoxy-N- 
methyl amide (76) was identified as an excellent precursor to the Grignard 
reaction. Weinreb"'®'' had first used these amides in the preparation of ketone 
and aldehydes. A major problem in the use of organometallics to form ketones, 
is the formation of unwanted tertiary alcohol. Due to the reactivity of the 
organometallic reagent and the electrophilic nature of the ketone, it is difficult to 
prevent further addition of the organometallic reagent to the ketone. However, 
the reaction involving the Weinreb amide proceeds through a very stable metal- 
chelated intermediate (see below. Scheme 2.7) and therefore even the use of 
excess Grignard does not result in tertiary alcohol formation.
R-
O
II O - C H 3 R' M
CHr THF
0-M
R - ^ ^ > - C H 3
R' 1CHg
H3O+ oIIR -C — R'
Scheme 2.7. Ketone formation via Weinreb amides.
Several routes towards the b/s-amide (76) were attempted. These included 
b/s-activation of L-tartaric acid via acid chloride and mixed anhydride formation. 
Both methods proved unsuccessful due primarily to insolubilty problems. Hence 
a method that used L-tartaric acid esters was needed. In this way the insolubility 
problems associated with the L-tartaric acid could be overcome. Seebach^# 
had synthesised the b/s-dimethyl amide from diethyi L-tartrate and so this 
method seemed promising. N, 0-dimethylhydroxylamine should react in a 
similar manner. However, reaction of diethyl L-tartrate and ketal protected
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diethyl L-tartrate (75) with N, 0-dimethylhydroxylamine proved unsuccessful.
The synthesis of the ketal protected b/s-cyclohexylmethyl ketone (77) was 
achieved by an alternative reaction using the method of Kikkawa et a/.^^ This 
method involves the reaction of Grignard reagents with carboxylic esters, using 
triethylamine to prevent tertiary alcohol formation. The exact role of the 
triethylamine is not weli understood, although it is believed to prevent tertiary 
alcohol formation by énolisation of the resultant ketone. Alternatively, the 
triethylamine may complex to the Grignard therefore lowering its reactivity. This 
reaction was attempted using ketal (75) and cyclohexylmethylmagnesium 
bromide in ether and after silica chromatography afforded the desired diketone 
(77) in 21% yield (see below. Scheme 2.8). An identical reaction in the absence 
of triethylamine, produced predominantly b/s-tertiary alcohol (identified by ‘•H 
NMR) and no diketone (77).
o o o o
RO^
%
Compound (77)
Where R = Methyl or Ethyl
Scheme 2.8. Synthesis of the diketone (77).
(i) 2.5 eq. Cyclohexylmethyl MgBr, 6 eq. EtgN, ether, 0 °C.
This reaction was successfully repeated on several occasions using 
previously prepared diethyl L-tartrate ketal (75) and the purchased dimethyl L- 
tartrate ketal. The best yield so far achieved was 32% after purification. The 
reaction was also successfully completed in THF, although this result has not 
been repeated by Neil Piggot. An insoluble solid which proved difficult to 
remove in the work up, appeared during the reaction in ether and therefore THF 
seemed a suitable alternative. However, Piggot has consistently produced the 
half tertiary alcohol, half ketone adduct probably due to the increased reactivity 
of the Grignard in THF. At present, a combination of THF/ ether is being used in
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order to improve the yield of this step.
The key step of the synthesis has yet to be achieved and involves reaction of 
the novel diketone (77) to form the 7 membered ring system. Preformed 
enolates of activated ketones and tricarbonyl analogues were used in an 
attempted reaction with the diketone (77). If a reaction at one of the diketone 
carbonyls could be achieved, cyclisation, producing the 7 membered ring, 
should occur in an intramolecular fashion. Cyclohexylalanine was chosen in 
preference to phenylalanine residues due to the decreased acidity of the
protons a to the carbonyl group. In this way the problem of intramolecular aldol- 
type condensation of the diketone could be avoided.
Reaction of the enolate of dimethyl acetonedicarboxylate (preformed using 
NaOMe) with the diketone (77) did not occur at room temperature. However, 
repeating the reaction under refluxing conditions produced a UV active spot by 
TLC. However, after purification and characterisation it was discovered that this 
reaction had produced a substituted cyclopentenone derivative (78) (see 
below, Figure 2.19). This was caused by the aforementioned intramolecular 
cyclisation of diketone (77).
Figure 2.19. Substituted cyclopentenone (78), produced from the 
Intramolecular cyclisation of diketone (77).
This reaction was a disappointment, although it highlights the synthetic utility 
of this type of diketone (77). For instance, this reaction gives an extremely short 
route to substituted cyciopentenones that contain a protected d id system with 
fixed absolute stereochemistry. The ketal can easily be removed to yield the 
subsequent diol. The absolute stereochemistry of the diol can be altered simply
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by using dimethyl D-tartrate or meso-dimethyl tartrate and variation of the 
Grignard reagent can be used to alter the side chains.
An examination of the literature revealed the reaction of dimethyl 
ace toned ica rboxy la te  w ith 1 , 2 -d icarbonyl com pounds to y ie ld  
cyclopentadienones. Cook and Weiss^®^ have used this methodology in the 
preparation of polyquinanes and Eguchi ef a/.^ Gs have used dibenzyl ketone in 
the same type of condensation reaction. Although, 1, 2-dicarbonyl compounds 
would be more reactive towards this type of condensation reaction than our 
diketone (77), this reaction was attempted under the same conditions (NaOH 
and EtOH), using both dimethyl acetonedicarboxylate and dibenzyl ketone. After 
a few days, no desired cyclisation had occurred, except for a small amount of 
the cyclopentenone derivative (78) (see Figure 2.19).
Unfortunately, the total synthesis of our target molecule has not been 
achieved by myself in the short term. This molecule is currently being pursued 
by Neil Piggot in our laboratory and future work includes the use of more 
reactive dianions in an attempt to achieve cyclisation. Reaction of the dianion of 
the Wittig reagent, diethyl (2-oxopropyl)-phosphonate (shown below in Figure 
2.20) with the diketone (77) will be attempted under kinetic conditions.
O O 
E tO ^  g
EtO'^ -
(1) (2)
Figure 2.20 Dianion required for the cyclisation.
The reaction of this dianion should proceed by an initial attack of the more 
reactive anion (2), followed by the intramolecular reaction of (1). If successful, a 
reaction with the corresponding dianion of dibenzyl ketone will be attempted 
under the same conditions. This allows the introduction of side chains, which 
can bind in the S2 and 82- subsites.
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CHAPTER THREE
EXPERIMENTAL
3.0 Experimental.
NMR Spectra were recorded on a Bruker AM-300 f.t. spectrometer (^H, 300 
MHz; 75 MHz; 121.5 MHz) and a Varlan Gemini f.t. spectrometer OH, 
200 MHz; ‘‘^C, 50 MHz). High field NMR spectra were obtained on a service 
basis at the University of Edinburgh OH, 600 MHz; 150 MHz; ^ip, 243 MHz) 
^H NMR spectra were referenced on chloroform, methanol or DMSO, ‘'^C NMR 
spectra were referenced on chloroform, methanol or DMSO and ^ ip  spectra on 
external H3PO4. NMR spectra are described in parts per million downfield shift 
from TMS and are reported consecutively as position (6 |-| or Ôq), relative 
integral, multiplicity (s-singlet, d-doublet, t-triplet, q-quartet, m-multiplet, d. of d.- 
doublet of doublets and br-broad), coupling constant (Jx.y Hz if applicable) and 
assignment. Infrared spectra were recorded using a Perkin Elmer 1420 ratio 
recording spectrometer and a Perkin Elmer 1710 f.t. i.r. spectrometer. The 
samples were prepared as nujol mulls or thin films between sodium chloride 
discs. Absorption maxima are given in wavenumbers (cm’ i) relative to a 
polystyrene standard. Melting points were measured using electrothermal 
melting point apparatus and are uncorrected. Optical rotations were measured 
on an Optical Activity Ltd. AA-100 polarimeter using 10 cm path length cells at 
room temperature. Mass spectra were recorded on a Kratos MS50 and 
obtained on a S.E.R.C. service basis at the University of Swansea using a VG 
ZAB E. Major fragments are given as percentages of the base peak intensity. 
Where appropriate, all solvents and reagents were freshly distilled prior to use. 
THF and ether were distilled from sodium/ benzophenone under a nitrogen 
atmosphere; DMF and CH2CI2 were distilled from CaH2. Flash chromatography 
was performed according to the procedure of StilF®® using Sorbisil C60 (40-60 
jL im ) silica gel. Analytical thin layer chromatography was carried out on 0.25 mm 
precoated siliga gel plates (MN SIL G/UV254) or on 0.1 mm precoated cellulose 
plates (CEL MN 300-10 /UV254), and compounds were visualised by UV 
fluorescence, iodine vapour, ethanolic phosphomolybdic acid, aqueous 
potassium permanganate or ninhydrin.
93
B.ag.-(2S)-i.sQlgucyhisQbuty.lamidg i lZ l
o
o
Boc-(2S)-isoleucine (4.62 g, 20 mmol) was dissolved in anhydrous THF (100 
ml), N-methylmorpholine (2.18 ml, 20 mmol) was added and the solution cooled 
to -15 °C. Isobutylchioroformate (2.72 ml, 20 mmol) was added with stirring. The 
solution was left for 5 min. Isobutylamine (1.99 ml, 20 mmol) was added at -15 
°C and the solution left for 5 min. The solution was allowed to stir at room 
temperature for a further 15 min. The hydrochloride salts were filtered off and 
the THF removed under reduced pressure to yield a white solid which was 
recrystallised from methanol/ water (4.85 g, 85%), m.p. 158-160 °C; (Found: C, 
63.07; H, 10.57; N, 9.82. C15H30N2O3 requires C, 62.90; H, 10.56; N, 9.78%);
m/z (Found: [M+  H]+ 287.2335. C15H31N2O3 requires 287.2335); [a]o-27.1°(c 1 
in MeOH); V^ nax (nujol)/ cm-i 3335 (NH str.), 1682 (CO str. (urethane)), 1655 (CO 
str. (amide)) and 1526 (NH bend); (200 MHz, C^HCy 0.9 (12H, m, CHg's 
(a,b,c)), 1.10 (1H, m, 1 x CHg (He)), 1.42 (9H, s, Boo), 1.50 (1H, m, 1 x CH2 (He)), 
1.7-1.9 (2H, m, CH (iBu) & CH (He)), 2.98-3.20 (2H, m, CH2 (iBu)), 3.84 (1H. d. of 
d., J7.0, 9.0 Hz, a H), 5.08 (1H, d, J 8.6 Hz, NH (urethane)) and 6.10 (1H, t, J
5.0 Hz, NH (amide)). Ôq (50.3 MHz, C^HCy 12.0 (IlH3 (a)), 16.2 (£H3 (b)), 21.0 
(ÜH3 ‘s (c)), 25.2 (ÛH2 (He)), 28.9 (Boo ÛH3’s), 29.0 (ÛH (iBu)), 37.9 {Qy{ (He)),
47.4 (ÜH2 (iBu)), 60.2 (a Û.H), 80.8 (Ü(CH3)3), 156.6 (Qp urethane) and 172.2 
{OP amide); m/z (Cl) 287 ([M+ H]+, 8%), 231 ([M + H- (H3C)2CCH2]+, 48), 213 
{[M + H -  (H3C)2CCHg - H20 ]+, 42) and 187 ([M + H - Boc]+, 100).
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(2SMsoleucvl-isobutvlamide hydrochloride (38).
HCI gas was bubbled Into ethyl acetate (150 ml) at 0 °C tor 1 h. Boc-(2S)-lle- 
NH-IBu (37) (4.94 g, 17 mmol) was added to the acidic solution and left for 1.5 
h. at room temperature. The solvent was removed under reduced pressure to 
yield an off white solid (3.45 g, 90%) that was used immediately in the 
preparation of Boc-(2S)-Pro-(2S)-lle-NH-iBu (39), m/z (Found: [M + H  - HCI]+ 
187.1810. C10H23N2O requires 187.1810); v^ax (nujol)/ cm’’ 3200 & 3080 (NH 
str.), 1668 (CO str.) and 1568 & 1520 (NH bend); 6^  (200 MHz, C^HCIg) 0.9 
(12H, m, CHg's (a,b,c)), 1.15 (1H, m, 1 x CHg (lie)), 1.55 (1H, m, 1 x CHg (lie)),
1.80 (2H, m, CH (IBu) & CH (lie)), 2.82 & 3.10 (2H, m, CHg (IBu)), 3.65 (1H, d, J
4.8 Hz, a  CH), 8.3 (3 H, br, NH3+) and 8.64 (1H, t, J5.4 Hz, NH (IBu)); Sg (50.3 
MHz, C2HCy 12.02 (CHg (a)), 15.17 (^Hg (b)), 20.89 (SIHg's (c)), 25.42 (fiHg 
(lie)), 28.69 (C.H (IBu)), 37.19 (£H (lie)), 47.86 (ilHg (iBu)), 58.48 (a £H) and 
168.91 (£.0  amide); m/z (Cl) 187 ([M+ H - HCI]+, 100%).
Boo-f2S1-prolvl-(2S1-isoleucvl-isobutvlamide (391.
A
Boc-(2S)-proline (430 mg, 2 mmol) was dissolved in anhydrous THF (20 ml), N- 
methylmorpholine (218 pi, 2 mmol) was added and the solution cooled to -15 
°C. Isobutylchioroformate (272 pi, 2 mmol) was added with stirring and the 
solution left for 5 min. at -15 °C. (2S)-lle-NH-iBu hydrochloride (38) (450 mg, 2 
mmol) and N-methylmorpholine (218 pi, 2 mmol) were dissolved in THF and 
added to the cold solution. The reaction was left at -15 for 5 min. and a 
further 15 min. at room temperature. The hydrochloride salts were filtered off
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and the THF removed under reduced pressure to yield a white solid which was 
recrystaliised from ethyl acetate/ light petroleum (698 mg, 91%), m.p. 126-128 
°C; m/z (Found; [M +  H]+384.286. CggHggNgO  ^requires 384.2862); [ajg -85.5° 
(c 1 in MeOH); V^ax (nujol)/ cm ’ 3292 & 3089 (NH str.), 1706 (CO str. 
(urethane)), 1645 (CO str. (amide)) and 1553 (NH bend); 5^ (200 MHz, C^HCy 
0.85 (12H, m, CHg's (a,b,c)), 1.05 (1H, m, 1 x CHg (He)), 1.40 (1H, m, 1 x CHg 
(He)), 1.45 (9 H, s, Boc), 1.7-2.3 (6H, m, CH (iBu), CH (lie) & CHg’s (2) & (3) 
(Pro)), 2.85-3.2 (2 H, m, CHg (iBu)), 3.45 (2H, br, CHg (1) (Pro)), 4.25 (2H, br, a 
CH’S) and 6.67 & 6.94 (2H, br, NH’s); 5q (50.3 MHz, C^HCy 12.0 (£Hg (a)),
16.0 (£H3 (b)), 20.8 (£Hg's (c)), 24.6 (GHj (2) Pro), 25.2 (£Hg (He)), 28.6 (£H 
(iBu)), 28.7 (Boc £Hg’s), 29.3 (£Hg (3) Pro), 36.4 (£H (He)), 47.4 (ÜHj (IBu)), 
47.7 (£Hg (1) Pro), 58.6 (a £H (He)), 61.0 (a £H  (Pro)), 81.3 (£(CHg)g), 156.2 
(£ 0  urethane), 171.4 (£ 0  (He)) and 172.4 (£ 0  (Pro)); m/z (Cl) 384 ([M + H]+, 
60%), 328 ([M+ H - (HgC)gCCH2]+, 66) and 284 ([M+ H- Boc]+, 53).
(2S)-Prolvl-(2S)-isoleucvl-lsobutvlattiide hydrochloride (401.
This deprotection was carried out in an identical manner to (38), using (39) (1.0 
g, 2.6 mmol) in acidic ethyl acetate (50 ml) to yield a white solid, which was 
recrystallised from methanol/ ethyl acetate (675 mg, 81%), m.p. 220 °C (dec.); 
(Found: C, 56.29; H, 9.23; N, 12.93. C^gHgoNgOgCI requires C, 56.39; H, 9.47; N, 
13.16%); m/z (Found: [M +H  - HCI]+284.2338. C15H30N3O2 requires 284.2338); 
[a)o-66 . r  (c 1 in MeOH); v^ax (nujol)/ cm ’ 3280 (NH str.), 1655 & 1637 (CO 
str. (amides)) and 1538 (NH bend); 5^ (600 MHz, d@-DMSO) 0.85 (12H, m, 
CHg’s a,b,c), 1.10 (1H, m, 1 X CH2 (He)), 1.45 (1H, m, 1 x CH2 (He)), 1.67 (1H, m, 
CH (iBu)), 1.74 (2H, m, 1 X CH2 (3) (Pro) & CH (He)), 1.84 (2H, m, CH2 (2) (Pro)),
2.29 (1H, m, 1 X CH2 (3) (Pro)), 2.80 (1H, m, 1 x CH2 (iBu)), 2.95 (1H, m, 1 x CHg
(iBu)) 3.15-3.3 (2H, m, CHg (1) (Pro)), 4.18 (1H, d. of d., J7.80, 8.50 Hz, o CH 
(He)), 4.23 (1H, d. of d., J6.90, 8.10 Hz, a CH (Pro)), 8.15 (1H, t, J5.85 Hz, NH 
(iBu) and 8.65 (1H, d, J8.50 Hz, NH (He)); ôq (50.3 MHz, dg-DMSO) 11.0 (£Hg 
(a)), 15.3 (£Hg (b)), 20.0 (£Hg (c)'s), 23.6 (£Hg (2) (Pro)), 24.4 (£Hg (He)), 28.0 
(£H (iBu)), 29.9 (£H2 (3) (Pro)), 36.8 (£H (He)), 45.4 (£Hg (1) (Pro)), 45.9 (£Hg
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(iBu)), 57.8 (et QH (Ile)), 58.6 (a QH (Pro)), 168.2 (D.0 (He)) and 170.8 (Qp 
(Pro)); m/z (Cl) 284 ([M +H - HCI]+, 100%).
Cbz-Phe-\|/fP(OM e)0-NHl-iBu (41).
Using a modification of the method of B a r t le t t ,m e th y l hydrogen [1-(N- 
benzyloxycarbonyl)-amino]-benzylphosphonate (35) (698 mg, 2 mmol) was
dissolved in anhydrous CH2CI2 (10 ml). Freshly distilled thionyl chloride (300 pi, 
4 mmol) was added and the solution flushed with argon for 1 min. After 4 h., the 
solution was flushed again and the solvent removed under reduced pressure. 
The colourless oil was rediluted with anhydrous GH2CI2 (5 ml) and reflushed 
with argon. This process was repeated and the colourless oil redissolved in
GH2CI2 (20  ml). Isobutylam ine (500 pi, 5mmol) was added to the 
chlorophosphonate at 0 °G and left to react at room temperature for 24 h. under 
an atmosphere of nitrogen. The organic solution was washed with 1 M HGI (2 x 
30 ml), saturated sodium bicarbonate (2 x 30 ml) and water (30 ml) and then 
dried over anhydrous sodium sulphate. After filtration, the solvent was removed 
under reduced pressure to yield an off white solid, which was recrystallised from 
ethyl acetate/ light petroleum (650 mg, 80%), m/z (Found: [M +  H]+ 405.1943. 
C21H30N2O4P requires 405.1943); 0^ (200 MHz, G2HGI3) 0.85 (6H, d, J7.5 Hz, 
GH3’s), 1.60 (1H, m, GH (IBu)), 2.5-2.8 (2H, m, GHg (IBu)), 2.9 (1H, m, 1 x 
ArGJd2G), 3.2 (1H, m, 1 x ArGH2G), 3.7 (3H, d, Jp ^ lO.O Hz, P0 (0 GH3)), 4.3 (1H, 
m, GH*), 4.95 (2H, s, ArGH20 ), 5.40 (1H, d, J8.5  Hz, NH) and 7.25 (10H, m, 
aromatic); Ôq (50.3 MHz, G2HGI3) 20.67 (G-Hg’s), 31.0 (G.H (iBu)), 36.5 
(ArIlH2G), 49.41 {QH2 (iBu)), 49.36 & 51.27 (d, QH* J p c  143.5 Hz), 51.79 &
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51.70 (d, P0 (0 £LH3), Jp,c7.2 Hz), 67.67 (Ar^HgO), 127.5-130.12 (aromatic ÛH),
137.32 & 137.8 (quat. aromatic) and 155.8 (^O urethane); m/z (Cl) 405 ([M + 
H]+, 49%), 349 ([M +H  - (CH3)2CCH2]+, 10), 332 ([M +H  - (GH3)2CHCH2NH2]+ 
68) and 297 ([M +H - ArCH2 0H]+, 20).
Cbz-Phe-x|/rP(OMe)0-N1-(2S)-Pro-(2S)-lle>NH-iBu (42),
.OCH
NH
2
3
The chlorophosphonate derivative was prepared in an identical manner to (41) 
using methyl hydrogen [1-(N-benzyloxycarbonyl)-amino]-benzylphosphonate 
(35) (1.22 g, 3.5 mmol). (2S)-Pro-(2S)-lle-NH-IBu hydrochloride (40) (1.12 g,
3.5 mmol) in CH2CI2 (20 ml) with triethylamine (1.05 ml, 7.5 mmol) was added 
dropwise at 0 °C. The reaction was left at room temperature for 24 h. under an 
atmosphere of nitrogen. The organic solution was washed with 1 M HGI (2 x 30 
ml), saturated sodium bicarbonate (2 x 30 ml) and water (30 ml) and then dried 
over anhydrous sodium sulphate. After filtration, the solvent was removed under 
reduced pressure to yield an off-white solid (1.40 g, 65%). The diastereomers 
were resolved by silica chromatography (5% EtOH/ GH2GI2);
Cbz-(R).Phe-\rt(S)-P(OMe)0-N]-(2S)-Pro-(2S)-He-NH-iBu (a);
M.p. 82 °C (dec.); m/z (Found: [M + H]+ 615.3311. G32H48N4O6P requires
615.3311); M o -129.8^ (c 0.5 in MeOH); v^^ax M o l) /  cm-i 3401 (NH str.), 1716 
(GO str. (urethane)), 1669 & 1652 (GO str. (amide)), 1260 (P=0 str.) and 1050 
(P-OGH3); 8|_j (600 MHz. G2HGI3) 0.85 (12H, m, GH3's (a,b,c)), 1.03 (1H, m, 1 x 
GH2 (lie)), 1.46 (1H, m, 1 x GH2 (lie)) 1.66-1.82 (4H, m, GH2 (2) (Pro), GH (iBu) &
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1 X CHg (3) (Pro)), 2.00 (1H, m, 1 x CHg (3) (Pro)), 2.15 (1H, m, CH (lie)), 2.88 
(1H, m, 1 X ArCMa), 3.00-3.20 (4H, m, CHg (IBu), 1 xCHg(1) (Pro) & 1 xArCÜ2),
3.30 (1H, m, 1 X CHg(1) (Pro)), 3.74 (3H,d,Jp H 10.71 Hz, PO(OCHg)), 4.11 (1H, 
m, a  CH (Pro)), 4.33 (1H, d. of d., J5.0, 9.3 Hz, a  CH (lie)), 4.46 (1H, m, CH*),
4.94 (2H, s, ArCHzO), 5.09 (1H, d, J  10.44 Hz, NH (urethane)), 6.93 (1H, t, J5.50 
Hz, NH (IBu)) and 7.18-7.32 (11H, m, aromatic & NH (lie)); Sg (74.76 MHz,
C^HCIg) 11.54 (QHa (a)), 15.71 (ÛH3 (b)), 20.03 (ÛH3 (c)), 24.52 (^Hg (lie)),
25.24 (C.Hg (2 ) (Pro)), 28.13 (CH (IBu)), 30.54 (CHg (3) (Pro)), 35.69 (AtCHgC),
36.32 (CH (lie)), 46.69 & 48.60 (d, CH*, V p c l44.2 Hz), 46.81 (CHg (IBu)), 46.91 
(CHg (1) (Pro)), 50.95 & 51.05 (d, P0 (0 CH3) /p ,c 7 .6 Hz), 57.90 (a CH (lie)), 
62.59 (a CH (Pro)), 66.84 (ArCHgO), 126.61-128.96 (aromatic CH’s), 135.99 &
136.25 (quat. aromatic), 155.77 (CO urethane), 170.80 (CO (lie)) and 172.84 
(CO (Pro)); 8p (121.5 MHz, C^HCIg) 31.14; m/z (FAB) 637 ([M+ Na]+, 32%), 615 
([M+ H]+, 22) and 332 ([M +H - Pro-lle-IBu]+, 37).
Cbz-(S)-Phe-v[(S)-P(OMe)0-N]-{2S)-Pro-(2S)-ile-NH-iBu (b);
M.p. 90 °C (dec.); m/z (Found: [M  + H]+ 615.3311. CggH^^gN^OgP requires
615.3311); [aJc -74.1° (c 0.5 In MeOH); (nujol)/ cm-i 3247 (NH str.), 1721 
(CO str. (urethane)), 1677 & 1645 (CO str. (amide)), 1224 (P=0 str.) and 1039 
(P-OCH3); 5h (600 MHz, C^HCy 0.85 (12H, m, CHg’s (a,b,c)), 1.01 (1H, m, 1 x 
CHg (lle)),1.44 (1H, m, 1 x CHg (lie)) 1.66 (2 H, m, CHg (2) (Pro)), 1.80 (1H, m, 
CH (IBu)), 1.98 (1 X CHg (3) (Pro)), 2.13 (2H, m, 1 x CHg (3) (Pro) & CH (lie)),
2.84 (1H, m, 1 X ArCHg)), 3.02 (1H, m, 1 x CHg (IBu)), 3.10 (2H, m, 1 x CHg (1) 
(Pro) & 1 X CHg (IBu) ), 3.21 (2H, m, 1 x CHg(1) (Pro) & 1 x ArCHg)), 3.69 (3H, d, 
Jp H 10.62 Hz, P0 (0 CH3)), 4.10 (1H, m, a  CH (Pro)), 4.33 (1H, d. of d., J4.95,
9.52 Hz, a CH (lie)), 4.49 (1H, m, CH*), 4.98 (2H, ABq, J  12.36 Hz, ArCHgO), 
5.18 (1H, d, J10.1 Hz, NH (urethane)) and 7.10-7.32 (12H, m, NH (IBu), NH (lie) 
& aromatic); Sg (74.76 MHz, C^HCIg) 11.48 (CH3 (a)). 15.87 (CH3 (b)), 20.07 
(CH3 (c)), 24.36 (CHg (lie)), 25.08 (CHg (2) (Pro)), 28.08 (CH (IBu)), 30.83 (CHg
(3) (Pro)), 35.93 (AiCHgC), 36.12 (CH (lie)), 46.86 (CHg (IBu)), 47.88 & 49.74 (d, 
CH*, Jp,c 139.9 Hz), 48.41 (CHg (1) (Pro)), 51.56 & 51.66 (d, PO(OCH3), Jp g 7.2 
Hz), 57.96 (a CH (lie)), 61.08 (a CH (Pro)), 66.88 (ArCHgO), 126.76-129.03
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(aromatic CH’s), 136.09 & 136.25 (quat. aromatic), 155.49 (CO urethane),
170.89 (CO (lie)) and 172.62 (CO (Pro)); 8p (121.5 MHz, C^HCIg) 30.19; m/z
(FAB) 637 ([M + Na]+, 10%), 615 ([M + H]+, 12) and 332 ([M + H- Pro-ile-iBu]+, 
21).
Cbz-(S)-Phe-\|/[(R)-P(OMe)0-N]-(2S)-Pro-(2S)-lle-NH-IBu (c);
M.p. 186-187 °C; (Found: C, 62.82; H, 7.88; N, 9.10. CggH^yN^OgP requires C, 
62.53; H, 7.71; N, 9.11%); m/z (Found: [M + H]+ 615.3311. CggH^gN^OgP 
requires 615.3311); [a]g -30.1° (c 0.5 in MeOH); (nujoi)/ cm-i 3252 (NH 
str.), 1721 (CO str. (urethane)), 1677 & 1645 (CO str. (amide)), 1225 (P=0 str.) 
and 1028 (P-OCHg); 8^  (600 MHz, C^HCIg) 0.85 (12H, m, CHg’s (a,b,c)), 1.06 
(1H, m, 1 X CHg (He)), 1.42 (1H, m, 1 x CHg (He)), 1.74 (2H, m, CHg (2) (Pro)),
1.80 (1H, m, CH (iBu)), 1.92 (1H, m, CH (He)), 1.98 & 2.12 (2H, m, CHg (3) (Pro)),
2.89 (1H, m, 1 X ArCHg)), 3.01 (1H, m, 1 x CHg (iBu)), 3.18 ( 3H, m, 1 x CHg (1) 
(Pro), 1 X CHg (IBu) & 1 X ArCHg). 3.29 (1H, m, 1 x CHg (1) (Pro)), 3.66 (3H, d,
10.68 Hz, PO(OCHg)), 4.22 (1H, d. of d., J8.10, 9.30 Hz, a  CH (He)), 4.27 
(1H, m, a CH (Pro)), 4.46 (1H, m, CH*), 4.92 (2H, ABq, J  12.36 Hz, ArCHgO),
6.47 (2 H, m, NH's (urethane & IBu)), 7.03 (1H, d, J9.30 Hz, NH (He)) and 7.25 
(10H, m, aromatic); 8q (74.76 MHz, C^HCy 10.71 (CHg (a)), 15.40 (CHg (b)),
20.03 (CHg (c)), 24.62 (CHg (He)), 25.31 (CHg (2) (Pro)), 28.21 (CH (IBu)), 31.48 
(CHg (3) (Pro)), 35.71 (ArCHgC), 36.25 (CH (He)), 46.84 (CHg (IBu)), 47.52 (CHg
(1) (Pro)), 48.16 & 50.12 (d, CH*, Jpg 148.3 Hz), 51.31 & 51.41 (d, PO(OCHg)_
Jp,c7.3 Hz), 57.73 (a CH (He)), 61.37 (a CH (Pro)), 66.65 (ArCHgO), 126.49-
129.13 (aromatic CH ’s), 136.28 & 136.70 (quat. aromatic), 156.35 (CO 
urethane); 171.17 (CO (He)) and 173.34 (CO (Pro)); 8p (121.5 MHz, C^HCIg) 
31.64; m/z (FAB) 637 {[M+ Na]+, 23%), 615 {[M+ H]+, 27) and 332 ([M +H  - Pro- 
He-iBu]+, 28).
Cbz-(R)-Phe-\t<[(R)-P(OMe)0-NH2S)-Pro-(2S)-jle-NH-IBu (d);
M.p. 163-164 °C; (Found: C, 62.70; H, 7.92; N, 9.21. CggH^^N^OgP requires C, 
62.53; H, 7.71; N, 9.11%); m/z (Found: [M + H]+ 615.3311. CggH^gN^OgP 
requires 615.3311 ); [a]g -47.0° (c 0.5 In MeOH); (nujol)/ cm-'' 3354 & 3209
1 0 0
(NH str.), 1695 (CO str. (urethane)), 1672 & 1652 (CO str. (amide)), 1252 (P=0 
str.) and 1036 (P-OCHg); 8^  (600 MHz, C^HCIg) 0.85 (12H, m, CHg’s a,b,c), 1.14 
(1H, m, 1 X CHg (lie)), 1.50 (1H, m, 1 x CHg (lie)), 1.76 (3H, m, CHg (2) (Pro) & 
CH (IBu)), 1.92 (1H, m, 1 X CHg (3) (Pro)), 2.05 (2H, m, 1 x CHg (3) (Pro)), CH 
(He)), 2.80 (1H, m, 1 X ArCJlg)). 2.98 (1H, m, 1 x CHg (IBu)), 3.07 (2H, m, 1 x CHg 
(IBu) & 1 X CHg(1) (Pro)), 3.18 ( 1H, m, 1 x CHg (1) (Pro)), 3.28 (1H, m, 1 x 
ArCHg), 3.60 (3H, d, Jp,H 10.53 Hz, PO(OCHg)), 4.18 (1H, d. of d., J  7.95, 8.85 
Hz, a  CH (He)), 4.32 (1H, m, a  CH (Pro)), 4.45 (1H, m, CH*), 4.97 (2H, ABq, J
12.3 Hz, ArCHgO), 5.08 (1H, d, J9.92 Hz, NH (urethane)), 6.61 (1H, t, J5.85 Hz, 
NH (IBu)), 7.25 (10H, m, aromatic) and 7.45 (1H, d, J 8.85 Hz, NH (He)); 8c  
(74.76 MHz, C^HCIg) 11.02 (CHg (a)), 15.51 (CHg (b)), 19.98 (CHg (c)), 24.67 
(C.Hg(He)), 25.80 (CHg (2) (Pro)), 28.18 (CH (IBu)), 31.12 (CHg (3) (Pro)), 35.61 
(ArCHgC), 35.88 (CH (He)), 46.73 (CHg (IBu)), 47.55 (CHg (1) (Pro)), 49.46 & 
50.40 (d, CH*, Jp,c 146.5 Hz), 51.51 &51.60 (d, PO(OCHg), Jp,c7.4 Hz), 58.22 (a 
CH (He)), 62.23 (a CH (Pro)), 66.89 (ArCHgO), 126.64-128.94 (aromatic CH’s),
136.04 & 136.30 (quat. aromatic), 155.77 (CO urethane), 170.91 (CO (He)) and
173.31 (CO (Pro)); 8p (121.5 MHz, C^HCIg) 28.90; m/z (FAB) 637 ([M + Na]+,
27%), 615 ([M+ H]+, 18) and 332 ([M+ H- Pro-lle-iBu]+, 13). 
Boc-(2S1-Asn-Phe-\|;rPfOMe10-N1-(2S>-Pro-(2Si-lle-NH-lBu (441.
X /
CONHg
Cbz-(R)-Phe-\i/[(S)-P(OMe)0-N]-(2S)-Pro-(2S)-lle-NH-iBu (42a) (70 mg, 110 
limol) was dissolved in methanol (5 ml) and palladium/ carbon catalyst (20 mg,
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30% w/w) was added. The solution was stirred vigorously under a pressure of 
hydrogen gas (balloon) for 3 h. When the reaction had finished (by TLC), the 
catalyst was filtered off using celite. The colourless solution was concentrated
under reduced pressure to yield H2N-(R)“Phe-\j/[(S)-P(OMe)0 -N]-(2S)-Pro-(2S)- 
lle-NH-iBu (43) as a colourless oil (47 mg, 86%).
Boc-(2S)-Asn (22 mg, 95 pmol) was dissolved in anhydrous THF (5 ml) with 
warming. N-methylmorpholine (10.5 pi, 95 pmol) was added and the solution 
cooled to -15 °C. Isobutylchioroformate (13 pi, 95 pmol) was added and the 
solution left for 5 min. H2N-(R)-Phe-\i4 (S)-P(OMe)0 -N]-(2S)-Pro-(2S)-!le-NH-iBu 
(47 mg, 98 pmol) (43) was dissolved in anhydrous THF (2 ml) and added 
dropwise to the solution at -15 °C. The reaction was left for 5 min. at this 
temperature and a further 25 min. at room temperature. The hydrochloride salts 
were filtered off and the THF removed under reduced pressure to yield an off- 
white solid which was purified by silica chromatography (10% EtOH/ CH2CI2) to 
yield pure diastereomer (52 mg, 79%).
B oc-(2S)-A sn-(R )-Phe-\{^;(S )-P (O M e)0-N ]-(2S)-Pro-(2S)-IIe-N H -iB u
(a); M.p. 120 °C (dec); m/z (Found: [M + H]+ 695.387. CgsHgeNeOaP requires 
695.3897); [ajp -127°(c0.5 in MeOH); v^ax (nujol)/cm-i 3315 (NH str.), 1683 & 
1652 (CO str., br), 1251 (P=0 str.) and 1030 (P-OCH3); 6^  (600 MHz, QSHCIg) 
0.85 (12H, m, CHg’s (a,b,c)), 1.10 (1H, m, 1 x CHg (He)), 1.42 (9H, s, Boc CHg’s),
1.50 (1H, m, 1 X CHg (He)), 1.78 (1H, m, CH (IBu)), 1.88 (2H, m, CHg (2) (Pro)),
2.05 (3H, m, CHg (3) (Pro) & CH (He)), 2.46 (1H, ABX, J5.77, 15.10 Hz, 1 x CHg 
(Asn)), 2.62 (1H, d, J 15.2 Hz, 1 x CHg (Asn)), 2.95 (2H, m, 1 x ArCJi2 & 1 x CHg 
(IBu)), 3.11 (1H, m, 1 X CHg (IBu)), 3.17 (2H, m, 1 x ArCHg & 1 x CHg (1) (Pro)),
3.31 (1H, m, 1 X CHg(1) (Pro)), 3.75 ( 3 H , d , J p H  10.80 Hz, PO(OCHg)), 4.15 (1H,
m, a  CH (Pro)), 4.28 (1H, d. of d., J6.23, 8.61 Hz, a CH (He)), 4.32 (1H, m, a CH 
(Asn)), 4.74 (1H, m, CH*), 5.68 (1H, s, 1 x CONHg), 5.76 (1H, d, J6 .9 6  Hz, NH 
(urethane)), 5.99 (1H, s, 1 x  CONHg), 6.95 (1H, br, NH (IBu)), 7.18-7.28 (5H, m, 
aromatic), 7.32 (1H, d, J  8.79 Hz, NH (He)) and 7.44 (1H, d, J  8.79 Hz, NH 
(Asn)); ÔQ (150 MHz, C^HCIg) 11.53 (QHg (a)), 15.77 (^Hg (b)), 20.22 (^H g (c)),
24.89 (ÜHg (He)), 25.53 (jQHg (2) (Pro)), 28.35 (Boc & Q.H (iBu)), 31.13 
(ÛHg (3) (Pro)), 35.80 (Ar^HgC), 36.70 (CH (He)), 37.22 (CHg (Asn)), 45.55 &
1 0 2
46.5 (d, C.H*, Jp_o135 Hz), 47.01 (ÛHg (iBu)), 47.17 (ÛHg (1) (Pro)), 51.45 
(P0 (0 £ H 3)), 51.60 (a £H  (Asn)), 58.30 (a &H (Ile)), 62.29 (a £H  (Pro)), 80.48 
(ü(CHg)3), 126.65-129.26 (aromatic £ H ‘s), 136.77 (quat. aromatic), 156.6 (£.0 
urethane) and 171.13 & 173.56 (£.0 amides); 8p (121.5 MHz, C^HCy 30.30; 
m/z (FAB) 717 ([M + Na]+, 100%), 695 ([M + H]+, 38) and 412 ([M + H  - Pro-lle- 
IBu]+, 17).
B oc-(2S )-A sn-(S )-P he-\|/[(S )>P(O M e)0-N ]-(2S )-P ro-(2S )-lle-N H -iB u
(b ); (This was prepared in an Identical manner to the (R, S) diastereomer); m/z  
(Found: [M + H]+ 695.3897. CggHggNgOgP requires 695.3897); [a]g -54.5° (o 0.5 
In MeOH); Vg,gj( (nujol)/ cm"' 3287 (NH str.), 1717 (CO str. (urethane), 1657 & 
1652 (CO str., br), 1253 (P=0 str.) and 1043 (P-OCHg); 8^  (600 MHz, C^HCIg) 
0.85 (12H, m, CHg’s (a,b,c)), 1.06 (1H, m, 1 x CHg (lie)), 1.42 (9H, s, Boc CHg’s), 
1.49 (1H, m, 1 X CHg (lie)), 1.82 (3H, m, CH (IBu) & CHg (2) (Pro)), 2.06-2.20 
(4H, m, CHg (3) (Pro), 1 x CHg (Asn) & CH (He)), 2.46 (1H, d, J 14.83 Hz, 1 x CHg 
(Asn)), 2.80 (1H, m, 1 x ArCHg), 3.02 (1H, m, 1 x CHg (IBu)), 3.12 (1H, m, 1 x 
CHg (IBu)), 3.27 (3H, m, 1 x ArCHg & CHg (1) (Pro)), 3.76 (3H, d, Jp H 10.62 Hz,
PO(OCHg)), 4.16 (1H, m, a  CH (Pro)), 4.35 (2H, m, a CH (lie) & a  CH (Asn)),
4.81 (1H, m, CH*), 5.50 (1H, s, 1 x CONHg), 5.92 (1H, s, 1 x CONHg), 5.97 (1H, 
d, J  7.87 Hz, NH (urethane)), 7.18-7.32 (7H, m, aromatic CH’s & NH’s (IBu &
lie)) and 7.47 (1H, d, J8.06 Hz, NH (Asn)); 8^  (150 MHz, C^HCIg) 11.52 (£Hg 
(a)), 16.0 (£Hg (b)), 20.24 (£Hg (c)), 24.68 (£Hg (He)), 25.45 (£Hg (2) (Pro)),
28.32 (Boc CHg’s & £H (IBu)), 31.11 (£Hg (3) (Pro)), 36.02 (Ar£HgC), 36.26 (£H 
(He)), 36.99 (£Hg(Asn)), 46.75 & 47.55 (d, £H*, Jpg 120 Hz), 47.09 (£Hg(IBu)),
48.52 (£Hg (1) (Pro)), 51.15 (a£H  (Asn)), 52.20 (P0(0£Hg)), 58.32 (a £ H  (He)),
61.52 (a £H  (Pro)), 80.3 (£(CHg)g), 126.85-129.26 (aromatic £H 's), 136.75 
(quat. aromatic), 155.5 (£ 0  (urethane)) and 170.93, 171.39 & 173.19 (£ 0  
amides); 8p (121.5 MHz, C^HCIg) 30.43; m/z (FAB) 717 ([M + Na]+, 31%), 695
([M+ H]+, 22) and 412 ([M +H - Pro-lle-IBu]+, 13).
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B oc-(2S )-A sn-(S )-P he-\|4 (R )-P (O M e)0-N ]-(2S )-P ro-(2S )-lle -N H -iB u
(c); (This was prepared in an identical manner to the (R, S) diastereomer); m /z 
(Found: [M + H]+ 695.3897. CggHggNgOgP requires 695.3897); [a ]g -25.6“ (c 0.5 
In MeOH); v^gx (nujol)/ cm-' 3233 (NH str.), 1700, 1684 & 1652 (CO str., br), 
1224 (P=0 str.) and 1045 (P-OCHg); (600 MHz, C^HCIg) 0.85 (12H, m, CHg’s 
(a,b,c)), 1.13 (1H, m, 1 X CHg (lie)), 1.39 (9H, s, Boc CHg’s), 1.51 (1H, m, 1 x CHg 
(lie)), 1.82 (3H, m, CH (IBu), 1 x CHg (2) (Pro) & CH (lie)), 1.91 (1H, m, 1 x CHg
(2) (Pro)), 2.00 (1H, m, 1 x CHg (3) (Pro)), 2.07 (1H, br, 1 x CHg (Asn)), 2.21 (2H, 
m, 1 X CHg (3) (Pro) & 1 x CHg (Asn)), 2.86 (1H, m, 1 x ArCHg), 3.02 (1H, m, 1 x 
CHg (IBu)), 3.16 (2H, m, 1 x ArCHg & 1 x CHg (1) (Pro)), 3.26 (1H, m, 1 x CHg 
(IBu)), 3.32 (1H, m, 1 X CHg (1) (Pro)), 3.66 (3H, d, 10.62 Hz, PO(OCHg)),
4.25 (2H, m, a CH (Pro) & a CH (He)), 4.55 (1H, m, a  CH (Asn)), 4.78 (1H, m, 
CH*), 5.57 (1H, s, 1 X CONHg), 5.76 (1H, br., NH (urethane)), 6.01 (1H, s, 1 x 
CONHg), 6.76 (1H, br., NH (IBu)), 7.18-7.28 (5H, m, aromatic), 7.34 (1H, br, NH
(He)) and 7.83 (1H, d, J8.06 Hz, NH (Asn)); Sq (150 MHz, C^HCIg) 10.70 (£Hg 
(a)), 15.46 (£Hg (b)), 20.25 (£Hg (c)), 24.87 (£Hg (He)), 25.97 (£Hg (2) (Pro)), 
28.28 (Boc CHg’s & £H (IBu)), 31.69 (£Hg (3) (Pro)), 35.54 (Ar£HgC), 35.86 (£H 
(He)), 37.94 (£Hg (Asn)), 45.85 & 46.80 (d, £H*, Jpg 143 Hz), 47.09 (£Hg (1)
(Pro)), 47.21 (£Hg (IBu)), 51.45 (a £H (Asn)), 51.85 (P0(0£Hg)), 58.38 (a £H
(He)), 62.88 (a £H  (Pro)), 79.84 (£(CHg)3), 126.73-129.44 (aromatic £ H ’s),
137.14 (quat. aromatic), 155.9 (£ 0  (urethane)) and 171.60, 172.51 & 174.02 
(£ 0 ’s); 5p (121.5 MHz, C^HCIg) 30.58; m/z (FAB) 717 {[M + Na]+, 57%), 695 
([M+ H]+, 15) and 412 ([M +H - Pro-lle-IBu]+, 10).
B oc-(2S )-A sn-(R )-P he-y[(R )-P (O M e)0-N ]-(2S )-P ro -(2S )-lle -N H -iB u
(d ); (This was prepared In an Identical manner to the (R, S) diastereomer); m /z 
(Found: [M + H]+ 695.390. CggHggNgOgP requires 695.3897); [a ]g-61“ (c 0.5 In 
MeOH); v^igx (nujol)/ cm-' 3280 (NH str.), 1717 (CO str. (urethane)), 1683 & 
1652 (CO str., br), 1251 (P=0 str.) and 1024 (P-OCHg); 6p| (600 MHz, C^HCIg) 
0.85 (12H, m , CHg’s (a,b,c)), 1.14 (1H, m, 1 x CHg (He)), 1.43 (9H, s, Boc CHg’s),
1.53 (1H, m , 1 X CHg (He)), 1.77 (1H, m, CH (IBu)), 1.82-1.92 (2H, m, CHg (2) 
(Pro)), 1.95 (1H, m, 1 x CHg (3) (Pro)), 2.05 (1H, m, CH (He)), 2.12 (1H, m, 1 x
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CHg (3) (Pro)), 2.45 (1H, ABX., J6.64, 14.88 Hz, 1 x CHg (Asn)), 2.84 (1H, d, J  
15.10 Hz, 1 X CHg (Asn)), 2.84 (1H, m, 1 x ArCHg), 2.99 & 3.11 (2 H, m, CHg 
(iBu)), 3.23 (1H, m, 1 x CHg (1) (Pro)), 3.28 (2H, m, 1 x CHg (1) (Pro) & 1 x
ArCHg)), 3.62 (3H, d, Jp,n 10.62 Hz, PO(OCHg)), 4.18 (1H, t, J8.40 Hz, a  CH 
(He)), 4.38 (2H, m, a  CH (Pro) & a  CH (Asn)), 4.66 (1H, m, CH*), 5.56 (1H, s, 1 
X CONHg), 5.76 (1H, d, J7.78 Hz, NH (urethane)), 6.22 (1H, s, 1 x CONHg), 6.81 
(1H, br., NH (iBu)), 7.05 (1H, d, J9 .1 5  Hz, NH (Asn)), 7.18-7.28 (5H, m,
aromatic) and 7.62 (1H, d, J8.42 Hz, NH (He)); ôq (74.76 MHz, C^HCIg) 10.95 
(£Hg (a)), 15.58 (£Hg (b)), 20.04 (£Hg (c)), 24.84 (£Hg (He)), 25.75 (£Hg (2 ) 
(Pro)), 28.15 (Boc £Hg's), 28.27 (£H (IBu)), 31.35 (£.Hg (3) (Pro)), 35.85 
(Ar£HgC), 36.58 (£H (He)), 37.24 (£Hg (Asn)), 46.83 (£Hg (IBu)), 47.83 & 49.80 
(d, £H*, Jp,c148 Hz), 47.83 (£Hg (1) (Pro)), 51.32 & 51.42 (d, P0(0£Hg), Jp_g
7.3 Hz), 51.52 (a £H (Asn)), 58.58 (a £H (He)), 61.66 (a £H  (Pro)), 80.26 
(£(CHg)3), 126.61-129.21 (aromatic £H's), 136.6 (quat. aromatic), 155.4 (£ 0  
(urethane)) and 171.09, 171.42, 172.64 & 173.70 (£ 0  amides); 5p (121.5 MHz, 
C^HCIg) 27.63; m/z (FAB) 717 ([M+ Na]+, 80%), 695 {[M+ H]+, 37) and 412 {[M 
+ H- Pro-He-IBu]+, 19).
Lithium propane-1-thlolate (45)
Using a modification of the method of Bartlett,'^® freshly distilled 1 -propanethlol 
(5 ml, 55 mmol) was added to a suspension of finely ground lithium hydride (1.5 
g, 189 mmol). In anhydrous oxygen-free DMF (30 ml) under an Inert 
atmosphere. The reaction was left to stir at 25 °C for 1 h. followed by filtration 
without contact with air. The reagent was stored at 0 °C under argon pressure. 
The concentration of lithium propane-1-thlolate was typically 0.5-0.6 M.
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Cbz-Phe-\i/fP(OLi)0-NHMBu (46).
.OU
NH
A solution of Cbz-Phe-\}4P{0Me)0-NH]-iBu (41 ) (50 mg, 124 jamol) in dioxan (1 
ml) and 1 M lithium hydroxide (495 jil, 495 jiimol) was refluxed for 24 h. The 
white paste was filtered off and washed with cold water (1 ml). After drying, the 
product was recrystallised from methanol/ ether to yield a white solid (38 mg, 
77%), m/z (Found: [M + H]+ 397.1669. C2oH27N204PLi requires 397.1869); 6j_| 
(200 MHz, cfg-DMSO) 0.85 (6H, d, J7.5 Hz, CHg’s), 1.60 (1H, m, CH (iBu)), 2.6-
2.85 (3H, m, CH2 (iBu) & 1 x ArCH.2 ), 3.10 (1H, m, 1x ArCHa), 3.88 (1H, m, CH*),
4.95 (2H, s, ArCH20 ), 5.40 (1H, d, J 8 Hz, NH) and 7.25 (10H, m, aromatic); m /z 
(FAB) 397 ([M+H]+, 17%).
Boc-(2S)-Asn-Phe-\|/rP(OLi)0-N1-(2SVPro-(2SMIe-NH-iBu (48).
CONHg
Method 1.
This was prepared in an identicai manner to (46) using diastereomers (44a) 
and (44b) (50 mg, 72 p.moi) and lithium hydroxide (1 M) (288 pi, 290 pmol) to
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produce a white precipitate which was washed with acetone to remove any 
starting materiai (27 mg, 55%), m/z (Derivatised as methyl ester using CHgNg,
Found: [M + H]+ 695.3936. CggHgQNgOgP requires 695.3897) 0^ (200 MHz, 
MeOH) 0,90 (12H, m, CHg’s (a,b,c)), 1.22 (1H, m, 1 x CHg (He)), 1.45 (9H, s, Boc 
CHg’s), 1.50 (1H, m, 1 x CHg (He)), 1.7-2.4 (8H, m, CH (iBu), CHg (2) (Pro), CH 
(He), CHg (3) (Pro), CHg (Asn)), 2.75-3.5 (6 H, m, ArCHg, CHg (iBu), CHg(1)
(Pro)), 3.85 (1H, m, a CH), 4.3 (2H, m, a CH’s), 4.65 (1H, m, CH*) and 7.1-7.4
(5H, m, aromatic); Ôq (50.3 MHz, C^HCIg) 12.35 (GHg (a)), 16.64 (£Hg (b)), 
21.22 (HHg (c)), 26.30 (^Hg (He)), 28.82 (IlHg (2) (Pro)), 29.33 (Boc C.Hg’s), 
29.97 (QH (iBu)), 32.84 (^Hg (3) (Pro)), 38.56-41.01 (Ar^HgC), (QH (He)), (QHg
(Asn)), 48.22-50.16 (IlHg (iBu), (QH*) & £Hg (1) (Pro)), 52.20 (a QH (Asn)),
59.45 (a QH (lie)), 63.58 (a QH (Pro)), 80.35 (C.(CHg)g), 128.17-130.89 
(aromatic £ H ’s), 138.5 (quat. aromatic), 155.8 (C.O (urethane)) and 174.0-176.0 
(ÛO amides); 6p (121.5 MHz, d^-MeOH) 18.14, 16.33;
Method 2.
This was prepared using a modification of the method of M c k e n n a .i^ s  To a 
solution of isobutylene in anhydrous CHgClg (5 ml) (prepared by sparging with 
isobutylene gas for 10 min.) was added freshly distilled trimethylsilylbromide 
(55 pi, 440 pmol) under an argon atmosphere.
HgN-Phe-\i/[P(OMe)0-N]-(2S)-Pro-(2S)-lle-NH-iBu (43) ((a) and (b); 100 mg, 
210 pmol) were dissolved in anhydrous CHgClg (2 ml) and added to the TMSBr 
solution and the reaction left to stir at room temperature. The reaction was 
followed to completion by TLC (12 h.) and the CHgClg was concentrated in  
vacuo to give a yellow oil that was rediluted and evaporated twice more with 
CHgClg (2 x 2 ml). The resultant oil was taken up in acetone (2 ml) and water 
added (0.5 ml). Removal of solvent under reduced pressure yielded a white 
solid (86 mg, 88%) that was used immediately in the preparation of (48). This
was prepared in an identical manner to (44) using HgN-Phe-\j/[P(0H)0-N]-(2S)-
Pro-(2S)-lle-NH-iBu (47) (a) and (b) diastereomers; 62 mg, 130 pmol) and Boc-
(2S)-asparagine (30 mg, 130 pmol) to produce an off-white solid (45 mg, 50%) 
that was dissolved in acetone and converted to (48) by the addition of 1 M
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lithium hydroxide (70 \x\, 70 |xmol). 
(1-Amino-(R)-2-phenyl)ethvl phosphonic acid (49).
o .OH
OH
Cbz-(R)-Phe-\i/[(S)-P(OMe)0-N]-(2S)-Pro-(2S)-lle-NH-iBu (42a) (50 mg, 80 
limol) was refluxed in a mixture of 6 M HCI and glacial acetic acid (2 ml, 1 :1) for 
2 h. The solvent was removed under reduced pressure and the solid 
redissolved in a minimum of water (0.5 ml). The hydrolysis mixture was purified 
by preparative TLC using a mixture of /sopropanol, conc. ammonia and water 
(26:12:6). The band with an Revalue of 0.2 was removed and the cellulose 
stirred in a methanol/ water mixture (10 ml, 1:1) for 2 h. The cellulose was 
filtered off and washed with water. The water was removed under reduced 
pressure to yield a white solid which was dissolved in 1 M NaOH (2 ml), filtered
through celite and the direction of optical rotation measured; [a j^ -0.046°; 0j_| 
(200 MHz, ZHgO) (sodium salt of (49)) 2.30 & 2.68 (2H, m, ArCHg), 3.02 (1H, m, 
CH*) and 7.20 (5H, m, aromatic). (‘‘H NMR data was found to be identical to that 
of previously prepared racemic (1 -amino-2-phenyl)ethyl phosphonic acid).
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Cbz-Cha-wrP(OMe>0-N1-(2S)-Pro-(2S)-lle-NH-IBu (50).
This was prepared in an identicai manner to (42), using methyi hydrogen [1-(N- 
benzyloxycarbonyi)-amino]-cyciohexylmethyiphosphonate (1.07 g, 3 mmoi) to 
g ive an o ff-w h ite  solid (1.08 g, 58%) which was purified  by s ilica  
chromatography (6% EtOH/ CHgCy, to yield two pairs of two diastereomers: 
Diastereomers 3 & 4; m/z (Found: [M + H]+ 621.3781. C32H53N4O6P requires 
621.3781); V^ax (nujoi)/ cm )^ 3259 (NH str. br.), 1724 & 1717 (CO str. 
(urethane)), 1660 & 1652 (CO str. (amide)), 1237 (P=0 str.) and 1027 (P- 
OCH3): 5h (600 MHz. C^HCy 0.90 (12H, m, CH3’s (a,b,c)), 1.0-1.70 (17H, m, 
CHg (lie), 5 X CHg(Cha), CH (Cha), CHg (2) (Pro), ChaCHCÜ2). 1.70-2.20 (4H, 
m, CHg (3) (Pro), CH (IBu), & CH (lie)), 2.90-3.30 (4H, m, CHg (IBu), CHg(1)
(Pro)), 3.61 & 3.64 (3H, d, 10 60 Hz, P0 (0 CH3)), 4.12-4.34 (3H, m, a  CH's 
& CH*), 5.10 (2H, m, ArCHgO) and 7.25-7.40 (5H, m, aromatic): Sg (150 MHz,
C^HCIg) 10.89 & 11.40 (QH3 (a)), 15.56 & 15.86 (ÜH3 (b)), 20.17 (ÛH3 (c)), 
24.83 (£Hg (lie)), 25.56 & 26.0 (&Hg (2) (Pro)), 25.94-26.46 (5 x £LHg (Cha)),
28.33 (£H (IBu)), 31.63 & 31.83 (C.Hg (3) (Pro)), 34.08 & 34.18 (£H (Cha)), 
35.82 & 36.29 (GH (lie)), 37.09 & 37.41 (ChaGHg), 45.00 & 45.99 (d, GH*, JpQ
148.4 Hz). 46.54 & 47.51 (d, GH*, Jp,c 146.5 Hz), 46.99 (GHg(iBu)), 47.72 (GHg 
(1) (Pro)), 51.8 & 52.4 (P0 (0 GH3)), 57.96 & 58.48 (aGH (lie)), 61.54 & 62.14 (a 
GH (Pro)), 67.06 & 67.32 (ArGHgO), 127.5-128.5 (aromatic GH’s), 136.21 & 
136.48 (quat. aromatic), 155.98 & 156.54 (GO urethane), 170.90 & 171.22 (GO 
(lie)) and 173.16 & 173.45 (GO (Pro)): 8p (121.5 MHz, C^HCIg) 31.08 & 33.04; 
m/z (FAB) 643 {[M + Na]+, 40%), 621 {[M + H]+, 34) and 338 {[M + H- Pro-lie-
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iBu]+,61).
C bz-Phe-vfP (0M e)0-N 1.(2S)-Phe-(2S>-lle-N H -IB u (51).
O -xA
This was prepared in an identical manner to (42), using methyl hydrogen [1-(N- 
benzyioxyoarbonyi)-amino]-benzyiphosphonate (35) (1.05 g, 3 mmol) and (28)- 
Phe-(2S)-ile-iBu hydrochloride (1.11 g, 3 mmol) to yield an off-white solid (837 
mg, 42%) which was purified by silica chromatography (10% EtOH/ CHgCig) 
prior to recrystailisation from methanol/ water to yield a mixture of four 
diastereomers, (Found: C, 64.96; H, 7.67; N, 8.27. CaeH^aN^OgP requires C, 
65.03; H, 7.43; N, 8.43%); m/z (Found: [M  + H]+ 665.3468. CggHgoN^OgP 
requires 665.3468); (nujoi)/ cm'^ 3296 (NH str.), 1726 (CO str. (urethane)), 
1694 & 1642 (CO str. (amide)), 1263 (P=0 str.) and 1052 (P-OCH3); Sy (500 
MHz, dg-DMSO) 0.85 (12H, m, CHg’s (a,b,c)), 1.18 (IN, m, 1 x CHg (lie)), 1.55 
(1H, m, 1 X CHg (lie)), 1.75 (1H, m, CH (IBu)), 1.82 (1H, m, CH (lie)), 2.28 (1H, m, 
1 X ArChfiCH*)), 2.45 (IN, m, 1 x ArCMgCH*)), 2.80 (1H, m, 1 x CHj (Phe)),
2.90 (1H, m, 1 X CHj (Phe)), 3.02 (2H, m, CHg (IBu)), 3.07, 3.24, 3.28 & 3.52
(3H, d, J p H i0.60 Hz, PO(OCHs)), 3.90-4.30 (3H, m, a  CH’s & CH*), 4.85-5.20 
(2H, m, ArCtlaO), 7.10-7.50 (15H, m, aromatic) and 7.95-8.25 (4H, m, NH's); 5q 
(74.76 MHz, dg-DMSO) 10.92 (IlHg (a)), 15.27 (^Hg (b)), 19.98 (GH3 (c)), 24.30 
(ÜHg (lie)), 27.80 (£H (iBu)), 36.70 & 36.80 (ArQHgC & £H  (lie)), 40.0 (SIHg
(Phe)), 46.0 (DHg (iBu)), 49.0-52.0 (£H* & P0 (0 £H 3)), 55.51 & 57.04 (a £H's),
65.04 (ArüHgO), 125.98-129.48 (aromatic £.H's), 137.98-138.13 (quat. 
aromatic), 155.60 (Qp urethane) and 170.70 & 172.50 {Qp (amides)); 5p (121.5
1 1 0
MHz, dg-DMSO) 29.62, 29.78, 29.94 and 30.08; m/z (FAB) 687 ([M+ Na]+, 20%) 
and 665 ([M+H]+,79).
C bz-C ha-\|/rP (0M e)0-N 1-(2S i-Phe-(2SM Ie-N H -IB u (521
This was prepared in an identical manner to (42), using methyl hydrogen [1-(N- 
benzyloxycarbonyi)-amino]-cyciohexylmethylphosphonate (1.07 g, 3 mmol) and 
(2S)-Phe-(2S)-ile-iBu hydrochloride (1.11 g, 3 mmol) to yield an off-white solid 
(1.46 g, 64%) which was purified by silica chromatography (5% EtOH/ CHgCig) 
prior to recrystaiiisation from methanol/ water to yield a mixture of four 
diastereomers, (Found: C, 64.41 ; H, 8.35; N, 8.32. CggHggN^OgP requires C, 
64.44; H, 8.27; N, 8.36%); m/z (Found; [M + H]+ 671.3937. CggHggN^OgP 
requires 671.3937); v^gx (nujoi)/ cm'^ 3281 (NH str.), 1721 (CO str. (urethane)), 
1665 & 1643 (0 0  str. (amide)) and 1263 (P=0 str.); 8^  (600 MHz, C^HCig) 0.85 
(12H, m, CHg’s (a,b,c)), 1.0-2.20 (17H, m, CHj (lie), 5 x CHg (Cha), CH (Cha), 
CH (lie), CH (IBu) & ChaCHCüa)), 2.88-3.12 (4H, m, CHj (Phe) & CHg (IBu)), 
3.35 (3H, d, Jp,H 10.90 Hz, PO(OCHg)), 3.43 (3H, d, Jp H 10.60 Hz, PO(OCHg)),
3.47 (3H, d, Jp H 10.90 Hz, PO(OCHg)), 3.59 (3H, d, Jp ^ 10.90 Hz, PO(OCHg)), 
4.02-4.28 (3H, m, a CH's & CH*), 5.00-5.16 (2H, m, ArCJd^O) and 7.14-7.36 
(10H, m, aromatic); Sq (74.76 MHz, C^HCIg) 11.2 (fiHg (a)), 15.5 (C.H3 (b)), 20.1 
(ÜH3 (C)), 24.8 (£H2 (iie)), 25.9, 26.3, 26.5 (5 x ÜH j (Cha)), 28.4 (GH (IBu)), 31.7 
(GH (Cha)), 34.0 (GH (lie)), 36.5 (ChaCHGHg), 40.0 (GHg (Phe)), 46.0-48.0 
(GH*), 47.0 (GHa (iBu)), 51.6 (PO(OGHg)), 56.5 & 56.8 (a GH), 58.2 & 58.4 (a 
GH), 67.2 (ArGHgO), 126.5-130 (aromatic GH's), 136.5-137.7 (quat. aromatic).
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156.4 (^O urethane) and 171.0 & 173.0 {QP (amides)); ôp (121.5 MHz, C^HCy 
30.54, 31.21, 32.05 and 32.35; m/z (FAB) 693 ([M+Na]+, 15%) and 671 {[M + 
H]+, 22).
Boc-(2S)-Asn-Cha-yrP(QMe)0-m-(2Sy-PrQ-(2S)-lle-NHHBu (54%
CONH
This was prepared in an identical manner to (44), using H2N-Cha-i|/[(P(0 Me)0 - 
N]-(2S)-Pro-(2S)-lle-NH-iBu (53) (diastereomers 3 & 4, 75 mg, 154 pmol) and
(2S)-Boc-Asn (36 mg, 155 pmol) to yield an off-white solid (80 mg, 74%) which 
was purified by silica chromatography (10% EtOH/ CH2CI2), to yield two 
d iastereom ers; D iastereom er 4; m/z (Found: [M  + Na]+ 723.419. 
GssHGiN^OePNa requires 723.4186); v^^ax (nujoi)/ cm-i 3294 (NH str. br.), 1716 (CO str. (urethane)), 1652 (GO str., br. amide's), 1261 (P=0 str.) and 1026 (P- OCH3); 0|_| (200 MHz, C2HCI3) 0.90 (12H, m, CH3's a,b,c), 1.0-1.70 (17H, m, GH2 (He), 5 X  GH2 (Gha), GH (Gha), GH2 (2) (Pro) & GhaGHGHg), 150 (9H, s. 
Boo GH3’s), 1.70-2.20 (4H, m, GH2 (3) (Pro), GH (iBu), & GH (lie)), 2.50-3.30 
(6 H, m, GH2 (iBu), GH2 (1) (Pro), GH2 Asn), 3.65 (3H, d, Jp^ H 10.60 Hz, 
P0 (0 GH3)), 4.10-4.60 (4H, m, a GH’s & GH*), 5.9 (1H, s, 1 x GONH2), 6.7 (1H, 
s, 1 X GONH2), 6.2-7.45 (NH’s); 5p (121.5 MHz, G^HCy 30.14; m/z (FAB) 723 
([M+ Na]+, 100%) and 701 ([M+ H]+, 25).
1 1 2
Boc-(2S)-Asn-Phe-\|/rP(OMe)0-N1-(2Sl-Phe-(2S)-lla-NH-iBu f56>.
CONH2
This was prepared in an identicai manner to (44), using H2N-Phe-\|/[(P(0 Me)0 - 
N]-(2S)-Phe-(2S)-iie-NH-iBu (55) (180 mg, 340 pmol) and (2S)-Boc-Asn (79 
mg, 340 pmoi) to yieid an off-white solid (180 mg, 71%) which was purified by 
silica chromatography (10% EtOH/ CH2CI2), to yieid four diastereomers; m /z 
(Found: [A4 + H]+ 745.4054. CayHgyNeOgP requires 745.4054); 6^  (200 MHz, 
C^HCIg) 0.90 (12H, m, CHg’s (a,b,c)), 1.15 (1H, m, 1 x CH2 (lie)), 1.50 (10H, s. 
Boo CHg’s & 1 X CHg (lie)), 1.80 (2 H, m, CH (IBu) & CH (lie)), 2.20-3.30 (8 H, m, 
ArCHgCH', CHg (Phe)), CHg (IBu) & CHg (Asn)), 3.40 (3H, m, PO(OCHg)), 3.90- 
4.60 (4H, m, a  CH's & CH*), 5.95 (1H, s, 1 x CONHg), 6.65 (1H, s, 1 x CONHg) 
and 7.10-7.50 (10H, m, aromatic); m/z (FAB) 767 ([A4+ Na]+, 5%) and 745 ([A4 + 
H]+, 25).
Boc-f2St-Asn-Cha-\|<rPfOMe10-m-(2S)-Phe-(2S1-lle-NH-iBu
CONH.
.OCH
NH
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This was prepared in an identical manner to (44), using H2N-Cha-\i/[(P(0 Me)0 - 
N]-(2S)-Phe-(2S)-lle-NH-iBu (57) in DMF (0.5 ml) (120 mg, 220 ^mol) and (2S)-
Boc-Asn (52 mg, 220 jimol) to yield an off-white solid (129 mg, 77%) which was 
purified by s ilica  chromatography (10% EtOH/ CHgClg), to yield four 
diastereomers; m/z (Found: [M  + H]+ 751.4521. CayHe^NeOgP requires 
751.4523); 0^ (200 MHz, C^HCy 0.90 (12H, m, CHg's a,b,c), 1.0-2.0 (17H, m, 
CHg (lie), 5 X CHg (Cha), CH (Cha), CH (lie), CH (IBu) & ChaCHCHg)), 1.50 (9H, 
s, Boo CHg's), 2.5-3.2 (6H, m, CHg (Phe), CHg (Asn) & CHg (iBu)), 3.32 & 3.48 
(3H, m, P0 (0 CH3)), 4.0-4.5 (4H, m, a CH's & CH*) and 7.14-7.36 (5H, m, 
aromatic); m/z (FAB) 773 {[M+ Na]+, 10%) and 751 ([M+ H]+, 100).
Qua-(2S)-asparaaine (59).
Of
g
o
H
N
OH
NH
0
Quinaldic acid (2 g, 11.5 mmol) was dissolved in anhydrous CH2CI2 (50 ml). 
Thionyi chloride (1.75 ml, 23 mmol) was added and the white precipitate 
redissolved with triethylamine (1.60 ml, 11.5 mmol). After 3 h. the solvent was 
removed under reduced pressure and the acid chloride was redissolved in 
toluene (40 ml). To the reaction mixture was added a solution of asparagine 
(1.53 g, 11.5 mmol) and potassium carbonate (3.18 g, 23 mmol) in water (20 ml) 
and the solution stirred vigorously for 4 h. The aqueous layer was adjusted to 
pH 9 and separated. The aqueous layer was adjusted to pH 2 with 6 M HCI and 
the brown solid was filtered off, redissolved in ethanol and the solution 
decolourised with charcoal. Removal of solvent under reduced pressure yielded 
an off-white solid which was recrystallised from ethanol (2.05 g, 62%), m.p. 209 
°C (dec.); (Found: C, 58.56; H, 4.32; N, 14.38. C14H13N3O4 requires C, 58.52; H, 
4.56; N, 14.63%); (Found: [M + H]+ 288.0984. C14H14N3O4 requires 288.0984);
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[o]0  +23.3° (c 0.5 in MeOH); v„,ax (nujoi)/ cm-' 3384 & 3365 (NH str. (amides)), 
1710 (CO str. (acid)) and 1662 (CO str. (amide)); 5^ (300 MHz. dg-DMSO) 2.80 
(2H, ABX, J  15.97, 4.94 & 5.67 Hz, CHg (Asn)), 4.82 (1H, m, a  CH (Asn)), 7.04 
(1H, s, 1 X CONHg), 7.54 (1H, s, 1 x CONHj), 7.76 (1H, X,J7  Hz, CH (f) (Qua)), 
7.88 (1H, t, J6.9 Hz, CH (g) (Qua)), 8.11 (2H, 2d, J 8.23 & 7.15 Hz, CH (b) & CH
(e) (Qua)), 8.18 (1H, d, J8.48 Hz, CH (h) (Qua)), 8.60 (1H, d, J8.51 Hz, CH (c) 
(Qua)) and 9.18 (1H, d, J8.56 Hz, NHt); ôq (74.76 MHz, dg-DMSO) 36.46 (ÜHg
(Asn)), 48.95 («Ü H  (Asn)), 118.47 (QH (b) (Qua)), 128.03 & 128.11 (£1H (e) & 
C.H (f) (Qua)), 128.88 (Q. (d) (Qua)), 129.14 (£.H (g) (Qua)), 130.53 (OH (h) 
(Qua)), 137.94 (OH (c) (Qua)), 145.90 (0 (i) (Qua)), 149.47 (0 (a ) (Qua)), 163.37 
(OO amide), 171.69 (OONHg) and 172.31 (OOOH); m/z (Cl) 288 ([Af + H]+, 12%). 
t  identified by DjO shake.
Qua-f2S1-Asn-Phe-wfP(0Me10-Nl-(2S1-Phe-(2S1-lle-NH-iBu (601.
HgNOC
This was prepared in an identical manner to (44), using H2N-Phe-v|/[(P(OMe)0 - 
N]-(2S)-Phe-(2S)-lle-NH-iBu (55) (40 mg, 76 pmoi) and (59) (22 mg, 77 pmol) 
to yie id an off-white solid (37 mg, 61%) which was purified by s ilica 
chromatography (10% EtQH/ CHgClg), to yieid four diastereomers; m/z (Found: 
[M + H]+ 800.3974. C^gHggNyOgP requires 800.3900); 5^ (200 MHz, d^-MeOH) 
0.80 (12H, m, CHg's (a,b,c)), 1.0-2.0 (4H, m, CHg (lie), CH (IBu) & CH (lie)), 2.20-
3.30 (8 H, m, ArCHgCH', CHg (Phe), CHg (IBu), CHj (Asn)), 3.30 (3H, m,
PO(OCÜ3)), 3.50-4.60 (4H, m, a CH's & CH*), 7.25 (10H, m, aromatic) and 7.6-
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8.5 (6 H, m, CH’s (Qua)); m/z (FAB) 822 {[M + Na]+, 100%) and 800 {[M + H]+, 
49).
Qua-(2S1-Asn-Cha-wfP(OMe10-N1-(2S)-Pro-(2S)-He-NH-IBu 161).
HoNOC
This was prepared In an identical manner to (60), using H2N-Cha-\|r[(P(0 Me)0 -
N]-(2S)-Pro-(2S)-lle-NH-iBu (53) (two diastereomers; 140 mg, 290 pmoi) and
(59) (83 mg, 290 pmoi) to yield an off-white solid (158 mg, 73%) which was 
purified by s ilica  chrom atography (8 % MeOH/ CH2CI2), to yield two 
diastereomers;
Diastereomer 3; V^ax (nujoi)/ cm'i 3282 (NH str. br.), 1700, 1696 & 1670 (CO 
str., br. amide’s), 1223 (P=0 str.) and 1039 (P-OCH3); (200 MHz, C^HCIg)
0.80 (12H, m, CHg’s (a,b,c)), 1.0-2.20 (21H, m, CH2 (lie), 5 x CHj (Cha), CH 
(Cha), CHg (2) (Pro), ChaCHChla, CH2 (3) (Pro), CH (IBu), & CH (lie)), 2.80-3.50 
(6 H, m, CHg (IBu), CHg (1) (Pro), CH2 (Asn), 3.65 (3H, d, Jp_H 10.60 Hz, 
P0 (0 CH3)), 4.21 (2H, m, a  CH’s (Pro) & (lie)), 4.60 (1H, m, CH*), 5.30 (1H, m, a 
CH (Asn))', 6.02 (1H, s, 1 x CONH2), 6.85 (1H, s, 1 x CONHg), 7.45 (1H, br., NH), 
7.62 (1H, t, J7  Hz, CH (f) (Qua)), 7.77 (1H, t, J6.9 Hz, CH (g) (Qua)), 7.9 (2H, m, 
CH (b) & CH (e) (Qua)), 8.15 (1H, d, J8.48 Hz, CH (h) (Qua)), 8.30 (1H, d, J8.51 
Hz, CH (c) (Qua)) and 9.15 (1H, d, J8 S  Hz, NH).
Diastereomer 4; m/z (Found: [M  + H]+ 756.427. C38H59N7O7P requires 
756.4214); 5^ (200 MHz, C^HCy 0.80 (12H, m, CH3 S (a,b,C)), 1.0-2.20 (21H, 
m, CHg (He), 5 x CH2 (Cha), CH (Cha), CH2 (2) (Pro), ChaCHCjjg, CH2 (3) (Pro), 
CH (IBu), & CH (He)), 2.80-3.50 (6H, m, CH2 (IBu), CH2 (1) (Pro), CHg (Asn)),
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3.64 (3H, d, Jp H 10.60 Hz, POpCHg)), 4.21 (2H, m, a CH’s), 4.60 (1 H, m, CH*),
5.30 (1H, m, a  CH (Asn)), 6.2 (1H, s, 1 x CONHg), 6.7 (1H, s, 1 x CONHj), 7.1 
(1H, br, NH (iBu)), 7.32 (1H, br, NH), 7.6-7.9 (4H, m, CH (f) (Qua), CH (g) (Qua), 
CH (b) & CH (e) (Qua)), 8.15 (1H, d, J8.48 Hz, CH (h) (Qua)), 8.20 (1H, d, J
8.51 Hz, CH (c) (Qua)) and 9.28 (1 H, d, J 8.6 Hz, NH); m/z (FAB) 778 ([M+ Na]+, 
94%) and 756 ([M+ H]+, 66).
(2R)-Phe-(2S>-lle-NH-IBu hydrochloride 1621.
This was prepared in an identical manner to (40), using Boc-(2R)-Phe (1.0 g, 
3.77 mmol) and (38) (840 mg, 3.77 mmol), followed by Boo deprotection, using 
HCI gas to yield a white solid, which was recrystallised from methanol/ ether
(1.23 g, 88%), m.p. 252 °C (dec.); m/z (Found: [M + H - HCI]+ 334.2495. 
C19H32N3Q2 requires 334.2494); [a ][,-79.6'' (c 0.5 in MeQH); V^ax (nujoi)/ cm'^ 
3350 & 3251 (NH str.) and 1679 & 1652 (CO str. (amides)); 8 ,^ (200 MHz, d@- 
DMSO) 0.63 (3H, d, J7.6  Hz, CH3 (b)), 0.75 (3H, t, J7.5 Hz, CH3 (a)), 0.87 (6 H, 
d, J 8 Hz, CH3 (c)), 1.02 (1H, m, 1 x CH2 (lie)), 1.18 (1H, m, 1 x CH2 (He)), 1.70 
(2H, m, CH (He) & CH (IBu)), 2.75-3.15 (4H, m, CH2 (IBu) & CH2 (Phe)), 4.13 
(1H, t, J7.0 Hz, a  CH), 4.27 (1H, t, J8.0 Hz, a  CH), 7.30 (5H, s. Aromatic), 8.17 
(1H, t, J5.85 Hz, NH (IBu), 8.45 (3H, br, NH3+) and 8.6 (1H, d, J8.76 Hz, NH
(He)); 5c (50.3 MHz, dg-DMSO) 11.44 (SH3 (a)), 15.42 ((IH3 (b)), 20.48 (£H3
(c)’s), 24.42 (Q.H2 (lie)), 28.12 (ÛH (IBu)), 36.89 (£H2 (Phe)), 37.35 (£H (He)), 
46.34 (£Ha (IBu)), 53.34 (a £H (Phe)), 57.54 (a £H (He)), 127.25, 128.66 & 
129.75 (aromatic £.H), 135.22 (quat. aromatic) and 168.11 & 170.32 (£.0 
amides); m/z (Cl) 334 ([M+ H - HCI]+, 100%).
Glv-(2Sf-lle-NH-IBu hydrochloride f63>.
This was prepared in an identical manner to (40), using Boc-Gly (875 mg, 5 
mmol) and (38) (1.11 g, 5 mmol), followed by Boo deprotection, using HCI gas 
to yield a white solid, which was recrystallised from methanol/ ether (1.22 g,
87%), m.p. 165 °C (dec.); m/z (Found: [M + H - HCI]+ 244.2025. C12H26N3O2
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requires 244.2025); [a]o-25.2° (c 0.5 in MeOH); (nujoi)/ cm-’ 3412 & 3280 
(NH str.) and 1674 & 1654 (CO str. (amides)); 5^ (200 MHz, dg-DMSO) 0.85 
(12H, m, CHg’s (a,b,c)), 1.12 (1H, m, 1 x CHg (lie)), 1.45 (1H, m, 1 x CHg (lie)),
1.70 (2H, m, CH (lie) & CH (IBu)), 2.72-3.08 (2H, m, CHg (iBu)), 3.63 (2H, s, CHg
(Gly)), 4.25 (1H, t, J8.0 Hz, a  CH (lie)), 8.25 (4H, br., NH3+ & NH (iBu)) and 8.58
(1H, d, J8.76 Hz, NH (He)); ôq (50.3 MHz, dg-DMSO) 11.38 (GHg (a)), 15.64 
(ÜH3 (b)), 20.44 (£H3's (c)), 24.53 (GHg (He)), 28.13 (£H (iBu)), 37.11 (QH (He)),
46.33 (ÛHj (iBu)), 51.0 (ÜHg (Gly)), 57.50 (a£H  (He)) and 165.88 & 170.64 (ÛO 
amides); w/z (Cl) 244 ([M +H - HCI]+, 100%).
Cbz-Phe->|/fP(0Me10-N1-(2R1-Phe-(2SMIe-NH-IBu (64).
o - a J^0CH3|
This was prepared in an identical manner to (51 ), using methyl hydrogen [1-(N- 
benzyloxycarbonyl)-amino]-benzylphosphonate (35) (349 mg, 1 mmol) and 
(2R)-Phe-(2S)-lle-iBu hydrochloride (62) (370 mg, 1 mmol) to yield an off-white 
solid (300 mg, 45%) which was purified by silica chromatography (10% EtOH/ 
CH2CI2) prior to recrystallisation from methanol/ water to yield a mixture of four 
diastereomers, m/z (Found: [M  + H]+, 665.3456. CggHsoN^OgP requires 
665.3468); v^ax (nujoi)/ cm  ^ 3269 (NH str.), 1703 (CO str. (urethane)), 1695 & 
1654 (CO str. (amide)), 1261 (P=0 str.) and 1049 (P-OCH3); 0^ (200 MHz, dg- 
DMSO) 0.80 (12 H, m, CHg's (a,b,c)), 1.05 (1H, m, 1 x CH2 (lie)), 1.32 (1H, m, 1 x 
CH2 (He)), 1.7 (2 H, m, CH (IBu) & CH (lie)), 2.5-3.0 (6 H, m, ArCH2CH*, CH2 
(Phe)& CH2 (iBu)), 3.07, 3.24, 3.28 & 3.52 (3H, d, ^ 10.60 Hz, PO(OCHs)),
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3.90-4.30 (3H, m, a CH’s & CH*), 4.85-5.20 (2H, m, ArCjigO), 7.10-7.50 (15H, 
m, aromatic) and 7.95-8.25 (NH’s): 8c  (74.76 MHz, dg-DMSO) 11.14 & 11.37 
(£H3 (a)), 15.59 (&H3 (b)), 20.22 & 20.36 (£H3 (c)), 24.36 & 24.48 (ilHg (Ile)),
28.04 & 28.15 (GH (iBu)), 35.19 (ArGHjC), 38.60 (GH (Ile)), 40.77 (GHg (Phe)), 
46.27 & 46.34 (GHg (IBu)), 49.0-52.0 (GH* & P0 (0 GH3)), 55.65, 55.81, & 57.11 
(a GH’s), 65.01 & 66.33 (ArGHgO), 126.19-129.88 (aromatic GH's), 137.4-
138.64 (quat. aromatic), 156.0 (GO urethane) and 171.0 ,173.2 & 173.3 (GO 
(amides)); 8p (121.5 MHz, dg-DMSO) 29.84, 30.10 and 30.24; m/z (FAB) 687 
{[M+ Na]+, 36%) and 665 ([M+ H]+, 28).
Cbz-Phe-vfP(O M e)0-N1-G lv-f2SM Ie-N H-[Bu (651.
This was prepared in an identical manner to (42), using methyl hydrogen [1-(N- 
benzyloxycarbonyl)-amino]“benzylphosphonate (35) (1,05 g, 3 mmol) and Gly- 
(2S)-lle-iBu hydrochloride (63) (840 mg, 3 mmol) to yield an off-white solid (826 
mg, 48%) which was purified by silica chromatography (10% EtOH/ CH2CI2) 
prior to recrystallisation from methanol/ water to yield a mixture of four 
diastereomers, m/z (Found: [M + H]+ 575.2979. C29H44N4O6P requires 
575.2998); v^nax (nujol)/ cm'1 3297 (NH str.), 1704 & 1696 (CO str. (urethane)), 
1684 & 1657 (CO str. (amide)), 1261 (P=0 str.) and 1049 (P-OCH3); 6^  (200 
MHz, dg-DMSO) 0.85 (12H, m, CHg’s (a,b,c)), 1.1 (1H, m, 1 x CHg (He)), 1.45 
(1H, m, 1 X CH2 (He)), 1.7 (2H, m, CH (iBu) & CH (He)), 2.6-3.2 (4H, m, 
ArCM2CH* & CH2 (iBu)), 3.62 (5H, m, CHg (Gly) & P0 (0 CH3)), 3.90-4.30 (2H, m, 
a CH (He) & CH*), 4.85-5.05 (2 H, m, ArCHgO), 7.10-7.4 (10H, m, aromatic) and 
7.6-8.15 (NH’s); Ôq (74.76 MHz, dg-DMSO) 11.34 (QH3 (a)), 15.61 (C.H3 (b)),
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20.38 (ÛHg (C)), 24.56 (Ile)), 28.17 {Q.H (iBu)), 34.81 (AraHgC), 37.23 {Q.H
(Ile)), 46.31 (ÛHa (IBu)), 49.0-52.0 (ÛH* & P0 (0 £ H 3)), 50.80 (£IH2 (Gly)), 57.05 
(a GH (Ile)), 65.22 & 65.33 (ArGHjO), 126.4-129.38 (aromatic GH's), 137.4-
138.64 (quat. aromatic), 156.04 (GO urethane) and 170.64 & 170.83 (GO 
(amides)); 5p (121.5 MHz, dg-DMSO) 31.01 and 31.44; m/z (FAB) 597 ([M + 
Na]+, 100%) and 575 ([M+ H]+, 80).
Boc-(2S)-isoleucvl-2-faminomethvn-pvridlne (661
(4) (3)
This was prepared In an Identical manner to (37), using Boc-(2S)-lle (463 mg, 2 
mmol) and 2-(amlnomethyl)-pyrldlne (210 pi, 2 mmol) to yield a yellow oil that 
was dissolved in an acetone/ water mixture (10 ml, 10:1) and left to crystallise 
overnight at room temperature, affording colourless needles (440 mg, 68%),
m/z (Found: [M + H]+ 322.2131. C17H28N3O3 requires 322.2131); V^ax (nujoi)/ 
cm"' 3335 (NH str.), 1682 (CO str. (urethane)), 1655 (00  str. (amide) and 1526 
(NH bend); Sp, (200 MHz, C2HCI3) 0.9 (6H, m, CHg’s (a & b)), 1.10 (1H, m, 1 x 
CH2 (lie)), 1.42 (10H, m. Boo CH3 S & 1 x CH2 (He)), 1.9 (1H, m, CH (He)), 3.84 
(1H, t, J7.0 Hz, a CH (He)), 4.55 (2H, d, J5.0 Hz, CH2 (Amp)), 5.25 (1H, d, J 8.6 
Hz, NH (urethane)), 7.10-7.40 (3H, m, NH (amide) & CH (3) & (4)), 7.62 (1H, m, 
CH (2)) and 8.52 (1H, d, J5.0 Hz, CH (1)); 8q (50.3 MHz, C2HCI3) 11.97 (GH3 
(a)), 16.12 (GH3 (b)), 25.18 (GH2 (He)), 28.79 (Boc GH3 S), 37.91 (GH (He)),
44.85 (GHg (Amp)), 59.83 (a GH), 80.21 (G(CH3)3), 122.41 & 122.81 (GH (2) &
(4)), 137.22 (GH (3)), 149.48 (GH (1)), 156.27 (GO urethane) and 156.81 (G{5)),
172.24 (GO amide); m/z (Cl) 322 ([M+ H]+, 100%), 266 ([M + H - (H3C)2CCH2]+, 
48), 213 ([M+ H- (H3C)2CCH2 - H20J+, 40) and 187 ([M+ H - Boc]+, 92).
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Bo.c:(2S)-iSQleucyh2-(amlnomethyl)rbsnzimidazQle (6Z1
This was prepared in an identical manner to (37), using Boc-(2S)-lie (463 mg, 2 
mmol) and 2-(aminomethyl)-benzimidazole dihydrochloride (476 mg, 2 mmol) 
(preneutralised with triethylamine 560 ml, 4 mmol) to yield a yellow oil that was 
dissolved in an acetone/ water mixture (10 ml, 10 :1) and left to crystallise 
overnight at room temperature, affording colourless needles (375 mg, 52%), 
m/z (Found: [M + H]+ 361.2240. CigHggN^Og requires 361.2239); (nujoi)/ 
cm-1 3344 & 3275 (NH str.), 1687 (CO str. (urethane)), 1656 (CO str. (amide)) 
and 1526 (NH bend); 0^ (200 MHz, C^HCIg) 0.9 (6H, m, CHg’s (a & b)), 1.15 
(1H, m, 1 X  CHg (lie)), 1.50 (10H, m, Boc CHg’s & 1 x CHg (lie)), 1.85 (1H, m, CH 
(lie)), 3.96 (1H, t, J6 .0  Hz, a  CH (lie)), 4.5-5.0 (3H, m, CHg& NH), 5.28 (1H, m, 
NH), 7.20 (2H, m, Aromatic), 7.52 (2H, m, Aromatic) and 7.65 (1H, m, NH); 5q 
(50.3 MHz, C^HCIg) 11.63 (QHg (a)), 16.03 (£Hg (b)), 25.42 (^H g (lie)), 28.83 
(Boc ^ H g ’s), 37.51 (C.H (lie)), 38.14 (C.Hg (Benz.)), 60.35 (a  Q . H ) ,  80.72 
(ü(CHg)g), 115.34 (QH (3) & (6)), 123.06 { Q H  (4) & (5)) 138.2 { Q H  (2) & (7)), 
152.20 (Q.H (1)), 156.75 (^O  urethane) and 174.32 (ÜO amide); m/z (Cl) 361
([M+H]+, 62%), 287 ([M+ H - (HgC)gCCH2 - HgO]+, 50) and 261 ([M+ H - Boc]+, 
58).
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Cbz-Phe-\vfP(OMe^O-N1-(2S>-Phe-NH-iBu (68 .^
o
This was prepared In an Identical manner to (42), using methyl hydrogen [1-(N- 
benzyloxycarbonyl)-amlno]-benzylphosphonate (35) (698 mg, 2 mmol) and 
(2S)-Phe-NH-IBu (440 mg, 2 mmol) to yield, after work up, an off-white solid 
which was recrystallised from methanol/ water to yield a mixture of four 
diastereomers (580 mg, 53%), m/z (Found: [M + H]+552.2627. CaoHggNgOgP 
requires 552.2627); v^ax (nujoi)/ cm''' 3296 (NH str.), 1695 (CO (urethane) 
1653 (GO str. (amide)), 1215 (P=0 str.) and 1056 (P-OOH3); 5^ (200 MHz, dg- 
DMSO) 0.85 (6H, m, CHg's (IBu)), 1.65 (1H, m, GH (IBu)), 2.4-2.7 (6H, m, GHg 
(Phe), GHgOBu) & ArGHaGH*), 3.0 & 3.40 (3H, d, dp H 10.60 Hz, PO(OGHa)), 3.8- 
4.2 (2H, m, a  GH (Phe) & GH*), 4.95 (2H, m, ArGHgO), 5.0-5.3 (1H, m, NH’s), 
7.0-7.5 (15H, m, aromatic) and 8.15 (1H, br., NH); 5q (74.76 MHz, dg-DMSO) 
20.33 (£Ha (IBu)), 28.17 & 28.26 (£H (IBu)), 33.86-34.52 (Ar ^Ha's), 46.31 & 
46.42 (ÜHa (IBu)), 48.5-52.0 (£H* & PO(OÜH3)), 55.65, 55.97, 56.09 & 56.22 (a
C.H (Phe)), 65.01, 65.19, 65.31 & 65.40 (Ar^HgO), 126.23-128.88 (aromatic 
£.H’s), 137.33-138.63 (quat. aromatic), 155.95 & 156.05 {QP urethane) and 
172.93 & 173.04 {QO (amide)); 8p (121.5 MHz, dg-DMSO) 29.44, 29.89, 30.04 
and 30.14; m/z (FAB) 574 ([M+ Na]+, 10%) and 552 {[M+ H]+, 35).
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Cbz-Phe-wfP(0Me>0-N1-(2S)-Phe-0Me (69).
O -A  ^
! X „  5
I  OCH,
NH .OCH3
This was prepared In an identical manner to (42), using methyl hydrogen [1-(N- 
benzyioxycarbonyi)-amino]-benzyiphosphonate (35) (349 mg, 1 mmol) and 
(2S)-Phe-OMe hydrochloride (323 mg, 1.5 mmol) to yieid, after work up, an off- 
white solid which was recrystallised from acetone/ petrol to yieid a mixture of 
four diastereomers (250 mg, 49%), m/z (Found: [A4 + H]+, 511.1998. 
C27H32N2O6P requires 511.1998); V^gj, (nujoi)/ cm*’ 3332 & 3185 (NH str.), 
1750 (CO str. (ester)), 1695 (GO (urethane)), 1653 (CO str. (amide)), 1259 (P= 0  
str.) and 1048 (P-OCH3); 8^  (200 MHz, dg-DMSO) 2.4-2.7 (2 H, m, CH2 (Phe)), 
2.7-3.2 (2H, m, ArCHgCH"), 3.10, 3.20, 3.35 & 3.50 (3H, d, Jpy  ^ 10.60 Hz, 
P0 (0 CH3)), 3.8-4.2 (2H, m, a CH (Phe) & CH*), 4.90 (2H, m, ArCHgO), 5.2-5.7 
(1H, m, NH's) and 7.25 (15H, m, aromatic CH's); 8q (74.76 MHz, dg-DMSO) 34- 
34.25 (Ar C.H2 S), 48.5-51.0 (^H* & PO(OaHg)), 51.97, 52.12 & 52.23 (O^lHg 
ester), 55.34, 55.58, & 55.68 (a C.H's), 65.11, 65.28 & 65.39 (AiC.H20 ), 126.28- 
130.04 (aromatic &H's), 137.56-138.83 (quat. aromatic), 155.86 (£.0 urethane) 
and 173.86, 173.81 & 174.05 (£ 0  (ester)); 8p (121.5 MHz, dg-DMSO) 28.88 &
29.64; m/z (Ci) 511 {[M+ H]+, 40%) and 403 ([A4+H- ArCH2 0 H]+, 58).
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Ifi.trahYdro-3,5-bjs(phenylmethyieneJii4jaitlitoayran-4-one (ZOl
A solution of sodium hydroxide (1 g, 25 mmoi) in water (10 mi) and ethanol (10 
mi) was prepared at 0 °C. Benzaidehyde (1.06 g, 10 mmoi) was dissolved in a 
minimum volume of ethanol (5 mi) and added to a solution of tetrahydrothio-4H- 
pyran-4-one (580 mg, 5 mmoi) in ethanol (5 mi). Half of this mixture was added 
dropwise to the alkali solution with vigorous stirring and the reaction mixture left 
for 15 mins at room temperature. The remainder of this mixture was then added 
and left for 1 h. The yellow precipitate was filtered and washed with water (100 
ml) to remove excess alkali. Recrystallisation from acetone yielded yellow 
crystals (905 mg, 62%), m.p. 149-151 °C (lit. (i) 150-151 (jj) 149-151 °C
■'®®); m/z (Found: 292.0922. CigHieSO requires 292.0922); (nujoi)/
cm-1 1660 (CO str.) and 1600, 1577 & 1569 (0=0 str.); 6^  (200 MHz, O^HOIg) 
3.95 (4M, s, OH2SOH2), 7.20-7.55 (10H, m, Aromatic), 7.80 (2H, s, 2 x ArOH=C); 
ÔQ (50.3 MHz, 02HOI3) 30.63 (^ngSilHg), 129.13, 129.49, 130.58 (Aromatic 
ÜH’s), 134.30 & 135.03 (quat. aromatic & (ArOH=Q), 137.42 (Ar^H=0) and 
189.51 (0.0); m/z (01) 293 ([M+ H]+, 100%).
TetrahydrQ-3»5-bis(phenvimethvlene)-4H-pyran-4-one (71).
This was prepared in an identical manner to (70) using sodium hydroxide (1 g,
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25 mmol), benzaidehyde (1.06 g, 10 mmol) and tetrahydro-4H-pyran-4-one 
(500 mg, 5 mmol), producing a yellow solid which was recrystallised from 
acetone to yield pale yellow needles (897 mg, 65%), m.p. 181-183 °C (lit.,’ ®® 
185 °C): m/2  (Found: [M + H]+, 277.1229. CigH^yOg requires 277.1228); v^ax 
(nujoi)/ cm-’ 1668 (CO str.) and 1612 & 1582 (0=0 str.); (200 MHz, O^HOig)
5.00 (4M, s, OÜ2OOÜ2), 7.30-7.60 (10H, m, Ar OJl's) and 7.90 (2H, s, 2 x 
Ar0E=0); Sq (50.3 MHz, O^HOig) 69.20 (£1H20ÛH2), 129.0, 129.8 & 131.0 
(Aromatic £ H ’s), 133.7 & 135.4 (quat. aromatic & (ArOH=C.)), 137.2 (Ar£,H=0) 
and 186.0 (Û0); m/z (Oi) 277 ([M+ H]+, 100%).
2.6-bis(Dhenvlmethvlene1-cvclohexanone (72).
This was prepared in an identicai manner to (70) using sodium hydroxide (1 g, 
25 mmoi), benzaidehyde (1.06 g, 10 mmoi) and cyciohexanone (490 mg, 5 
mmoi), producing a yellow solid which was recrystailised from acetone to yield 
pale yellow needles (1.05 g, 77%), m.p. 116-118 “0  (lit.’ ®® 117-118 °0); (Found: 
0, 87.42; H, 6.72; O20H18O requires 0, 87.56; H, 6.61%); m/z (Found: [M + H]+ 
275.1436. 02oHigO requires 275.1436); (nujoi)/ cm ’ 1662 (0 0  str.) and 
1606, 1576 & 1569 (0 = 0  str.); 6^ (200 MHz, O^HOIg) 1.80 (2H, m, 
OH2OM2CH2), 2.95 (4H, m, OM2OH2OM2). 7.30-7.60 (10H, m. Aromatic), 7.84 
(2H, s, 2 X Ar0H=0); 5 ^  (50.3 MHz, O^HOig) 23.53 (OH2C.H2OH2), 28.97 
(ÛH20H2ÛH2), 128.90, 129.11, 130.88 (Aromatic£H’s), 136.45 & 136.69 (quat. 
aromatic & (ArOH=£)), 137.44 (Ar£H=0) and 190.89 {Qp); m/z (Oi) 275 {[M + 
H]+, 100%).
125
Tetrahvdro-3.5-bisfDhenvlmethvlene>-4H-thiopvran-4-ol (731.
Tetrahydro-3,5-bis(phenylmethylene)-4H-thiopyran-4-one (70), (153 mg, 520 
pmol) was suspended in ethanol (5 mi) and sodium boro hydride (22 mg, 570 
limol) added portionwise over 15 min. at room temperature. The reaction was 
followed to completion both by colour change (yellow to colourless solution) 
and TLC. Water (5 ml) was added to the solution and the white precipitate 
filtered and washed with more water (10 ml). Recrystallisation from acetone/ 
water afforded colourless needles (145 mg, 94%), which were prone to 
decolourisation at room temperature and were stored at 0 °C in the dark; m.p.
117-119 °C; m/z (Found: M+ 294.1078. CigHigSO requires 294.1078); v^ax
(nujoi)/ cm-1 3367 (OH str.) and 1598 & 1576 (C=C str.); 6^  (200 MHz, C^HCIg)
2.0 (1H, d, J  6 Hz, OH), 3.54 (2H, d, J 13.60 Hz, 2 x  CH(b)), 3.86 (2H, d, J 13.60 
Hz, 2  X  CH(a)), 4.79 ( 1 H, d, J 6 Hz, CjHOH), 6.63 (2H, s, 2 x  ArCH=C), 7.25-7.40
(10H, m. Aromatic); ôq (50.3 MHz, C^HCIg) 26.81 (jQHgSÛHg), 81.04 (ilHOH), 
125.31 (ArüH=C), 127.63, 128.89 & 129.47 (Aromatic HH's), 136.82, 140.82 
(quat. aromatic & (ArCH=£)); m/z (El) 294 (M+, 8%), 278 ([M + H - OH]+, 15) 
and 261 ([M -SH ]+,12).
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Tetrahydro-3,5-bis(phenylmethyigne)-4M-pyran-4-Ql (74),
This was prepared in an identical manner to (73) using (71) (168 mg, 610 
pmol) and sodium borohydride (25 mg, 660 jimol) to yield a white solid which 
was recrystallised from acetone/ water to yield colourless needles (156 mg, 
92%), which were prone to decolourisation at room temperature and were
stored at 0 °C in the dark; m.p. 115 °C (dec.); m/z (Found: M +, 278,1307. 
CigHigOg requires 278.1307); (nujoi)/ cm-i 3300 (OH str.), 1599 and 1575 
(C=C str.);ÔH (200 MHz, C^HCIg) 2.48 (1H, d, J6.2 Hz, OH), 4.55 (2H, d, J 13.55 
Hz, 2 X CH(b)), 4.80 (2H, d, J  13.55 Hz, 2 x CH(a)), 4.93 (1H, d, J  6.2 Hz, 
CHOH), 6.68 (2H, s, 2 x ArCH=C) and 7.15-7.40 (10H, m. Aromatic); Ôq (50.3
MHz, CmClg) 67.25 (aHgO^Hg), 76.27 (^HOH), 126.05 (ArlIH=C), 127.74, 
128.88, 129.35 (Ar C.H’s), 136.58, 139.21 (quat. aromatic) and (ArCH=Q; m/z
(El) 278 (M+, 3%), 262 ([M +H-OH]+, 2) and 248 ([M-CH20 ]+, 4).
Diethyl 2,3-O-lsoDroDvlidene-L-tartrate (75).
O O
Using a modification of the method of Ikemoto,''^® diethyl L-tartrate (1 g, 4.85 
mmol) was stirred for 24 h. at room temperature in a solution of concentrated 
H2SO4 (0.5 ml) in acetone (125 ml). The solution was cooled to 0 °C and
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NaHCOg solution added until the solution reached pH 9. The acetone was 
removed under reduced pressure and the aqueous phase extracted with 
CH2CI2 (3 X 50 ml). The organic layers were combined and washed with brine 
(2 X 30 ml), dried over anhydrous IVIgSO  ^and concentrated in vacuo to give a 
pale yellow oil which was purified by silica chromatography (2% EtOH, CH2CI2) 
to yield pure ketal (717 mg, 60%), (Found: C, 53.46; H, 7.64. CiiH^gOg requires 
C, 53.65; H, 7.37%); m/z (Found: [A4 + H]+ 247.1182. C^iHigOg requires 
247.1182); [ajp -28.7° (c 1 in CHCI3) (lit.167 -40.2 (c 1 in CHCI3)); v^ax (neat)
3468 (CH stretch) and 1758 (GO stretch); 0|_| (200 MHz, C^HCy 1.32 (6H, t, J 
7.6 Hz, 2 X OGH2OH3), 1.50 (6H, s, G(GH3)2), 4.28 (4H, q, J 7.6 Hz, 2 x 
OGH2CH3) and 4.77 (2H, s, 2 x GH); Ôq (50.3 MHz, G2HGI3) 14.59 (OGH2ÜH3),
26.86 (G(^H3)2), 62.37 (OÜH2GH3), 77.64 & 77.68 (^H's), 114.24 (G(GH3)2) 
and 170.13 (Qp)] m/z (Gl) 247 ([M+ H]+, 100%).
1.6-D icvclohexyl-(3R .4R )-i?-lsopropylidene-hexane"2.5-dione (77).
Using a modification of the method of K ik k a w a , ' '® ^  magnesium turnings (243 
mg, 10 mmol) and a few crystals of iodine were covered with anhydrous ether 
(10 ml) under an argon atmosphere. Freshly distilled cyclohexylmethyl bromide 
(2.21 g, 12.5 mmoi) in anhydrous ether (20 ml) was added dropwise and the 
solution refluxed for 15 min. (until magnesium had dissolved) using a water 
bath. The solution was cooled to 0 °G and triethylamine (3.34 ml, 24 mmol) 
added, followed by dropwise addition of dimethyl 2,3-Olsopropylidene-L- 
tartrate (872 mg, 4 mmol) in anhydrous ether (15 ml) over 30 min. The reaction 
mixture was left at 0 °G for 2 h. and then methanol (5 ml) added. The ether was 
removed under reduced pressure and the resultant oil taken up in ethyl acetate 
(100 ml), washed with 1 M HGI (3 x 25 ml), NaHG03 (1 x 25 ml), brine (2 x 25
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ml) and dried over anhydrous MgSO^. The ethyl acetate was concentrated in  
vacuo to give a pale yellow oil which was purified by silica chromatography 
(100% CH2CI2) to yield pure diketone (448 mg, 32%), m/z (Found: [M + H]+ 
351.2535. C21H35O4 requires 351.2535); [a ]g -5.5° (c 0.5 In MeOH); v^gj, (neat)
3436 (CH stretch) and 1724 (0 0  stretch); 6|_| (200 MHz, C^HCIg) 0.80-1.35 
(10H, m, 5 X OH2 (Chex)), 1.40 (6H, s, 0 (01^3)2), 1.55-1.75 (10H, m, 5 x CH2 
(Chex)), 1.88 (2H, m, CH (Chex)), 2.50 (2H, d, J 6.86 Hz, ChexCHgCO) and 4.50
(2H, s, 2 X CH); Sq (50.3 MHz, C^HCIg) 26.53 (£H2 (Chex)), 26.64 ((lH2 (Chex)), 
26.81 (C(ÛHa)2), 33.59 (£H2 Chex), 33.65 (QH (Chex)), 33.68 (CHg (Chex)), 
47.03 (ChexC.H2CO), 82.09 (£H), 112.88 (£1(CH3)2) and 208.67 (£0); m/z (Cl)
351 ([M+ H]+, 100%) and 333 ([M + H - HgOr, 60).
2 -C v c lo h e x v l-3 -c v c lo h e x v lm e th v l-(4 R .5 R 1 -0 -ls o D ro p v lid e n e -  
cvclopent-2-enone (781.
H(d)
r.iiiii o
(c)H
(a)H
Isolated from the base catalysed cyclisation of (77), m/z (Found: M *,  332.236 
C21H32O3 requires 332.235); (C^HCIg) 1713 (CO stretch) and 1624 (C=C 
stretch); 5^ (200 MHz, C^HCIg) 0.80-2.00 (21H, m, 10 x CHg (Chex) & CH (a) 
(Chex)), 1.30 (3H, s, 1 X C(CJl3)2), 140 (3H, s, 1 x C(CJd3)2), 2.30-2.60 (3H, m, 
CH (b) (Chex) & ChaCHgC), 4.37 (1H, d, J 6 Hz, CH (c)) and 5.02 (1H, d, J 6 Hz, 
CH (d)); 5c (50.3 MHz, C^HCIg) 26.16, 26.69, 26.90, 26.99 & 27.18 (GHg 
(Chex)), 27.37 & 28.31 (C(Q.H3)2), 29.58, 29.88, 30.57, 33.63 & 33.70 (&Hg
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Chex), 36.57 (Q.H (a) (Chex)), 36.77 (^H (b) (Chex)), 36.93 (ChexilHgC), 77.50 
(ÜH (c)), 78.88 {Q.H (d)), 114.54 (Q(CH3)2), 145.68 (CHgCRrrjQR’CO), 169.13
(CH2^ R=CR’C0 ) and 204 (£0); m/z (El) 332 (M +, 3%), 317 ([M - CHs]+, 12), 
302 {[M- 2 X CH3]+, 2), 290 ([M- C(CH3)2]+, 2) and 274 ([M-(CH3)2CO]+, 54).
HIV-1 ptfitease assays 179). 
in vitro assay.
The assays are based upon the cleavage of the decapeptide Lys-Ala-Arg-Val- 
N le -(N 0 2 )P he-G lu -A la -N le -G ly-N H 2 between the norleuc ine  and 
nitrophenylalanine residues to give a reduction in absorbance at 300 nm. The
peptide is stored as a 10 mg m|-i solution in water and 2 pi is added to 1 ml of 
the assay buffer. The assay buffer is;
100 mM NaOAc 
200 mM NaCi 
1 mM DTT 
pH 5.6
The inhibitors were made up as 1-10 mM stock solutions in methanol and were 
used at concentrations in the range 1-100 pM. Methanol was added to give a 
final concentration of 2% and the mixture was allowed to thermally equilibrate at 
37 °C for 5 min. The reaction was then initiated by the addition of 15 pi of 
enzyme. The enzyme was stored as a 0.993 pM solution in 10 mM NaOAc,
0.05% 2-mercaptoethanol, 1 mM EDTA, 20% glycerol and 5% ethylene glycol. 
The procedure for pre-incubated assays was similar to the above, except that 
the enzyme and inhibitor were mixed and allowed to incubate together for 15 
mins at 37 °C and the reaction was initiated by the addition of the substrate. The 
linear portion of the plot was used to give initial rates. Each assay was 
performed both in duplicate and on two separate occasions. The K|  ^ for the 
substrate was determined to be 33 pM under the assay conditions.
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Antigen reduction assay.
C8166 T-lymphoblastoid cells were Infected with 10 TCID50 of HIV-1 of the RF 
stock (HIV-lp^p) and washed three times with PBS. Aliquots of 2 x 10® cells were 
resuspended in growth medium, RPMI 1640 supplemented by 10% fetal calf 
serum, with each compound to be tested at log dilutions from 0.001 to 100 pM. 
The cells were incubated at 37 °C for 72 h. under a 95% air/ 5% CO2 
atmosphere. The HIV antigen was measured in duplicate in the supernatants 
using a commercial ELISA assay.
Toxicity assay.
Aliquots of 2 X 10® uninfected C8166 cells were suspended in 1.5 ml of the 
above growth medium and cultured with the test compounds at the same log 
dilutions for 72 h. The cells were then washed with PBS and resuspended in 
200 pi of growth medium containing “'^C protein hydrolysate. The cells were 
harvested after 16 h. and the incorporation measured. Untreated cells were 
used as controls.
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APPENDIX A
Publications.
1. Camp, N.P,, Hawkins, P.C.D., Hitchcock, P.B. and Gani, D.,Bioorg. Med. 
Chem. Lett., 2, 1992,1047.
2 . Camp, N.P., Hawkins, P.C.D., Perrey, D.A. and Gani, D., in preparation.
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APPENDIX B
Crystallographic data.
Crystal lographic data have been deposited at the Cambridge Data Centre. 
C32H47N406P,M= 614.7. Orthorhombic, P2^2^2^ (No. 19). a = 9.265 (5), b = 15.654 
(10), c = 23.929 (11 ) Â; V = 3470.4 A^; Z = 4; d j = 1.18 g cm-3. Crystal size 0.25 x
0.15 X 0.02 mm. Total unique reflections = 3462, R = 0.118 for 738 reflections with 
|F2|>2a(F2).
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